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Preface 
There is a lack of robust biomarkers of CRC risk. Epigenetic changes in the 
WNT-related SFRP4, a gene whose expression is down-regulated early in CRC 
development, may be a potential CRC risk biomarker. If SFRP4 promoter 
methylation proved to be a useful biomarker of CRC risk, it would have potential 
implications for CRC screening. In addition, it could be used as a surrogate 
endpoint for investigations of CRC risk modifying interventions.  
SFRP4 methylation at several CpG sites was quantified in macroscopically 
normal rectal mucosal biopsies from volunteers at a relatively lower and higher 
CRC risk in two studies viz. the BORICC Study and the DISC Study. In the 
BORICC Study, the mean SFRP4 methylation of the 5 CpG sites investigated 
was significantly (p=0.036) higher in those in the higher risk group than in 
healthy controls. In the DISC Study, SFRP4 methylation was also higher at all 
CpG sites in the higher risk groups than in healthy controls but the differences 
were not statistically significant. 
In the BORICC Study SFRP4 methylation was also quantified in buccal cells 
matched to the rectal biopsies for the volunteers at a relatively lower and higher 
CRC risk. In contrast with the findings from the rectal mucosa, SFRP4 
methylation was significantly (p<0.001) lower at all CpG sites in those in the 
higher risk group than in healthy controls. At CpG sites 1 and 4 only, SFRP4 
methylation in the rectal biopsies and buccal cells was correlated significantly 
(p=0.001 and p=0.041 respectively). 
The healthy controls in the DISC Study were entered into a 50 day dietary 
intervention study and randomised to two potential chemoprevention agents; 
resistant starch and polydextrose in a 2  2 factorial design. SFRP4 methylation 
levels were quantified before and after the dietary intervention. Individually, 
resistant starch and polydextrose had no detectable effect on SFRP4 
methylation levels. However, there was evidence of an interaction between the 
two intervention agents which was qualitatively similar at all CpG sites 
investigated. This interaction was statistically significant (p=0.008) at CpG site 2. 
The biological interpretation of this interaction cannot be determined until the 
study is unblinded. 
IV 
 
This study has provided preliminary evidence that SFRP4 methylation may be a 
novel epigenetic biomarker of CRC risk and that measurement in DNA from 
buccal cells may be a useful surrogate for invasive measurements on rectal 
mucosa.  
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1 Introduction 
 
1.1 Colorectal cancer 
Colorectal cancer (CRC) arises from uncontrolled cell growth in the columnar 
epithelium most commonly in the rectum but this cancer can occur anywhere in 
the large intestine (Figure 1.1). It is the 3rd most common cancer (males and 
females combined) in the United Kingdom with approximately 110 new cases 
diagnosed daily (CRUK 2013).  The lifetime risk of developing CRC in the UK is 
1 in 16 for men and 1 in 20 for females (CRUK 2013). 
 
Figure 1.1Distribution of cancer within the colon, UK (2007-2009) (CRUK 2013) 
 
Permission for use obtained from Cancer Research UK 
 
CRC risk increases progressively with age with 86% of cases arising in those 
who are over 60 years old (CRUK 2013).  Below the age of 50 years, there are 
similar rates of CRC in both sexes, but after this age, CRC becomes more 
common in males (CRUK 2013) (Figure 1.2). 
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Figure 1.2 Number of new CRC cases per year and age-specific incidence rates, 
UK (2007-2009) (CRUK 2013) 
 
Permission for use obtained from Cancer Research UK 
 
1.2 CRC mortality 
In 2008, there were 608,000 deaths from CRC and 1,234,000 new cases of 
CRC worldwide (Ferlay et al. 2010).  Current trends in CRC mortality statistics 
from many developed countries are encouraging but only 50% of those 
diagnosed with CRC survive more than 5 years from diagnosis (CRUK 2013).   
 
1.3 CRC epidemiology 
The incidence of CRC is not uniform across the world.  CRC is predominantly a 
disease of developed countries with over 63% of cases occurring in the 
developed world (Hagger & Boushev 2009).  Identifying the reasons responsible 
for the inequality in CRC distribution globally would provide a starting point in 
reducing incidence and increasing survival from CRC. However, it is relevant to 
note that increasing age is a known risk factor for CRC (Section 1.4.1); and life 
expectancy is significantly greater in developed countries (where there is a 
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higher incidence of CRC) than in developing countries.  However, this alone is 
unlikely to account for the ten-fold difference between the countries with the 
highest (Australia and New Zealand) and lowest (Africa) CRC incidence (Jemal 
et al. 2010, CRUK 2013) (Figure 1.3).   
 
Figure 1.3 Worldwide incidence rates of CRC, 2008 (CRUK 2013) 
 
Permission for use obtained from Cancer Research UK 
 
1.4 CRC aetiology 
There are several risk factors associated with the development of CRC which 
can be categorized into modifiable and non-modifiable risk factors.   
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1.4.1 Non-modifiable CRC risk factors 
Non-modifiable risk factors include increasing age and hereditary factors.  CRC 
increases with age, with more than 90% of CRC occurring in people over the 
age of 50 years (CRUK 2013, Howlander et al. 2013) (Figure 1.2).  CRC 
incidence is greatest in those over the age of 80 years, where CRC incidence 
peaks (CRUK 2013).  Therefore with an ageing population, it is expected that 
the incidence of CRC will rise.  Up to the age of 80 years, CRC incidence is 
greater in males.  Above the age of 45 years, the incidence is significantly 
higher in males than in females (CRUK 2013). 
 
Five percent of CRCs are hereditary and arise in individuals who have a genetic 
defect which predisposes them to the early development of CRC (Burt 2000).  A 
genetic defect that predisposes to CRC is suspected in individuals who have a 
family history of CRC (Burt 2000, Fearnhead et al. 2002); though it is possible 
that a family history of CRC may be the result of family members being exposed 
to the same environmental factors that may impact upon the risk of CRC. 
 
The most common inherited CRC-related conditions are Familial Adenomatous 
Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
which both demonstrate an accelerated progression through the pathways that 
lead to CRC (Burt 2000, Fearnhead et al. 2002, Lynch & de la Chapelle 2003).  
Some of the genes responsible for these forms of inherited CRC have been 
identified.   
 
1.4.1.1 Hereditary non-polyposis colorectal cancer 
Up to 6% of CRC is as a result of HNPCC (WCRF 2007).  HNPCC is an 
autosomal dominant condition associated with mutations in genes involved in 
the DNA mismatch repair (MMR) pathway.  The lifetime risk of developing CRC 
in an individual with an inherited MMR mutation is as high as 80%, with CRC 
usually presenting before the age of 50 years (Fearnhead et al. 2002, Lynch & 
de la Chapelle 2003, Burt 2007, Steinke et al. 2013).  HNPCC patients are also 
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at an increased risk of cancer at other anatomical sites including the 
endometrium, ovary, stomach, small intestine, hepatobiliary system and brain 
(Lynch & de la Chapelle 2003, Burt 2007, Steinke et al. 2013).   
 
HNPCC is caused by inherited mutations in one of five DNA MMR genes: 
MSH2, MLH1, PMS1, PMS2, MSH6; which can be identified phenotypically by 
microsatellite instability (MSI), a hallmark feature of HNPCC.  Ninety percent of 
HNPCC is a result of an inherited mutation in the MSH2 and MLH1 DNA MMR 
genes (Lynch & de la Chapelle 2003).   
 
Microsatellites are segments of the DNA sequence containing tandem repeats 
in the nucleotide sequence which are vulnerable to errors during DNA 
replications (Chung & Rustgi 1995, Boland et al. 1998, Boland & Goel 2010).  
This vulnerability or (microsatellite) instability results in changes in the length of 
the nucleotide repeats, which can be of varying lengths.  All of the 4 nucleotide 
bases may be involved, though nucleotide repeats of cytosine and adenine are 
the most common (Boland & Goel 2010) (Section 1.6.1.6).   
 
1.4.1.2 Familial adenomatous polyposis 
FAP is an autosomal dominant condition which accounts for less than 1% of 
CRC cases and is caused by mutations in the tumour suppressor gene 
adenomatous polyposis coli (APC) which is located at chromosome 5q21-q22 
(Chung 2000, Galiatsatos & Foulkes 2006) (Section1.6.1.1).  Individuals 
suffering from FAP characteristically develop multiple adenomatous polyps at a 
relatively young age (often in adolescence) and malignant transformation of at 
least one of these adenomatous polyps occurs on average by the age of 35 
years (mean age of CRC diagnosis) (Galiatsatos & Foulkes 2006, Hagger & 
Boushev 2009).   
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If untreated, the incidence of malignancy in patients with FAP approaches 100%; 
with almost 100% of malignant transformation occurring by the time the patient 
is 40 years old (Fearnhead et al 2002, Davies et al. 2005, Burt 2007).  
Therefore, in individuals with FAP, CRC is almost inevitable and preventative 
measures must be taken to prevent the occurrence of CRC.  This is achieved 
with surgery to remove the colon (Fearnhead et al. 2002, WCRF 2007).  
However, despite prophylactic colectomy, individuals with FAP remain at a high 
risk of other cancers (stomach, duodenum) and regular endoscopic surveillance 
to screen for these cancers is still required (Burt 2007). 
 
1.4.1.3 Colorectal polyps 
Colorectal polyps or adenomas are benign growths occurring on the lining of the 
colon or rectum (Zuber & Harder 2001).  They arise from the epithelial lining of 
the colorectum and the 2 most common types are hyperplastic polyps and 
adenomatous polyps.  Other types of colorectal polyps which are less common 
are juvenile polyps and hamartomatous polyps (Zuber & Harder 2001). 
 
1.4.1.4 Hyperplastic polyps 
Hyperplastic polyps account for the majority (90%) of colorectal polyps (Hyman 
et al 2004).  Histologically, hyperplastic polyps contain larger numbers of 
glandular cells with less cytoplasmic mucus.  They lack nuclear 
hyperchromatism and atypia (Jass 2007, Guarinos et al. 2012) (Figure 1.4).  
Hyperplastic polyps are benign growths but do have malignant potential if they 
occur because of a hyperplastic polyposis syndrome (Hyman et al. 2004).  
Hyperplastic polyposis syndromes result when there are multiple colorectal 
serrated polyps (Guarinos et al. 2012).  Risk factors for increased CRC risk in 
hyperplastic polyps include: polyp size greater than 1cm in diameter; a focus of 
adenoma within the hyperplastic polyp (a serrated adenoma); more than 20 
hyperplastic polyps in the colon; a family history of hyperplastic polyposis or 
CRC (Jass & Burt 2000, Guarinos et al. 2012). 
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A serrated adenoma is a pre-cancerous lesion of the large bowel.  Serrated 
adenomas develop into CRC via the serrated pathway which differs from the 
majority of CRCs which arise from adenomatous polyps via the adenoma-
carcinoma sequence (Guarinos et al. 2012) (Figure 1.18). 
 
The serrated adenoma pathway accounts for approximately 20% of sporadic 
CRC (Jass 2007).  In this pathway, colorectal cells acquire genetic mutations in 
the BRAF oncogene and/or the K-RAS oncogene (Yang et al. 2004, Stefanius 
et al. 2011).  The BRAF oncogene is associated with high MSI (as a result of 
hypermethylation of the promoter region of MLH1) (Section 1.6.1.6) and high 
CpG island methylation phenotype (CIMP) (Section 1.10.1) (Kambara et al. 
2004).  K-RAS mutations result in low levels of methylation and MSI (Stefanius 
et al. 2011). 
 
Figure 1.4 Histology of hyperplastic polyp (Owens et al 2008) 
Hyperplastic polyps have small basal crypts largely lacking in cytoplasmic 
mucus production (a and b) 
 
Permission for use obtained from Nature Publishing Group 
 
1.4.1.5 Adenomatous polyps 
Adenomatous colorectal polyps have malignant potential and are of particular 
interest to this research project.  The malignant potential of adenomatous 
polyps is demonstrated by  i) evidence that the prevalence of adenomatous 
polyps peaks approximately 5 years earlier than that of CRC (Muto et al. 1975); 
8 
 
ii) the prevalence of adenomas in different geographical areas correlates with 
that of CRC incidence in those areas (Clark et al. 1985); iii) approximately one 
third of bowel resections for CRC will also contain one or more adenomatous 
polyps (Leslie et al. 2002); and iv) the risk of CRC increases significantly with 
increasing number of adenomatous polyps (Leslie et al. 2002). 
 
Adenomatous polyps contain nuclei that are large, hyperchromatic and crowded 
together (Figure 1.5).  Adenomatous polyps can be classified on histological 
grounds into 3 types viz. tubular, villous and tubulovillous (a combination of 
tubular and villous).  Tubular adenomas are composed of branched tubules.  
Villous adenomas are composed of digitiform villi.  Tubulovillous adenomas 
contain a mixture of branched tubules and digitiform villi (Cappell 2005). 
 
Figure 1.5 Histology of tubular adenoma (A) and tubulovillous adenoma (B) 
(Fleming et al. 2012) 
 
Permission for use obtained from Journal of Gastrointestinal Oncology 
 
Approximately 5-10% of adenomatous polyps develop into CRC and the risk of 
an adenomatous polyp progressing to CRC is related to the type of 
adenomatous polyp and its size and shape (Muto et al. 1975).  Those polyps 
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which are larger than 1cm, with a villous component greater than 25% and are 
sessile in shape (as opposed to pedunculated) are at an increased risk of 
progressing to CRC (Bond 2000). 
 
Adenomatous polyps of the large intestine are precursor lesions of CRC.  The 
development from adenomatous polyp to sporadic CRC is demonstrated by 
Fearon and Vogelstein’s (1990) adenoma-carcinoma sequence (Figure 1.6).  
Fearon and Vogelstein (1990) proposed a genetic model for CRC development 
and suggested that a combination of oncogene activation and tumour 
suppressor gene inactivation results in the stepwise progression from 
adenomatous polyp to sporadic CRC development (Figure 1.6).  This genetic 
model is based on the extensive data that suggest that the majority of CRCs 
arise from pre-existing benign adenomatous polyps.  The total accumulation of 
these genetic changes was more important than the order in which they 
occurred with a minimum of mutations in 4–5 genes being required for CRC 
development (Fearon & Vogelstein 1990). Therefore individuals with a history of 
this type of polyp are at an increased risk of developing CRC and removal of the 
polyp before malignant transformation will reduce CRC risk (Winawer et al. 
1993).   
 
Figure 1.6 Fearon and Vogelstein’s (1990) adenoma-carcinoma model of CRC 
(Davies et al. 2005) 
 
Permission for use obtained from Nature Publishing Group 
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The transformation from adenomatous polyp to CRC requires a long latency 
period (Hagger & Boushev 2009).  Therefore regular surveillance of the colon 
with endoscopy (colonoscopy or flexible sigmoidoscopy) to identify and remove 
the polyps will reduce the risk of the development of CRC (Atkin et al. 1992, 
Selby et al. 1992, Muller & Sonnenberg 1995, Thiis-Evensen et al. 1999).  This 
is supported by the findings of the National Polyp Study which reported that 
CRC incidence was reduced by endoscopic removal of adenomatous polyps 
(Winawer et al. 1993).  More recent evidence from a study by Zauber et al. 
(2012) corroborates the findings of the National Polyp Study (Winawer et al. 
1993).  Zauber et al. (2012) found that patients with adenomatous polyps did 
not have an increased incidence of CRC when compared with the patients from 
the non-adenomatous polyps group and the general population following 
endoscopic removal of their adenomatous polyp.  Atkin et al. (2010) have 
suggested that regular endoscopic surveillance may not be needed and that 
only one flexible sigmoidoscopy screening test between the ages of 55 and 64 
years is sufficient to reduce sporadic distal CRC incidence and mortality. The 
rationale for this is that if distal CRC was to develop, an adenomatous polyp 
would be expected by 60 years of age. 
 
1.4.1.6 Ulcerative Colitis 
Ulcerative colitis (UC) is an idiopathic, chronic relapsing inflammatory disease 
of the bowel where there is inflammation of the mucosa of the colon and rectum 
and long-standing, poorly-controlled UC increases the risk of CRC development 
(Fish & Kugathasan 2004).  The incidence of UC is increasing, and is higher in 
westernized countries (Cosnes et al. 2011).  Currently the worldwide incidence 
ranges from 1.2 to 20.3 cases per 100,000 people per year (Danese & Fiocchi 
2011).  Although UC accounts for only 1% of CRC, cancer is a serious 
consequence of UC occurring in up to 20% of patients (Eaden et al. 2001, 
Matter et al. 2011).  The relative risk of CRC in all patients with UC has been 
estimated to be 4 to 20 fold (Gillen et al. 1994). 
 
The environment, genetics and immunological factors play a role in UC 
development. Smoking is the only environmental factor reproducibly shown to 
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impact on UC. It is associated with milder disease, demonstrated by trials 
showing that nicotine can induce remission in active UC (McGrath et al. 2004); 
whereas smoking cessation is associated with UC relapse resulting in more 
hospital admissions and operations (McGrath et al. 2004, Danese & Fiocchi 
2011, Cabre & Domenech 2012). 
 
Many environmental factors have been investigated, including diet but the 
findings are inconsistent (Molodecky & Kaplam 2010).  In the European 
Prospective Investigation into Cancer and Nutrition (EPIC) Study, the only 
significant dietary agent implicated in UC was linoleic acid (Hart 2008). In this 
study 126 out of 200,000 participants developed UC and analysis of their 
dietary intake showed that a higher intake of linoleic acid was associated with 
more than double risk of UC (odds ratio 2.49) (Hart 2008). 
 
Lower faecal short chain fatty acid (SCFA) levels have been found in UC 
patients (Takaishi et al. 2008, Huda-Faujan et al. 2010).  The SCFA level 
correlates with severity of inflammation; with lower SCFA levels found with 
increasing severity of inflammation (Topping & Clifton 2001).  SCFA are end-
products of anaerobic fermentation of dietary fibre within the large intestine.  
SCFA play a role in maintaining colonic health and is the principle energy 
source for colonocytes (Topping & Clifton 2001) (Section 1.4.2.4). In the colon, 
butyrate is the most important SCFA because it is the principle energy source 
for colonocytes (Wong et al. 2006).  Impaired oxidation of butyrate has been 
demonstrated in patients with both active and inactive UC (Cabre & Domenech 
2012). 
 
Genome-wide association studies have suggested there are many gene 
variants associated with UC.  Currently, there are 99 confirmed associations but 
at present most of the associated variants do not have any known function and 
many implicate regions within multiple genes (Khor et al. 2011). The various 
genes implicated in the development of UC include those affecting: (i) the 
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function of the epithelial lining of the colon; (ii) transcriptional regulation; (iii) the 
interleukin-23 signalling pathway; and (iv) cell death (Khor et al. 2011). 
 
A genetic component is further suggested by the strong familial aggregation 
demonstrated in twin studies; with a sibling risk of 9-fold greater for UC 
compared to the general population, and an overall UC concordance rate in 
non-selected twin studies of 15% in monozygotic and 4% in dizygotic twins 
(Khor et al. 2011). 
 
1.4.2 Modifiable CRC risk factors 
Modifiable risk factors are environmental factors which include social and 
lifestyle factors such as diet, physical activity and smoking. 
 
1.4.2.1 Dietary factors and CRC 
Dietary factors account for 30% of all cancers in developed countries (WCRF 
2007).  60% of CRC occurs in developed countries, with particularly high CRC 
rates in North America and Western Europe (CRUK 2013) (Figure 1.3).   
 
Dietary products are one of the most common luminal antigens in the intestine 
that may influence intestinal health.  Mechanisms of action include: a direct 
antigenic effect, alteration of gene expression, modulation of inflammatory 
mediators, changes in the composition of intestinal flora, and altered gut 
permeability (Cabre & Domenech 2012).   
 
Studies have shown that CRC incidence increases among migrants when they 
move from a low to a high risk country and that CRC rates for second 
generation migrants can be double that of the first (Boyle & Langman 2000, 
Cappell 2005, Center et al. 2009, CRUK 2013).  This suggests that 
environmental factors may play an important role in the development of CRC.  
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One possible environmental factor is the “westernisation” of dietary intake that 
occurs on moving from a low to a high risk country (Boyle & Langman 2000, 
Key et al. 2004, CRUK 2013).   
 
The World Cancer Research Fund (2007) reported that CRC risk was 
significantly affected by various lifestyle factors (Table 1.1).  These same 
lifestyle factors have been found to affect the development of CRC by Lee et al. 
(2011) and Parkin et al. (2011).  In general, as found by the World Cancer 
Research Fund (2007), a high intake of red and processed meat is associated 
with a higher CRC risk and a high intake of fruit and vegetables and calcium 
may lower the risk of CRC.  There is evidence that not smoking, avoiding 
excess alcohol consumption and avoiding weight gain by maintaining regular 
physical activity can reduce the risk of CRC (WCRF 2007, Parkin et al. 2011). 
 
In comparison with the developing world, the “Western diet” has a higher intake 
of red meat, animal fat and alcohol and a lower intake of dietary fibre, fruit and 
vegetables (Cordain et al. 2005).  Therefore the “Western diet” may contribute 
to the higher incidence of CRC in the Western world. 
 
1.4.2.2 Dietary fibre and CRC 
The intake of dietary fibre differs between high and low CRC risk countries and 
this may be partly accountable for the differences in CRC rates in Africa (low 
risk) and Westernised (high risk) countries (Boyle & Langman 2000, Key et al. 
2004, Cordain et al. 2005, Center et al. 2009, CRUK 2013). 
 
The EPIC Study reported a linear decrease in the risk of CRC with increasing 
dietary fibre intake (Bingham et al. 2003).  However, the results of multiple 
epidemiological studies investigating the association between CRC risk and 
dietary fibre intake have been inconsistent (COMA 1998, Fuchs et al. 1999, 
Pietinen et al. 1999, Alberts et al. 2000, Bonithon-Kopp et al. 2000, Schatzkin et 
al. 2000, Terry et al. 2001, WCRF 2007).  This is because of differences in the 
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study designs and dietary data collected using food frequency questionnaires; 
and the possibility of confounding by other dietary components (Day et al. 2001, 
Kipnis et al. 2001).  In 2011, Aune et al. (2011) published a meta-analysis of the 
outcomes from prospective cohort studies on the relationship between dietary 
fibre on CRC risk.  The meta-analysis consisted of 21 prospective studies and 
included over 1.7 million participants and 12,000 CRC cases, providing 
sufficient statistical power to show there is an inverse association between 
dietary fibre intake and CRC risk.  Aune et al. (2011) concluded that there was a 
10% reduction in CRC risk for each 10g/day intake of dietary fibre. 
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Table 1.1 Summary of World Cancer Research Fund (2007) findings of 
relationships between dietary and anthropometric factors and CRC risk  
Strength of Evidence Decreases CRC risk Increases CRC risk 
Convincing Physical activity of all 
types  
(occupational, 
household, recreational) 
Red meat 
Processed meat 
Alcohol (men) 
Body fatness 
Abdominal fatness 
Probable Dietary fibre 
Garlic 
Milk 
Calcium 
Alcohol (women) 
Suggestive Non-starchy vegetables 
Fruits 
Folate 
Selenium 
Fish  
Vitamin D 
Iron 
Cheese 
Animal fats 
Sugars 
Inconclusive Cereals, potato, poultry, seafood, other dairy 
products, total fat, fatty acid composition, 
cholesterol, caffeine, total carbohydrate, starch, 
vitamin A, C, E retinol, meal frequency, energy 
intake 
Substantial effect on risk 
unlikely 
None identified 
 
 
The Polyp Prevention Trial investigated the effect of a low fat, high fibre and 
high fruit/vegetable diet on the recurrence of resected adenomatous polyps in 
the colon (Lanza et al. 2007).  Just over 2000 participants with recently excised 
polyps were randomized into 2 groups: (1) Participants underwent intensive 
counselling to adopt a low fat, high fibre and high fruit/vegetable diet; and (2) 
participants were given a brochure on healthy eating (control group).  After 4 
years, there was no difference in the rate of polyp recurrence in both groups 
(Lanza et al. 2007).  However, it is possible that dietary fibre may influence 
cellular events that result in the prevention of adenomatous polyp formation, but 
has no effect upon reducing adenomatous polyp and CRC risk once the initial 
insult to the colorectal tissue has occurred (Kim & Milner 2007). 
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The Wheat Bran Fibre Study investigated the effect of a wheat bran fibre 
supplement on the recurrence of resected adenomatous polyps in the colon 
(Earnest et al. 1999).  Just fewer than 1,500 participants with recently excised 
polyps were randomized into 2 groups: (1) Daily high wheat bran fibre cereal 
supplement; and (2) low wheat bran fibre cereal supplement.  After 3 years, 
there was no difference in the rate of polyp recurrence between the 2 groups 
(Earnest et al. 1999).   
 
It is possible that the participants of both the Polyp Prevention Trial and the 
Wheat Bran Fibre Study were not followed up for an adequate length of time or 
the intervention was not given for long enough.  The development of CRC takes 
many years and interventions lasting 4 years and 3 years respectively may not 
have been long enough to have a significant impact.  The participants of the 
Polyp Prevention Trial were followed up for a further 4 years after completion of 
the initial study and even after 8 years, participants taking a low fat, high fibre 
and high fruit/vegetable diet did not have a reduced polyp recurrence rate when 
compared to the group following a standard healthy diet (Lanza et al. 2007). 
 
1.4.2.3 Dietary fibre 
Dietary fibre is a collective term for a group of dietary carbohydrates with a 
diverse range of physical, physiological and chemical properties (Cummings & 
Stephen 2007).  Dietary fibre refers to a physiological concept – the proportion 
of food derived from the cellular wall of plants which is resistant to digestion by 
human digestive enzymes.  More specifically, dietary fibre consists of intrinsic 
plant cell wall polysaccharides (Cummings & Stephen 2007). 
 
Two categories of dietary fibre have been described: Insoluble dietary fibre and 
soluble dietary fibre.  In general, insoluble dietary fibres are those that are 
slowly and incompletely fermented, allowing them to have a bulking action and 
thus more pronounced effects on bowel habit (Cummings & Stephen 2007). 
Soluble dietary fibres are viscous and fermentable in the large intestine.  They 
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delay gastric emptying and slow the transit of food material through the small 
intestine and have effects on glucose and lipid absorption in the small intestine 
(Cummings & Stephen 2007).  However, the separation of dietary fibre into 
these two categories is pH dependent, thus making associations with specific 
distinct physiological properties uncertain (Cummings & Stephen 2007). 
 
Dietary fibre has multiple beneficial effects on the gastrointestinal tract related 
to its inability to be digested in the small intestine (Cummings & Stephen 2007).  
The two most important actions with regards to colonic health are: (i) it protects 
against CRC by absorbing or diluting potential carcinogens within the large 
intestine (Fuchs et al. 1999, Lipkin et al.1999); and (ii) it acts as a substrate for 
fermentation by anaerobic bacteria within the large intestine, where it may be 
hydrolysed and metabolised to products such as SCFA.  Butyrate, acetate and 
propionate are the 3 major types of SCFA which are produced as end-products 
of fermentation of dietary fibre in the colon.  Of these, butyrate is the most 
important with regards to colonic health because it is the principle energy 
source for colonocytes (Cook & Sellin 1998, Nugent 2005). 
 
1.4.2.4 Butyrate 
Butyrate promotes cell differentiation and induces apoptosis in CRC cells; both 
actions are protective against CRC (Scheppach et al. 1992, Hague et al. 1995).  
Butyrate is a natural histone deacetylase inhibitor (Section1.9), and has anti-
carcinogenic effects on colonic epithelial cells such as down-regulation of 
expression of oncogenes (Davis 2003, Rada-Iglesias et al. 2007).  Evidence 
exists that butyrate reduces the number and size of aberrant crypt foci (ACF) 
(the earliest detectable change to the normal colorectal cell that suggests it may 
progress to CRC), and ultimately the development of CRC (Kim & Milner 2007).  
It also stimulates colonic blood flow and fluid and electrolyte uptake (Scheppach 
et al. 1994, Topping & Clifton 2001).  Butyrate also reduces the conversion of 
primary bile acids to secondary bile acids.  Secondary bile acids have been 
linked to an increased risk of CRC (Topping & Clifton 2001, Costarelli et al. 
2002). 
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The mechanism responsible for the antineoplastic effects of butyrate is not 
known, but butyrate influences several processes important in tumourigenesis, 
including cell proliferation, apoptosis, angiogenesis, immunosurveillance and 
inflammation (Scheppach et al. 1992, Perrin et al. 1994, Hague et al. 1995, 
Davis 2003, Mathers 2003, Rada-Iglesias 2007).  These effects of butyrate 
have been attributed to changes in gene expression, possibly as a 
consequence of epigenetic processes including hyperacetylation of histones 
(Boffa et al. 1978, Parker et al. 1986, Boffa et al. 1994, Davis 2003, Williams et 
al. 2003, Rada-Iglesias et al. 2007). 
 
 
1.4.2.5 Resistant Starch 
Starch is a glucose homopolymer found in two forms: amylose and amylopectin.  
Starch is present as crystalline granules in raw food.  Resistant starches are all 
the starch and starch degradation products that resist small intestinal digestion 
and are therefore available to enter the large intestine where they act as 
substrates for fermentation into SCFA such as butyrate (Englyst et al. 1996).  
They are now included within the broad classification of dietary fibre.  There are 
4 types of resistant starch, classified by their (botanical) source and food 
processing effects which result in resistance to pancreatic α-amylase 
(Cummings & Stephen 2007) (Table 1.2). 
 
Resistant starch has an energy value of 2kcal/g which is half that of digestible 
starch (Narina et al. 2012).  It is found in various foods including rye bread, 
bananas and cooked potatoes which have been left to cool, and can be 
commercially manufactured (Hi-maize) and used in the production of many 
foods such as cereal bars, baked products and nutrition bars (Nugent 2005). 
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Table 1.2 Types of resistant starch (Nugent 2005) 
RS1 Physically inaccessible starch – starches are trapped within the plant 
cell wall which resists digestion because of a physical barrier 
RS2 Starches consisting of poorly gelatinized granules. Starch is packed 
tightly in a radial pattern and relatively dehydrated.  This compact 
structure limits the accessibility of digestive enzymes and are 
hydrolysed slowly and resistant to digestion 
RS3 Retrograded starches (after food processing) – the most resistant 
starch fraction. Mainly retrograded amylose formed during the cooling 
and crystallization of gelatinized starch – the process of heating and 
then cooling has rendered the starch resistant to digestion 
RS4 Chemically modified starches as a result of novel chemical bonds 
 
 
The Concerted Action Polyp Prevention (CAPP) 2 Study published by Mathers 
et al. (2012) investigated the effect of resistant starch with and without aspirin 
taken daily for up to 4 years in a randomised control trial using a 22 factorial 
design on 937 participants with HNPCC.  The CAPP2 Study found no significant 
effect of resistant starch on the development of CRC.  There was also no 
significant effect of aspirin on colorectal neoplasia during the study (Burn et al. 
2008).  However, the CAPP2 Study did find that 600mg aspirin daily provided 
protection against CRC development in long-term follow up (Burn 2011).  
Furthermore, the CAPP1 Study also investigated the effect of resistant starch 
and/or aspirin given daily for at least a year in a randomised control trial on 
participants with FAP.  Despite showing that resistant starch led to reduced cell 
proliferation, there was no significant difference in the adenomatous polyp count 
in the large intestine of the participants who had taken resistant starch 
compared to those who had not (Burn et al. 2011). 
 
The CAPP1 Study and CAPP2 Study have not found any clinical effect of 
resistant starch on the development of CRC (Burn et al. 2011, Mathers et al. 
2012).  However, there are multiple observational studies that do show a 
protective effect of dietary fibre such as resistant starch (Trock et al. 1990, 
20 
 
Howe et al. 1992).  Aune et al. (2011) reported that dietary fibre significantly 
reduced CRC development in a meta-analysis of 21 prospective cohort and 
nested case-control studies.  It is possible that resistant starch affects 
individuals genetically predisposed to CRC development (e.g. HNPCC, FAP) 
differently to the general population. 
 
1.4.2.6 Polydextrose 
Polydextrose is a synthetic polysaccharide which is largely non-digestible in the 
small intestine and only partially fermentable in the large intestine.  It has a low 
energy value (1 kcal/g) (Cummings & Stephen 2007).  It is a low molecular 
weight randomly bonded polysaccharide and is prepared by the bulk melt 
polycondensation of glucose and sorbitol with small amounts of food grade acid 
in vacuo (Flood et al. 2004).  It is used widely as a low calorie sugar 
replacement (Flood et al. 2004).  Extensive studies supported by the Food and 
Drug Administration (FDA) has shown polydextrose to be safe for dietary 
consumption (FDA 2013). 
 
Polydextrose has physiological actions similar to that of dietary fibres as a result 
of its poor digestibility in the small intestine and incomplete fermentation in the 
large intestine (Topping & Clifton 2001).  In individuals with a higher intake of 
polydextrose, the production of butyrate has been observed to increase (Jie et 
al. 2000).  Polydextrose also promotes growth of colonocytes, with growth 
occurring mainly at the base of the colonic crypts where the stem cells are 
found (Topping & Clifton 2001) (Section 1.5). 
 
1.4.2.7 Physical activity, body mass index and CRC 
Observational evidence has suggested that body mass index (BMI) and levels 
of physical activity (occupational, household, recreational activity) play a role in 
the development of CRC.  Higher body fatness and abdominal fatness increase 
CRC risk (WCRF 2007, Vrieling & Kampman 2010).  The mechanistic link 
between raised adiposity and CRC remains uncertain but increased BMI is 
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associated with insulin resistance which results in hyperinsulinaemia and 
hyperinsulinaemia may induce cell division (Godsland 2010).  An increased BMI 
is also associated with chronic low grade inflammation as a result of the release 
of proinflammatory cytokines by adipose tissue which may have a carcinogenic 
effect in the colon (van Kruijsdijk et al. 2009).  Ben et al. (2012) performed a 
meta-analysis to investigate the effect of BMI on CRC risk and demonstrated 
that a 5 unit increase in BMI was associated with a 19% increased risk of CRC. 
 
Higher levels of physical activity are associated with reduced risk of CRC and 
may be protective against CRC.  There is evidence to suggest a dose-response 
effect, with frequency and intensity of physical activity inversely associated with 
CRC risk (Boyle & Langman 2000, WCRF 2007, Hagger & Boushev 2009). 
 
1.4.2.8 Smoking and CRC 
Cigarette smoking is a risk factor for CRC development and is the most 
important avoidable risk factor for cancer in the UK (Zisman et al. 2006, Tsong 
et al. 2007, Hagger & Boushev 2009).  Cigarette smoking may be causally 
linked to CRC by exposure of the colonic epithelium to carcinogenic compounds 
in the cigarette smoke via the systemic circulation or from direct exposure from 
their ingestion (Chan & Giovannucci 2010).  There is a: (i) 38% increase in CRC 
risk for an increment of 40 cigarettes/day; (ii) 20% increase in CRC risk for an 
increment of 40 years duration; (iii) 51% increase in CRC risk for an increment 
of 60 pack years; and (iv) 4% decrease in CRC risk for a delay of 10 years in 
smoking initiation (Chan & Giovannucci 2010).    
 
Cigarette smoking is important in both the formation and growth rate of 
adenomatous polyps which is demonstrated by an earlier average age of onset 
of CRC and the presence of larger polyps in smokers (Zisman et al. 2006, 
Tsong et al. 2007, Botteri et al. 2008).  There is a time lag of approximately 30-
40 years between the exposure to carcinogenic compounds from cigarette 
smoking and the development of CRC (Giovannucci et al. 1994).  The incidence 
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of CRC is also higher than normal in previous cigarette smokers suggesting that 
the carcinogenic compounds in cigarette smoke may be important in the 
initiation of CRC (Snowden 2009). 
 
Interestingly, smoking protects against the acute exacerbation of UC 
(Molodecky & Kaplam 2010, Cosnes et al. 2011, Danese & Fiocchi 2011).  The 
mechanism(s) by which this occurs requires further investigation.  It has been 
suggested that cigarette smoke compounds may: alter gut permeability; modify 
gut motility; alter mucosal blood flow; increase the production of colonic mucus; 
and/or change the levels of circulating cytokines (Birrenback & Bocker 2004).  
Individuals with more severe forms of UC or with frequent exacerbations of the 
disease are at an increased risk of CRC (Kewenter et al. 1978, Hendriksen et al. 
1985, Gillen et al. 1994).  Therefore it seems contradictory that cigarette 
smoking is also a significant factor in the development of CRC.  This would 
suggest that multiple factors play a role in the development and risk of CRC. 
 
1.4.3 Aetiology of CRC:  Conclusions 
CRC aetiology is complicated because many of the aetiological factors are 
correlated.  Multiple epidemiological studies have investigated the effects of 
dietary choices, BMI and physical activity on the development of CRC.  These 
studies are subject to confounding e.g. one dietary choice may be associated 
with another or various dietary components may interact with one another.  It is 
also possible that an individual opting for a healthier diet may also have a 
healthier lifestyle with more physical activity, decreased alcohol intake and is 
less likely to smoke cigarettes. 
 
Several diverse factors contribute to the increased risk and development of 
CRC including the environment, age, genetics, cigarette smoking, physical 
activity and diet (Figure 1.7).  With the exception of hereditary CRC, there does 
not appear to be any one factor that is causative for CRC.  Therefore there are 
likely to be different pathways that results in development of CRC. 
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Genetic   
factors 
Age 
Environmental 
factors: 
• Smoking 
• Physical 
activity 
• Diet 
• Geography 
CRC 
Figure 1.7 Factors that play a role in the development of sporadic colorectal 
cancer 
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1.5 CRC development 
Cancer is a disease involving dynamic changes in the genome (Vogelstein & 
Kinzler 1993).  Cancer is a multistep process in which a normal human cell is 
transformed progressively into a malignant cell by multiple genetic and 
epigenetic alterations that disrupt the regulatory controls on cell proliferation, 
homeostasis and cell death (Vogelstein & Kinzler 1993).  Disruption of normal 
cell proliferation and/or homeostasis and/or cell death may occur by one or 
more alterations allowing the cell to acquire unique molecular, biochemical and 
cellular traits including self-sufficiency in growth signals, insensitivity to growth-
inhibitory signals, evasion of programmed cell death, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis 
(Hanahan & Weinberg 2011) (Figure 1.8).  Each of these changes represents 
the successful overriding of a normal cell’s anti-cancer defence mechanisms. 
 
CRC arises from cells within the single layer of columnar epithelial cells which 
forms the barrier between the gut lumen and the inside of the body (van der 
Flier & Clevers 2009).  Within this layer of epithelial cells, colorectal stem cells 
are found at the base of colonic crypts (invaginations of the colorectal 
epithelium).  CRC stem cells proliferate and give rise to the cells that line the 
colonic crypt (Figure 1.9 (A)).  Damage to these colorectal stem cells gives rise 
to CRC (Humphries & Wright 2008). 
 
Pathological studies have demonstrated that a normal cell transforms into 
invasive CRC via a series of pre-malignant states which become more frequent 
with age (Vogelstein & Kinzler 1993).  This suggests there are multiple genetic 
and/or epigenetic changes that occur in the development of CRC with each 
genetic and/or epigenetic adaptation conferring a growth advantage that allows 
the progressive change from a normal cell to a cancerous cell (Vogelstein et al. 
1988).  The fact that there are multiple intermediate steps in the pathway from a 
normal cell to cancer provides multiple possible steps that could potentially be 
“intercepted” and prevented or reversed to halt the progression of a normal cell 
to cancer. 
25 
 
Figure 1.8 Acquired capabilities of cancer (Hanahan & Weinberg 2011)  
 
Self-sufficiency in growth signals:  Cancer cells alter exogenous growth signals 
and the way in which exogenous growth signals are transferred across cell 
membranes.   
Insensitivity to anti-growth signals: Multiple anti-growth signals maintain cellular 
quiescence and tissue homeostasis in normal tissue.  Uncontrolled proliferation 
results from the insensitivity of cancer cells to growth-inhibitory signals. 
Evading apoptosis:  Acquired resistance against programmed cell death is a 
hallmark of cancer.  An apoptotic program is present in a latent form in all cell 
types.  Once triggered, it results in programmed cell death.  Cancer cells are 
able to “switch off” the activation of programmed cell death.  
Limitless replicative potential:  Cancerous cells are immortalized, having 
acquired limitless replicative potential during cancer development. 
Sustained angiogenesis:  Cell function and survival is dependent upon oxygen 
and nutrient supply via blood vessels.   
Tissue invasion and metastasis:  The capability for invasion and metastasis 
enables cancer cells to colonize sites distant from its primary location.  
Successful invasion and metastasis depend upon all five acquired hallmark 
capabilities of cancer cells already described. 
Permission for use obtained from Elsevier Limited 
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Figure 1.9 The colonic crypt (Humphries & Wright 2008) 
 
(A) Stem cells reside at the base of colonic crypts where they communicate with 
the cells within the colonic niche. 
(B) Types of stem cell division: (a) asymmetric stem cell division results in the 
production of one differentiated progenitor cell and one identical stem cell; (b) 
“lineage expansion” – symmetric stem cell division results in the production of 
two identical stem cells; (c) “lineage extinction” – symmetric stem cell division 
results in the production of two differentiated cells. 
(C) Development of CRC: (a) colonic crypt niche houses the stem cells; (b) a 
stem cell (blue) develops a mutation; (c) asymmetric division results in the 
production of clones of the mutated cell amongst the non-stem cells lining the 
colonic crypt; (d) the niche is colonized as further clones of the mutant stem cell 
are produced; (e) the mutant stem cell dominates the niche. 
(D) Clonal conversion: the progeny of a mutant stem cell replaces all other cells 
in the crypt. 
Permission for use obtained from Nature Publishing Group 
 
 
1.5.1 Stem cells and CRC 
Colorectal stem cells are characterized by their ability to self-renew throughout 
the lifetime of the individual (Radtke & Clevers 2005, Boman et al. 2007).  The 
accumulation of mutations and other genomic damage, including epigenetic 
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changes, within colorectal stem cells causes CRC (Humphries & Wright 2008, 
Salama & Platell 2009) (Figure 1.9 (C) and (D)).   
 
Colorectal stem cells within the base of the colonic crypt divide to produce 
transit amplifying cells which, after a small number of rounds of proliferation, 
undergo differentiation to provide a continuous supply of the cell lineages 
required for normal crypt function including colonocytes, goblet cells and 
enteroendocrine cells (Humphries & Wright 2008).  These cell lineages migrate 
towards the surface of the colonic crypt where they die or are sloughed into the 
colonic lumen within 4-8 days (Stappenbeck et al. 1998, Radtke & Clevers 
2005).  The stem cell niche is the microenvironment that houses the stem cell 
and controls its functions (Spradling et al. 2001, Humphries & Wright 2008).   
 
There are two types of stem cell division: (i) symmetrical stem cell division and 
(ii) asymmetrical stem cell division (Humphries & Wright 2008, Salama & Platell 
2009) (Figure 1.9 (B)).  Symmetric stem cell division is the division of a stem 
cell to produce either two stem cells or two differentiated cells.  If two stem cells 
are produced, symmetric stem cell division results in “lineage expansion” 
(Figure 1.9 (B:b)) whereas if two differentiated cells are produced, the result is 
“lineage extinction” (Figure 1.9 (B:c)).  Symmetric division of CRC stem cells is 
essential in achieving exponential numbers of tumour cells (Boman et al. 2007). 
 
Asymmetric stem cell division results in the production of one progenitor cell 
and a stem cell identical to the parental cell which allows for both the 
maintenance of the stem cell population and the production of  a progenitor cell 
that may further divide into differentiated cells to allow a constant regeneration 
of organs and tissues (Humphries & Wright 2008) (Figure 1.9 (B:a)).  The new 
stem cell retains the original strand of DNA to minimize DNA replication errors; 
the “immortal strand hypothesis” (McDonald et al. 2006).   
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1.6 Genetics and CRC 
Fearon and Vogelstein (1990) described the adenoma-carcinoma sequence, a 
genetic model for CRC, where multiple genetic alterations are responsible for 
the stepwise progression from a “normal” cell to dysplastic epithelium to 
carcinoma (Figure 1.6).  The accumulative effect of each genetic alteration may 
confer a significant growth and/or survival advantage over the “normal” cell; 
which may subsequently lead to the further development of dysplasia and 
ultimately CRC (Fearon & Vogelstein 1990).  These genetic alterations occur at 
the stem cell level and 3 classes of genes play a central role in the genetic 
alterations which result in tumour development i.e. oncogenes, tumour 
suppressor genes and DNA repair genes (Vogelstein et al. 2000).   
 
Oncogenes have the potential to cause cancer.  Under normal conditions, 
oncogenes promote cell growth by encouraging mitosis (Land et al. 1983, 
Knudson 1985).  Cancer may be the result of abnormal oncogene activation 
which may occur by a variety of mechanisms including (i) oncogene mutation 
resulting in increased activity or a loss of the usual control mechanisms; (ii) 
defective protein expression leading to increased concentration of the protein 
encoded by the oncogene and (iii) defective gene expression resulting from 
chromosomal translocation (Hanahan & Weinberg 2000).  Aberrantly activated 
oncogenes result in exaggerated growth signals, causing survival of malignant 
cells and their resistance to anti-growth signals (Hanahan & Weinberg 2000, 
Vogelstein et al. 2000). 
 
Tumour suppressor genes act as “stop” signals halting the progression of a cell 
through the cell cycle or promoting apoptosis.  When the expression of tumour 
suppressor genes is abnormal, normal inhibitory control is lost and the cell may 
progress to cancer (Vogelstein et al. 2000). 
 
Cells cannot function if DNA damage corrupts the integrity and accessibility of 
essential information in the genome.  The majority of DNA damage affects the 
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primary structure of the DNA double helix (Lodish et al. 2004).  Damaged DNA 
may be “repaired” by DNA repair genes and cells use unmodified 
complementary strands of DNA to recover its original information.  DNA repair 
genes then act by restoring the original spatial configuration of the DNA helix by 
binding to the site of damage and inducing other molecules to bind and form a 
complex that enables repair to occur (Watson et al. 2004).  DNA repair genes 
are only able to “repair” DNA that has been structurally damaged (Dinant et al. 
2008). 
 
Mutations to DNA repair genes render them unable to recognise and repair 
damaged DNA and as a result, the damaged cells may (i) enter a state of 
dormancy; (ii) die by apoptosis or (iii) divide in an unregulated fashion.  
Unregulated cell division may lead to the development of cancer (Hanahan & 
Weinberg 2000). 
 
1.6.1 Genetic Alterations and CRC 
The earliest detectable macroscopic change to the normal colorectal cell that 
suggests it may progress to CRC is the ACF.  ACF are clusters of mucosal cells 
with an enlarged or thicker layer of epithelia that surround the normal crypt cells 
(Bird 1987, Alrawi et al. 2006).  Further genetic alterations in ACF are needed 
for progression to adenomatous polyps and CRC (Alrawi et al. 2006). 
 
1.6.1.1 Adenomatous polyposis coli 
APC is a tumour suppressor gene located on chromosome 5q21-q22 (Bodmer 
et al. 1987).  APC mutations or allelic losses of 5q are present in 40-80% of 
CRC (Vogelstein et al. 1988, Miyoshi et al. 1992, Powell et al. 1992, Miyaki et al. 
1994), occur early in the adenoma-carcinoma sequence and are the first step in 
the initiation of CRC (Bodmer et al. 1987).  This results in the progression from 
a normal colon cell to ACF (Figure 1.6).  The APC gene is responsible for CRC 
resulting from FAP (Bodmer et al. 1987).  APC mutation is a very important 
initiation step that sets a normal colonocyte onto a pathway that may potentially 
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lead to adenomatous polyp or CRC development. Therefore, individuals with 
FAP, who inherit a mutant form of the APC gene, are predisposed to the 
accelerated development of adenomatous polyps and CRC (Burt 2000, 
Fearnhead et al. 2002). 
 
The APC gene produces a large multifunctional protein that interacts with many 
proteins, most importantly β-catenin and glycogen synthase kinase (GSK) 3β 
(Rubinfeld et al. 1996, Kaplan et al. 2001) to form a complex which regulate 
intracellular β-catenin concentrations through the phosphorylation of β-catenin 
which signals β-catenin degradation (Munemitsu et al. 1995) (Figure 1.10 (A)).   
 
Mutated APC may result in no APC protein being formed or may code for a 
protein that is unable to bind β-catenin or GSK 3β. In such cases, β-catenin is 
no longer degraded, but instead accumulates within the cytoplasm (Munemitsu 
et al. 1995, Ricci-Vitiani et al. 2008) and translocates to the nucleus where it 
binds to the T-cell factor (TCF) family of transcription factors and activates gene 
transcription (Molenaar et al. 1996) (Figure 1.10 (B)).   
 
The effects of mutant APC can be observed in colonic stem cells residing at the 
base of colonic crypts.  When a stem cell divides, its daughter cells proliferate 
further and migrate up the crypt towards the surface.  The APC protein usually 
acts from the mid-crypt level upwards resulting in -catenin degradation and 
suppression of cell proliferation.  Mutated APC results in cells that are 
independent of physiological signals controlling -catenin activity (insensitivity to 
growth inhibitory signals (Figure 1.8)).  These aberrant cells continue to migrate 
to the crypt surface where ACF results (Bach et al. 2000, Sansom et al. 2004). 
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Figure 1.10 The actions of APC within the WNT signalling pathway (Ricci-Vitiani 
et al. 2008) 
 
(A) In the normal colon epithelial cell, the APC-β-catenin-GSK 3β complex 
results in the binding of β-catenin; causing β-catenin degradation. 
(B) Mutant APC is unable to bind β-catenin or GSK 3β; β-catenin is no longer 
degraded, instead it accumulates and translocates to the nucleus where it is 
able to activate gene transcription.   
Permission for use obtained from BMJ Publishing Group 
 
 
1.6.1.2 K-RAS 
K-RAS is an oncogene located on chromosome 12p12.1 (Shuangshoti 2011).  
K-RAS mutations occur early in the adenoma-carcinoma sequence and are 
present in 35-42% of CRC (Bos et al. 1987, Forrester et al. 1987, Vogelstein et 
al. 1988, Andreyev et al. 1998).  K-RAS mutations are responsible for the 
progression of ACF to adenoma and for the further development of an adenoma 
to become more dysplastic (Fearon & Vogelstein 1990) (Figure 1.6).   
 
The K-RAS oncogene produces a protein involved in the signal transduction of 
regulatory pathways.  In its non-mutated form, K-RAS ensures that normal cell 
proliferation and differentiation occurs.  In its active state, K-RAS is bound to 
guanosine 5’triphosphate (GTP) protein in the cell membrane.  K-RAS becomes 
A B 
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inactive when GTP is hydrolysed by GTPase to guanosine 5’diphosphate.  
GTPase activity is reduced when K-RAS becomes mutated, leading to 
constitutively active K-RAS protein; abnormal cell proliferation and 
differentiation follows (Bos et al. 1989, McCormick 1989, Bourne et al. 1990). 
 
1.6.1.3 Chromosome 18q loss 
Chromosome 18q is lost in 70% of CRC (Vogelstein et al. 1988, Boland & Goel 
1995).  The tumour suppressor genes SMAD2 and SMAD4 are carried on 
chromosome 18 and play a role in the development of CRC; in particular, loss 
of SMAD2 and SMAD4 increases the degree of dysplasia within an adenoma 
(Leslie 2002) (Figure 1.6).  SMAD2 and SMAD4 are intracellular mediators of 
the inhibitory transforming growth factor (TGF)  signalling pathway which 
regulates cell growth, differentiation and cell death (Heldin et al. 1997, Duff & 
Clarke 1998). 
 
1.6.1.4 P53 
P53 is a tumour suppressor gene which is located on the short arm of 
chromosome 17 (Vogelstein et al. 1988).  17p allelic loss or P53 mutation 
occurs in 50-75% of CRC (Vogelstein et al. 1988, Kaklamanis et al. 1993, 
Darmon et al. 1994, Boland et al. 1995, Hardingham et al. 1998, Kaserer et al. 
2000).  P53 mutation is implicated in the progression of an adenoma and its 
malignant transformation to adenocarcinoma (Vogelstein et al. 1988, Fearon & 
Vogelstein 1990, Boland et al. 1995) (Figure 1.6).   
 
When there is DNA damage, P53 normally blocks cell proliferation and 
stimulates DNA repair.  If this DNA repair is unsuccessful, P53 promotes cell 
death.  Mutated P53 causes defective cell proliferation and the accumulation of 
damaged DNA as a result of the defective cell’s ability to evade apoptosis (Lane 
1992, Carder et al. 1995) (programmed cell death (Figure 1.8)). 
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1.6.1.5 Chromosome instability 
The genetic alterations described: APC mutations, K-RAS mutations and 
chromosome 18q loss, are each implicated in CRC development via the 
chromosome instability pathway.  The chromosomal instability pathway, which 
accounts for 85% of sporadic CRC, (Grady & Markowitz 2000, Worthley & 
Leggett 2010) (Figure 1.11) occurs when there are increased rates of 
chromosome mis-segregation during mitosis.  This leads to an inability to 
maintain the correct chromosomal complement via one of two mechanisms: (i) 
Mis-segregation which leads to aneuploidy as a result of loss or gain of whole 
chromosomes and (ii) unbalanced structural rearrangements which result in the 
loss of, and/or gain of, chromosomal regions (Pino & Chung 2010).  Extensive 
loss of heterozygosity is a hallmark of chromosome instability and is the loss of 
either the maternal or paternal allele (Lengaur et al. 1998).  
 
1.6.1.6 Microsatellite instability (section 1.4.1.1) 
The MSI pathway accounts for 10-15% of sporadic CRC (Aaltonen et al. 1998, 
Salovaara et al. 2000, Samowitz et al. 2001, Hampel et al. 2008, de la Chapelle 
& Hampel 2010) (Figure 1.11).  Defective MMR resulting in MSI may occur at 
any point along the adenoma-carcinoma sequence (Figure 1.6).  MSI is a 
measure of defective MMR.  Normally, the DNA MMR system eliminates 
mismatch of nucleotide insertions and deletions resulting from strand slippage 
occurring during DNA synthesis.  MMR proteins recognise these errors and 
correct them.  The mismatched nucleotide bases are removed leaving a gap in 
the DNA double helix and DNA repair polymerase fills in the gap by adding new 
correct bases.  When defective MMR function is present, the nucleotide repeat 
sequences are at risk of replication errors (Chung & Rustgi 1995). 
 
CRC with MSI have distinct features. They tend to arise in the proximal colon, 
have a poorly differentiated, mucinous or signet ring appearance and have a 
worse prognosis in comparison with CRC without MSI (Boland & Goel 2010).  
To classify whether or not a CRC expresses MSI, a panel of five specific 
microsatellite markers have been recommended for MSI evaluation.  This was 
the outcome of the National Cancer Institute Workshop on MSI held in 
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Bethesda in 1996 to promote consistency amongst studies evaluating MSI 
(Boland et al. 1998).  The five microsatellite markers are three dinucleotide 
repeats (D2S123, D5S346, D17S250) and two mononucleotide repeats (BAT26, 
BAT25).  MSI is deemed to be present if 40% or more of the markers tested are 
unstable (at least 2 of the 5 marker panel) and these CRCs are termed MSI-
high (MSI-H).  The remainder of CRCs with no MSI and are described as 
microsatellite stable (MSS).  The minority of CRCs that display low levels of MSI 
(0-40% unstable markers) are MSI-low (MSI-L) (Boland et al. 1998) (Table 1.3). 
 
Table 1.3 Classification of MSI (de la Chapelle & Hampel 2010) 
MSI classification Proportion of unstable 
markers 
Positive markers in the 
5 marker panel 
MSI high ≥40% ≥2/5 
MSI low ˂40% 1/5 
Microsatellite stable 0% 0/5 
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Figure 1.11 The classification of colorectal cancers (de la Chapelle & Hampel 
2010) 
 
Permission for use obtained from American Society of Clinical Oncology 
 
1.7 WNT signalling pathway 
WNT proteins are a family of 19 glycoproteins that activate WNT signalling 
pathways and play a role in tissue homeostasis, cell growth and differentiation.  
WNT signalling pathways can be grouped as “canonical” and “non-canonical” 
pathways (Katoh & Katoh 2007, Bovolenta et al. 2008).   
 
The canonical pathway is involved in cell fate determination (Katoh & Katoh 
2007).  This results from canonical WNT signals that are transduced to the β-
catenin signalling cascade via binding of WNT proteins to frizzled membranes 
receptors (FZ) and LRP5/LRP6 co-receptors (Bhanot et al. 1996, Katoh & Katoh 
2007). LRP5 and LRP6 are low density lipoprotein related protein receptors that 
assist FZ in binding WNT proteins (Bovolenta et al. 2008).  In the normal cell, 
WNT proteins bind to cell surface (frizzled) receptors which activates the 
Dishevelled (DVL) family proteins.  The DVL family proteins are signal 
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transduction proteins.  The DVL family protein-WNT receptor complex inhibits 
APC.  As discussed above, APC regulates intracellular β-catenin levels by 
promoting its degradation (Munemitsu et al. 1995) (Figure 1.12(A)).  Inhibition of 
APC allows β-catenin to accumulate within the cell and to enter the nucleus, 
where it interacts with the TCF family of transcription factors to promote gene 
transcription and thus modify cell behaviour (Baylin & Ohm 2006) (Figure 1.12 
(B)) (Section 1.6.1.1).  The non-canonical pathway plays a role in the control of 
cell movement and tissue polarity.  The non-canonical WNT signals are also 
transduced through FZ to affect cytoskeletal reorganisation during metastasis 
(Katoh & Katoh 2007). 
 
1.8 Secreted frizzled related proteins 
Secreted frizzled related proteins (SFRPs) are a family of 5 secreted 
glycoproteins structurally related to the cysteine rich domain of FZ of the WNT 
protein (Bovolenta et al. 2008).  They are tumour suppressor genes that play a 
role in controlling cell growth and differentiation (Suzuki et al. 2004).  SFRPs 
mediate cell communication pathways involving the canonical WNT signalling 
pathway (Figure 1.12) through binding both WNT ligands and FZ.  They inhibit 
the WNT signalling pathway by competition with FZ for WNT ligands or by direct 
formation of non-signalling complexes with FZ (Baylin & Ohm 2006, Bovolenta 
et al. 2008).   
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Figure 1.12 WNT signalling pathway and the actions of SFRP (Baylin & Ohm 
2006) 
 
(A) In the normal colon epithelial cell, SFRP competes with WNT proteins for 
binding to the FZ.  When WNT signalling is inactive, the APC complex degrades 
-catenin. 
(B) When SFRP expression is lost, WNT signalling is activated.  This inactivates 
the APC complex, which allows -catenin to accumulate in the cytoplasm and 
nucleus, where it activates gene transcription. 
(C) Persistent activation of the WNT signalling pathway.  These aberrant cells 
are selected because of their survival and proliferative advantages. 
Permission for use obtained from Nature Publishing Group 
 
 
Aberrant WNT pathway signalling is an early event in CRC development (Fodde 
et al. 2001, Suzuki et al. 2004).  In the normal colon epithelial cell, SFRP 
competes with WNT proteins for binding to FZ.  When WNT signalling is 
inactive, the APC complex degrades -catenin (Figure 1.12(A)).  When SFRP 
expression is lost, WNT signalling is activated which inactivates the APC 
complex allowing β-catenin to accumulate in the cytoplasm and then to 
translocate to the nucleus, where it activates transcription (Baylin & Ohm 2006) 
(Figure 1.12(B)). 
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There is relatively little literature on the various members of the SFRP family.  It 
is known that SFRP3 has a different structure to the other four members 
(Hoang et al. 1996, Bovolenta et al. 2008).  SFRP1, 2, 4 and 5 are similar in 
structure and are thought to play a role in CRC development by negatively 
regulating the WNT signalling pathway (Rattner et al. 1997, Suzuki et al. 2004, 
Bovolenta et al. 2008).  Huang et al. (2010) showed that there was no 
difference in the expression of SFRP2 between CRC and normal tissue.  In the 
same study, Huang et al. (2010) also showed that SFRP4 was overexpressed 
in CRC in comparison with normal tissue.  The difference in study results for the 
different members of the SFRP family suggests that each member of the SFRP 
family may work in different ways.  Further studies are needed in order to clarify 
this. 
 
Promoter hypermethylation of SFRP1 and SFRP2 have been observed from the 
earliest stages of CRC development.  However, Sfrp null mice do not show 
increased incidence of spontaneous CRC formation which implies that 
additional genetic alterations may be needed for CRC development (Esteve & 
Bovolenta 2010).  This supports Fearon and Vogelstein’s (1990) hypothesis that 
multiple genetic mutations are required in order for CRC to occur. 
 
Hypermethylation of the genes coding for SFRP1 and SFRP2 may lead to 
suppression of SFRP1 and SFRP2 gene expression respectively, which may 
silence their tumour suppressor actions, leading to constitutively active WNT 
signalling and CRC formation (Suzuki et al. 2004).  This has been reported in 
colorectal adenomas and premalignant ACF, the earliest lesion in the pathway 
from normal colon mucosa to CRC.  The frequency of hypermethylation of 
SFRP1 and SFRP2 is increased from normal mucosa to hyperplastic polyp to 
adenoma (Wang & Tang 2007). 
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1.8.1 SFRP4 
The SFRP4 gene is located on chromosome 7 (NCBI 2013).  SFRP4 plays an 
important role in phosphorus homeostasis by inhibiting the synthesis of vitamin 
D, and thus intestinal absorption of inorganic phosphate (Berndt et al. 2003, 
Berndt & Kumar 2009).  SFRP4 specifically inhibits the activity of 25-
hydroxyvitamin D3 (25(OH)D3) 1,-hydroxylase which thus reduces the 
synthesis of the active form of the vitamin i.e. 1,25-hydroxyvitamin D3 
(1,25(OH)2D3) (Berndt et al. 2003) (Figure 1.13).  The mechanisms by which it 
does this require further research.  SFRP4 also has an important role in soft 
tissue homeostasis because inorganic phosphate is required for basic cell 
processes including nucleic acid synthesis and energy metabolism (Berndt & 
Kumar 2009). 
 
Figure 1.13 Overview of Vitamin D synthesis 
(image adapted from Lamprecht & Lipkin 2003) 
 
The active form of vitamin D, 1,25(OH)2D3 is formed in a multistep pathway:  
Following cutaneous production or intestinal absorption from dietary sources, 
inactive vitamin D3 is transported to the liver, where it undergoes hydroxylation 
to produce 25-hydroxyvitamin D3 (25(OH)D3).  Further hydroxylation by 
25(OH)D3 1,-hydroxylase in the kidneys produces 1,25(OH)2D3 (the active 
form) which is lipophilic and is transported in the blood to target cells bound to 
vitamin D binding protein (DBP).  
Permission for use obtained from Nature Publishing Group 
 
 
SFRP4 inhibits 25(OH)D3 
1,-hydroxylase activity; 
which reduces synthesis of  
1,25(OH)2D3 
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Interestingly, low levels of vitamin D intake, and low vitamin D status (usually 
measured as circulating concentrations of 25-hydroxyvitamin D3), have been 
associated with increased risk of CRC (Table 1.1).  Touvier et al.  (2011) 
performed a systematic review on vitamin D intake, 25-hydroxyvitamin D3 
status, vitamin D receptor polymorphisms and CRC risk.  They found a 
statistically significant inverse association between dietary vitamin D and CRC 
risk for an increase of 100IU/day based on data from 10 independent studies 
(Figure 1.14).  Vitamin D is a major regulator of gene expression and may lower 
CRC risk by reducing cell proliferation and inducing apoptosis in colon cancer 
cells (Lamprecht & Lipkin 2003, Palmer et al. 2003, Larriba et al 2008, Krishnan 
& Feldman 2011).  The active form of vitamin D3 inhibits the accumulation of -
catenin by facilitating its degradation (Kim & Milner 2007). 
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Figure 1.14 Dose-response meta-analysis of dietary and total vitamin D intake, 
circulating 25-hydroxyvitamin D3 and CRC risk (for an increase of 100IU/day) 
(Touvier et al. 2011) 
 
Permission for use obtained from American Association for Cancer Research 
 
Since abnormal expression of SFRP1 and SFRP2 genes is implicated in CRC 
development, abnormal SFRP4 gene expression may also be implicated in 
CRC development (Suzuki et al. 2004, Wang & Tang 2007, Esteve & Bovolenta 
2010, Huang et al. 2010).  Whilst the underlying mechanism for this proposed 
link is uncertain, it is possible that this may involve vitamin D.  Abnormal SFRP4 
gene expression prevents the production of the active form of vitamin D3 and as 
summarised above, low vitamin D intake and low vitamin D status are 
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associated with increased CRC risk (Berndt et al. 2003, Berndt & Kumar 2009, 
Touvier et al. 2011).  Further research is needed to ascertain whether defective 
SFRP4 gene expression causes an increased risk of CRC by preventing the 
production of the active form of vitamin D. 
 
1.9 Epigenetics 
Epigenetic alterations leading to aberrant expression of tumour suppressor 
genes and oncogenes play a role in the multistep pathway that initiates changes 
in the normal cell and causes its progression to CRC (Jones & Laird 1999, 
Jones & Baylin 2002, Herman & Baylin 2003).  Epigenetics is the branch of 
biology which studies the causal interactions between genes and their products, 
which bring the phenotype into being (Waddington 1942) .  Epigenetic patterns 
are biomarkers that can be used to identify pathways to disease, such as CRC; 
and therefore possible treatments (Berg & Soreide 2011).  Epigenetic 
epidemiology can illuminate the mechanisms by which genes are regulated and 
the consequences of changes in epigenetic signals to be identified (Jones & 
Baylin 2002, Ushijima 2005, Baylin & Ohm 2006). 
 
Epigenetic inheritance is defined as cellular information, other than the DNA 
sequence, that is heritable from one cell to its daughter cell during cell division.  
Importantly, epigenetic marks and molecules regulate gene expression 
(Feinberg & Tycho 2004).  There are three ways in which epigenetic marks can 
be inherited viz. DNA methylation, genomic imprinting and histone modification 
(Feinberg & Tycho 2004).   
 
Genomic imprinting refers to those genes that are silent when maternally 
inherited but expressed with paternally inherited, and vice versa (Ubeda 2008). 
Genomic imprinting is an epigenetic process that involves DNA methylation and 
histone modifications which results in monoallelic gene expression without 
altering the genetic sequence (Bartolomei & Ferguson-Smith 2011).   
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Histones are proteins found within cell nuclei that package the DNA into 
nucleosomes.  Histones play a role in gene regulation via a complex post-
translational modification of the N-terminus tails including covalent addition (or 
removal) of acetyl, methyl, phosphate and ubiquitin groups (Lugor 2001, 
Lachner et al. 2003, Wong et al. 2007, Bannister & Kouzarides 2011).  The 
patterns of histone modifications alters their interaction with DNA and nuclear 
proteins which alters cell function e.g. through regulating gene expression and 
through allowing access for the DNA repair machinery.  The balance of the 
opposing actions of histone acetyltransferase (HAT) (which acetylates histones) 
and histone deacetylases (HDAC) (which remove acetyl groups from histones) 
regulates gene expression via chromatin modification (Figure 1.15).  Removal 
of acetyl groups from histones results in chromatin condensation and 
transcriptional inactivation of the associated DNA which can contribute to the 
suppression of tumour suppressor gene expression and enhanced 
tumorigenesis.  Histone acetylation allows transcription by weakening the 
association of the histone with DNA and permits binding by transcription factors 
and other components of the transcription machinery (Fukeda et al. 2006, 
Sharma et al. 2010, Bannister & Kouzarides 2011).   
 
Figure 1.15 Acetylation of histones and gene expression (Gillet et al. 2007) 
 
Histone acetyl transferase (HAT) adds acetyl groups to histones and histone 
deacetylase (HDAC) removes acetyl groups from histones. 
Use permitted under the Creative Commons Attribution Licence 
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1.10 DNA methylation 
DNA methylation is an important epigenetic mark and is the addition of a methyl 
group at the 5’ position on a cytosine residue located 5’ to a guanosine residue 
in a CpG dinucleotide.  Within the human genome, there are CpG islands which 
are CpG rich regions of DNA that are often associated with the transcription 
start sites of genes.  Here CpG islands are normally unmethylated (Bird 1986) 
(Figure 1.16). 
 
The transcription start site of a gene, and therefore the CpG islands, are at the 
proximal promoter region of a gene (Vavouri & Lehner 2012).  CpG islands are 
normally unmethylated in expressed genes (Bird 1985, Wong et al. 2007, 
Illingworth et al. 2010) and hypermethylation of the CpG islands within these 
proximal promoter regions causes transcriptional silencing of genes by 
interfering with transcription initiation (Bird 2002, Wong et al. 2007).   
 
Epigenetic regulation of gene expression is essential for the normal function of 
cells and epigenetic marks and molecules are often abnormal in cancerous cells 
resulting in aberrant gene expression (Jones & Laird 1999, Jones & Baylin 2002, 
Feinberg & Tycho 2004).  Promoter hypermethylation is a mechanism that can 
suppress gene activity (Figure 1.16) and there appears to be a reciprocal 
relationship between the density of methylated cytosine residues in promoter 
regions and the transcriptional activity of the corresponding gene (Wong et al. 
2007).  Therefore abnormal promoter CpG island hypermethylation may result 
in transcriptional silencing (Jones & Baylin 2002) (Figure 1.17).  Such 
epigenetic changes may precede genetic changes in premalignant cells or may 
facilitate the accumulation of further genetic and/or epigenetic changes. 
 
 
The process of methylation involves methionine, the substrate for s–
adenosylmethionine (SAM), which is the methyl group donor for DNA 
methylation.  Dietary folate is converted to the circulatory form 5-
methyltetrahydrofolate (5-methylTHF) and this metabolite plays an important 
role by providing methyl groups for the re-synthesis of methionine from 
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homocysteine.  The enzyme methylenetetrahydrofolate reductase (MTHFR) 
catalyzes the conversion of 5,10-methylenetetrahydrofolate (5,10-methylene 
THF) to 5-methyl THFwhich is the primary methyl donor for the remethylation of 
homocysteine to methionine (Krumen & Fowler 2014, Tang et al. 2014).  
Deficiencies in folate would result in a lack methionine and, therefore of SAM, 
and this can lead to mis-methylation of DNA (Nijhout & Reed 2014).  In addition, 
alcohol appears to antagonise the processes that allow the production of SAM.  
Therefore, the availability of methyl groups for SAM production may be affected 
adversely by high alcohol intake and inadequate intake of dietary folate 
(Krumen & Fowler 2014).  
 
 
1.10.1 DNA methylation and CRC 
The first epigenetic abnormality identified in cancer was the loss of DNA 
methylation (hypomethylation) (Feinberg & Tycho 2004).  DNA hypomethylation 
can lead to oncogene activation and chromosome instability (Ehrlich 2002, 
Gaudet et al. 2003).  Epigenetic abnormalities can also lead to 
hypermethylation which can result in gene silencing and silencing of tumour 
suppressor genes by promoter hypermethylation will increase CRC risk (Jones 
& Baylin 2002). 
 
There are at least four types of genetic abnormalities described in CRC: 
Chromosome instability; MSI; CIMP (DNA hypermethylation of gene promoters 
containing CpG islands); and global DNA hypomethylation (Pancione et al. 
2012) (Figure 1.18). 
 
  
46 
 
Figure 1.16 CpG methylation in normal and cancer cells (Wong et al. 2007) 
 
 
 
(A) (Green panel): In the normal cell, CpG islands remain unmethylated (white 
pins); whereas scattered cytosine residues elsewhere are methylated (red pins).  
In the absence of methylation of this CpG island, DNA in the promoter region is 
accessible to transcription factors and the gene may be expressed. 
(B) (Red panel): A cancer cell shows characteristic CpG island methylation, 
causing silencing of gene expression. 
Permission for use obtained from BMJ Publishing Group 
 
 
  
A 
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Figure 1.17 The relationship between DNA methylation and gene expression 
(Bell et al. 2011) 
 
DNA methylation is negatively correlated with gene expression.  Methylation 
levels are low in the top quartile of highly expressed genes (left); and high in the 
bottom quartile of lowly expressed genes (right); data from 12,670 autosomal 
genes examined in 77 lymphoblastic cell lines.  Gene expression was measured 
using RNA sequencing. 
Use permitted under the Creative Commons Attribution Licence 
 
Figure 1.18 Pathways for CRC development (Wong et al. 2007) 
 
Permission for use obtained from BMJ Publishing Group 
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CpG islands within the promoter regions of genes may be methylated which 
leads to gene silencing (Wong et al. 2007).  CIMP defines a group of cancers 
with a 3-5 fold elevated frequency of aberrant gene methylation.  These cancers 
represent a clinically and aetiologically distinct group of cancers that are 
characterised by epigenetic instability (Issa 2004). 
 
Cancer associated DNA hypomethylation is as prevalent as cancer-linked 
hypermethylation (Ehrlich 2002).  These two types of epigenetic abnormalities 
affect different parts of the DNA sequence.  DNA hypermethylation tends to 
occur within CpG islands within the promoter region of genes whereas 
hypomethylation is observed frequently in the main gene body in cancer (Bird 
2002, Ehrlich 2002, Jones & Baylin 2002, Feinberg & Tycho 2004, Wong et al. 
2007, Pancione 2012).  Global DNA hypomethylation is thought to result in 
chromosomal instability (Ehrlich 2002, Gaudet et al. 2003). 
 
1.10.2 Reversibility of DNA methylation 
Both epigenetic marks and germ-line mutations are heritable from one cell to its 
daughter; however, unlike germ-line mutations, epigenetic processes such as 
DNA methylation are potentially reversible.  It is possible for gene expression to 
be re-established by the demethylation of hypermethylated promoter regions 
offering the potential for therapeutic treatments to be designed to treat cancer or 
environmental adaptation, for example through diet, to reduce the risk of cancer 
development (Yoo & Jones 2006, Huang et al. 2010, Ushijima 2010). 
 
Proof of principle of the reversibility of DNA methylation marks can be seen 
from the action of 5-aza-2-deoxycytidine which inhibits DNA methyltransferase, 
the enzyme responsible for DNA methylation.  5-aza-2-deoxycytidine is a 
powerful inhibitor of DNA methylation because it is incorporated into the nucleic 
acids of dividing cells, where it is able to act as a mechanism-based inhibitor of 
DNA methyltransferases.  Reduction of DNA methyltransferase activity by 5-
aza-2-deoxcytidine reduces colorectal adenoma formation (Robertson & Jones 
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2000, Das & Singal 2004).  However, re-expression of the silenced gene in 
response to 5-aza-2-deoxycytidine is transient and the gene is re-silenced as a 
result of DNA hypermethylation upon removal of 5-aza-2-deoxycytidine (Bender 
et al. 1998, Egger et al. 2007).  Also, the use of DNA methylation inhibitors may 
cause inappropriate activation of genes within normal healthy cells because it is 
not known whether they will be selective for just the hypermethylated cancerous 
cell. 
 
1.11 The Human Epigenome Project 
DNA methylation is an important epigenetic modification that is known to affect 
various cellular processes and is implicated in the development of various 
human diseases.  The Human Epigenome Project aims to identify, catalogue 
and interpret genome-wide DNA methylation patterns of all human genes in all 
major tissues.  Methylation combined with genetics and the environment, plays 
a role in disease aetiology.  Differences in gene methylation gives rise to distinct 
patterns that are believed to be specific for different disease states.  Therefore, 
the degree of DNA methylation is a potential epigenetic marker and this has 
implications in the diagnosis, treatment and prevention of disease (HEP 2013). 
 
1.12 Epigenetic biomarkers of CRC risk 
Hypermethylation of CpG islands is an early event in CRC development and is 
detectable in the macroscopically normal rectal epithelium of individuals who 
are at an increased risk of CRC or who have already developed CRC (Baylin & 
Ohm 2006, Belshaw et al. 2010).  Hypermethylation can be measured with a 
high degree of sensitivity and, therefore, quantification of DNA methylation 
levels may allow the identification of individuals with early CRC or who may go 
onto develop CRC (Jones & Baylin 2002).  The literature describes differential 
levels of DNA methylation in those with and without CRC in DNA derived from a 
variety of biological sources (including rectal tissue and stool samples).  The 
quantification of DNA methylation as an epigenetic biomarker of CRC risk 
shows promise. 
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Adult cancers may derive from stem or early progenitor cells and epigenetic 
regulation of gene expression is essential for the normal functioning of these 
early cells.  Ohm et al. (2007) studied 29 tumour suppressor genes known to be 
frequently hypermethylated in various cancer cell lines and in primary tumour 
samples (evidence from a review of the literature and from their previous 
studies).  The epigenetic status (levels of DNA methylation) in both normal 
embryonic stem (ES) cells and their malignant counterparts (embryonal 
carcinoma (EC) cells) of these 29 selected genes were compared.  The genes 
which exhibited promoter CpG island DNA hypermethylation in adult human 
cancer cells tended to remain unmethylated in both ES and EC cells.  13 of the 
29 genes studied were hypermethylated in one adult colon cancer line (HCT-
116).  None of these were hypermethylated in ES cells and only a small fraction 
was completely methylated in the EC cells (Ohm et al. 2007). 
 
It is suggested that aberrant DNA promoter hypermethylation and subsequent 
gene silencing in adult cancers is a result of transient silencing of important 
growth regulatory genes in stem or progenitor cells.  Ohm et al. (2007) have 
shown that genes with frequently hypermethylated DNA in adult cancers usually 
lack such DNA methylation in normal and neoplastic embryonic cells.  Of the 29 
genes studied by Ohm et al. (2007), SFRP1, SFRP2, SFRP4, DAPK, GATA-4 
and GATA-5 were i) hypermethylated in the adult colon cancer cell line HCT-
116, ii) unmethylated in both embryonic stem cells and embryonal carcinoma 
cells and iii) had notable methylation described in the literature.  Therefore 
SFRP1, SFRP2, SFRP4, DAPK, GATA-4 and GATA-5 could be potential 
epigenetic biomarkers of CRC risk.  This research project focuses on SFRP4 as 
an epigenetic biomarker of CRC.   
 
1.13 Prevention of CRC 
CRC screening programmes are an opportunity to alter the survival of patients 
with precancerous lesions or early CRC (Moiel & Thompson 2011).  The 
common screening tests for CRC and advanced adenoma are faecal occult 
blood testing (FOBT) and visualisation of the bowel.  Several expert groups, 
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including the NHS Bowel Cancer Screening Programme (2013) recommend 
that those who are at average risk should undergo CRC screening from the age 
of 60 years. 
 
CRC screening aims to prevent deaths from CRC by identifying CRC at a pre-
cancerous or early stage to maximise the chance of curative treatment.  In 
addition, it has a role in the secondary prevention of CRC.  There are three 
levels of prevention: (i) Primary prevention employs health promotion activities 
to prevent the occurrence of CRC (for example, promotion of a healthy diet and 
more physically active lifestyle); (ii) secondary prevention promotes screening in 
those at high risk for CRC (for example, regular colonoscopies in those with a 
history of adenomatous polyps or a familial predisposition for CRC); and (iii) 
tertiary prevention is directed towards preventing the reoccurrence of CRC once 
treated or the reduction of CRC related complications (for example, blood 
transfusions for anaemia) (WHO 2010).  
 
Visualisation of the bowel can be by colonoscopy, sigmoidoscopy or computed 
tomography colonography (Figure 1.19).  Colonoscopy and sigmoidoscopy 
have the benefit of allowing simultaneous biopsy of the bowel mucosa and 
removal of premalignant lesions.  Colonoscopy is the most effective means of 
detecting CRC (Strul & Arber 2007). 
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Figure 1.19 Flexible sigmoidoscopy versus colonoscopy 
 
(A) Flexible sigmoidoscopy visualises the left side of the large bowel. 
(B) Colonoscopy visualised the entire bowel. 
 
FOBT is advantageous because it is safe, non-invasive, cheaper than 
endoscopy and can be undertaken at home without the need for a healthcare 
professional.  FOBT relies on the stool sample coming into contact with blood 
shed into the colon from a CRC.  A limitation of FOBT is that any bleeding into 
the colon can result in a positive test and therefore all positive FOBT results 
should be followed up with colonoscopy (Strul & Arber 2007). 
 
DNA-related biomarkers can also be measured in faecal-based assays (Strul & 
Arber 2007).  These assays rely on the mutant DNA, for example K-RAS, APC, 
and P53, present in cancerous lesions in the bowel being shed into the 
gastrointestinal tract and excreted in stool.  It has been claimed that such 
faecal-based DNA assays have a higher sensitivity and no reduction in 
specificity when compared with FOBT (Alquist et al. 2000, Calistri et al. 2003, 
Tagore et al. 2003, Imperiale et al. 2004, Strul & Arber 2007) but, at present, 
there is a lack of robust biomarkers that can predict CRC risk (Song et al. 2004).  
Currently, tissue biopsies are often taken at endoscopy and processed in the 
laboratory to look for features of cancer.  Theoretically, these tissue biopsies 
could also be processed to identify the presence of any DNA-related biomarkers 
of CRC risk but there is insufficient reproducible scientific evidence to support 
A B 
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the regular use of DNA assays for the diagnosis of CRC (Song et al. 2004, Strul 
& Arber 2007). 
 
1.14 The Alimentary Canal 
The alimentary tract runs from the mouth to the anus.  Therefore cells from the 
alimentary tract can be obtained from both the rectum and the mouth, as well as 
other locations such as the oesophagus, stomach and small intestine.  The 
literature describes a phenomenon known as “field changes”.  Field changes 
are defined as abnormalities in epithelial gene expression affecting the mucosal 
surface, rendering it vulnerable to neoplasia (Polley et al. 2006, Belshaw et al. 
2008).  Field abnormalities of the colon may encompass the entire mucosal field, 
and DNA extracted from any point along the colon has been shown to 
demonstrate abnormal gene promoter methylation at sites distant to the area of 
pathology (Polley et al. 2006).  Field changes have only been described within 
the colon for CRC.  There is no literature investigating whether the phenomenon 
of field changes extends to the entire alimentary tract in respect of CRC risk.  If 
such field changes extended throughout the whole GI tract, this would raise the 
possibility that any abnormality in gene promoter methylation in rectal biopsies 
might be reflected in buccal cells obtained from the mouth. 
 
The potential for use of buccal cells as a surrogate for rectal mucosal biopsies 
has not been investigated previously.  Buccal cells are easily obtained by taking 
a swab of the buccal mucosa.  This contrasts with rectal biopsies which require 
the individual to undergo either a rigid or flexible sigmoidoscopy or colonoscopy 
in order to obtain a rectal tissue sample.  It is possible to extract DNA from both 
buccal cells and rectal biopsies and the DNA can then be processed in the 
same way. 
 
1.15 Buccal cells and SFRP4 
There is little literature regarding SFRP4 in buccal cells.  Pannone et al. (2010) 
observed increased levels of SFRP4 methylation in DNA extracted from oral 
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squamous cell carcinoma (OSCC) tissue in comparison with oral mucosal 
biopsies obtained from matched individuals without OSCC. 
 
1.16 Formulation of research hypotheses 
Of the five members of the SFRP family, SFRP3 is unusual because it lacks 
CpG islands in its promoter region.  The other 4 members of the SFRP family 
(SFRP1, SFRP2, SFRP4, SFRP5) do contain CpG islands in their promoter 
regions and are thought to have similar modes of action (Hoang et al. 1996, 
Bovolenta et al. 2008).  There is good evidence that SFRP1 and SFRP2 are 
differentially methylated in those with and without CRC (Wang & Tang 2007). 
As yet there is limited information about the methylation status of SFRP4 in 
respect of CRC and it was hypothesised that SFRP4 would be differentially 
methylated in those at higher CRC risk. 
 
This research project aimed to test the hypothesis that SFRP4 was differentially 
methylated in those at higher and lower risk for CRC.  For this purpose, the 
higher risk group were patients with a history of adenomatous polyps or of UC, 
and the lower risk group were healthy volunteers.  A difference in SFRP4 
methylation between those at a higher and lower risk for CRC seemed plausible 
since SFRP1 and SFRP2 methylation levels increased with increasing CRC risk 
from normal volunteers to adenomatous polyp patients to CRC patients (Wang 
& Tang 2007). 
 
The use of buccal DNA as a possible surrogate for DNA from mucosal rectal 
biopsies is of interest because it may provide a more acceptable (to patients) 
method of collecting DNA for CRC screening programmes and for the 
investigation of modifiers of CRC risk.  If the “field effect” phenomenon 
(whereby an abnormality in epithelial gene expression renders the whole 
mucosa vulnerable to CRC development) (Polley et al. 2006), extended 
throughout the alimentary track, such vulnerability might be detectable in the 
mouth as well as in the colorectum. 
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If there is a difference in SFRP4 methylation between those at a higher and 
lower CRC risk, the reversibility of SFRP4 hypermethylation may provide a 
useful biomarker to assess the effect of potential CRC risk modifiers, e.g. 
resistant starch and polydextrose. 
 
1.17 Project hypotheses, aims and objectives 
Hypothesis 1: 
The SFRP4 promoter is differentially methylated in rectal DNA in those at a 
lower and higher risk for CRC. 
Hypothesis 2:  
Buccal cells will show the same patterns of SFRP4 promoter methylation as 
rectal biopsies in subjects at a lower and higher risk of CRC and will act as a 
surrogate tissue for CRC biomarker assay. 
Hypothesis 3:  
SFRP4 promoter hypermethylation in rectal biopsies is reversible by dietary 
supplements of resistant starch and polydextrose (both alone and in 
combination). 
 
Aims and Objectives 1:  
To test Hypothesis 1 by using pyrosequencing to quantify SFRP4 promoter 
methylation in rectal DNA obtained from volunteers at a lower (normal healthy 
volunteers) and higher (patients with a history of adenomatous polyps or a 
history of non-active UC) risk for CRC using rectal mucosal biopsies obtained in 
the BORICC Study (Mathers et al. 2010) and the Dietary Intervention, Stem 
Cells and Colorectal Cancer (DISC) Study (2011). 
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Aims and Objectives 2:  
To test Hypothesis 2 by using pyrosequencing to quantify SFRP4 promoter 
methylation in matched samples of rectal DNA and buccal DNA from volunteers 
at a lower (normal healthy volunteers) and higher (patients with a history of 
adenomatous polyps) risk for CRC using rectal mucosal biopsies and buccal 
cells obtained in the BORICC Study (Mathers et al. 2010).   
To investigate possible correlations between SFRP4 promoter methylation 
levels in matched samples of rectal DNA and buccal DNA. 
Aims and Objectives 3:  
To test Hypothesis 3 by using pyrosequencing to quantify SFRP4 promoter 
methylation levels in rectal DNA obtained from healthy volunteers in the DISC 
Study (2011) before and after a randomised controlled trial of effects of dietary 
supplementation with resistant starch and polydextrose in a 22 factorial design. 
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2 General methods 
 
2.1 Introduction 
Mucosal rectal biopsies and buccal cell samples collected in previously 
conducted, or ongoing, studies at Newcastle University were used in this 
research project.  These biological samples have been collected from healthy 
volunteers in the BORICC1 Study (Mathers et al. 2010) (relatively lower CRC 
risk) and from volunteers with adenomatous polyps in the BORICC2 Study 
(Mathers et al. 2010) (relatively higher risk of CRC).  The DISC Study (2011) 
provided equivalent biological samples from healthy volunteers, from patients 
with adenomatous polyps and also from patients with inactive UC (both 
relatively higher CRC risk).  The healthy volunteers in the DISC study (2011) 
participated in a dietary intervention study, providing two sets of biological 
samples; one before and one after the dietary intervention.  Table 2.1 
summarises the participant groups within this research project. 
 
2.2 Ethical approval 
The biological samples used in this research project are taken from the biobank 
established by the BORICC Studies (Mathers et al. 2010) and the DISC study 
(2011).  Ethical approval was gained from the Northumberland Local Research 
Ethics Committee for both studies (BORICC Study: Project reference 
04/Q0902/6/, 2004; DISC Study: Project reference 09/H0907/77). 
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Table 2.1 Overview of studies and of participant groups 
Study Participant group Population represented 
BORICC1 Study Healthy volunteers Relatively lower risk of CRC¹ 
BORICC2 Study Patients with a history of 
adenomatous polyps 
Relatively higher risk of CRC² 
DISC Study Healthy volunteers Relatively lower risk of CRC¹ ³ 
DISC Study Patients with a history of 
adenomatous polyps 
Relatively higher risk of CRC² 
DISC Study Patients with inactive UC Relatively higher risk of CRC 
¹These two groups are thought to be comparable 
²These two groups are thought to be comparable 
³This group also participated in a dietary intervention study 
 
 
2.3 The Biomarkers of Risk in Colorectal Cancer (BORICC) Study 
The BORICC study (Mathers et al. 2010) was designed to identify and to 
validate novel biomarkers of CRC risk and to investigate their relationships with 
dietary intake and with nutritional status.  The biological samples (rectal 
mucosal biopsies, buccal cell swabs, urine, stool and blood) were collected in 
2004/05.  In the BORICC1 Study (Mathers et al. 2010), the biological samples 
were collected from healthy volunteers whereas in the BORICC2 Study 
(Mathers et al. 2010), the biological samples were collected from participants 
with a current or recent history of colorectal adenomatous polyps.  One set of 
biological samples was obtained from each volunteer and, in both studies, the 
rectal mucosal biopsies were collected from the macroscopically normal bowel. 
 
2.4 The Dietary Intervention, Stem cells and Colorectal cancer (DISC) Study 
The DISC Study (2011) is a dietary intervention study in which healthy 
volunteers were randomised to two potential chemoprevention agents, resistant 
starch and polydextrose, in a 22 factorial design.  Two sets of biological 
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samples were collected from each volunteer; one before the intervention 
(baseline), and one after.  A single set of biological samples was also collected 
from patients with a current or recent history of colorectal adenomatous polyps 
and patients with non-active UC.   
 
2.5 Participant recruitment 
All volunteers for both the BORICC Study (Mathers et al. 2010) and the DISC 
Study (2011) were recruited via endoscopy lists within Northumbria Healthcare 
NHS Foundation Trust.  Patient details were reviewed at least 5 days before the 
scheduled endoscopy appointment and those without any exclusion criteria 
(section 3.2.1) were posted information about the study prior to their attendance 
for endoscopy of the large bowel (flexible sigmoidoscopy or colonoscopy) (see 
appendix) and inviting them to participate.  For those indicating willingness to 
volunteer, at their scheduled endoscopy appointment, the information about the 
study was reiterated, potential recruits were offered the opportunity to ask 
questions and written consent was obtained.   
 
2.6 Biological samples 
An extensive panel of biological samples was collected from each participant in 
both the BORICC Study (Mathers et al. 2010) and the DISC Study (2011) for 
immediate use in each study and to create a “biobank” for future studies.  The 
biological samples of interest to this research project are the rectal mucosal 
biopsies and buccal cell samples. 
 
2.7 Demographic data 
Age, sex, smoking status and anthropometric measurements were also 
obtained for each study participant. In both studies, the anthropometric 
measurements included height and weight (for calculation of BMI) and waist 
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and hip circumferences.  In the DISC Study (2011) only, upper thigh 
circumference was also measured. 
 
2.8 Data Recording  
Data from laboratory analyses were collected and transferred to a Microsoft 
excel 2010 spreadsheet for storage.  To ensure the correct data had been 
transferred against the correct sample identifier, the data were checked on a 
second occasion and then on a third occasion if, upon statistical analysis, 
Minitab (version 16) statistical software had identified particular data-points as 
being unexpected. 
 
2.9 Statistical analyses 
All statistical analyses were performed using Minitab (version 16) statistical 
software. 
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3 SFRP4 promoter methylation in rectal DNA: Lower 
Vs higher CRC risk 
 
3.1 Introduction 
This chapter aims to investigate whether the SFRP4 promoter is differentially 
methylated in rectal DNA in those at a higher and lower risk for CRC. 
 
3.2 Methods 
Participants were recruited to the BORICC Studies (Mathers et al. 2010) and 
the DISC Study (2011) from endoscopy lists within Northumbria Healthcare 
NHS Foundation Trust as outlined in section 2.5.  Those without any exclusion 
criteria were invited to participate. 
 
3.2.1 Exclusion criteria 
3.2.1.1 The BORICC Study and the DISC Study participant exclusion criteria 
Table 3.1 lists the exclusion criteria for volunteers who wanted to participate in 
the BORICC Study (Mathers et al. 2010) and DISC Study (2011). 
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Table 3.1 Exclusion criteria for healthy volunteers participating in the BORICC 
Study and the DISC Study 
General exclusion criteria 
Age <16 or >85 years 
Familial adenomatous polyposis (FAP)  
Hereditary non-polyposis colorectal cancer (HNPCC) 
Known CRC 
Previous colorectal surgery 
Pregnancy 
Chemotherapy within the past 6 months 
Aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs)  
Immunosuppressive medication/therapy 
Active colonic inflammation at endoscopy 
Incomplete left sided examination 
CRC found at endoscopy or on histology 
Iatrogenic perforation at endoscopy 
 
 
There were two main types of exclusion criteria: (1) Exclusion criteria for 
practicality reasons (e.g. age, pregnancy); and (2) exclusion of participants who 
may have an altered risk of CRC (e.g. those with a personal or family history of 
CRC and those taking non-steroidal anti-inflammatory drugs (NSAIDs).  A 
normal endoscopic examination to the splenic flexure (left-sided examination) 
using a flexible sigmoidoscope or colonoscope was required to deem a 
participant at a lower risk of CRC (providing other exclusion criteria did not 
exist).  This is also provided the examination of the rectum and sigmoid colon 
by flexible sigmoidoscopy is normal and the patient has no iron deficiency 
anaemia or abdominal mass (Thompson et al. 2008).  Colorectal specialists 
triage patients referred for large bowel endoscopy to flexible sigmoidoscopy or 
colonoscopy based upon their symptoms and signs. Therefore, in this study, it 
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is assumed the appropriate endoscopy test has been performed and that those 
who have a normal flexible sigmoidoscopy are low risk for CRC. 
 
Individuals with FAP and HNPCC are at a higher risk of CRC (Burt 2000, 
Fearnhead et al. 2002, Lynch & de la Chapelle 2003)  It is possible that some 
individuals may not be aware of a family history of FAP or HNPCC and 
therefore in screening potential study participants, the Amsterdam II criteria 3-2-
1 rule was used (Vasen et al. 1991) (Table 3.2).  Any potential volunteers with 
any of the Amsterdam II criteria were excluded from the study. 
 
The CAPP2 Study demonstrated that 600mg aspirin given daily for 2 years 
significantly reduces the risk of CRC in patients with HNPCC (Mathers et al. 
2012).  Therefore, aspirin, and other NSAIDs may protect against CRC and 
regular use of these drugs by potential participants resulted in their exclusion 
from the study.  An individual’s immune response is suppressed by 
chemotherapy and other immunosuppressive therapies leading to an increased 
risk of CRC (CRUK 2013).  Therefore potential participants undergoing these 
treatments were excluded.  
 
Table 3.2 Clinical criteria for identifying persons at risk of HNPCC. The 
Amsterdam II criteria: The 3-2-1 rule (Vasen et al. 1991) 
Amsterdam II criteria 
At least 3 relatives with HNPCC associated cancer  
(colorectal, endometrium, ovarian, gastric, small intestine, hepatobiliary, urinary, 
brain, skin) 
2 generations affected by HNPCC associated cancer 
1 HNPCC cancer diagnosed before the age of 50 years   
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3.2.1.2 Exclusion criteria for those with ulcerative colitis (UC) 
The DISC Study (2011) recruited patients with UC as a higher CRC risk group.  
Individuals with a simple clinical colitis activity index score greater than 5 were 
excluded from the study (Table 3.3).  This validated tool is able to predict active 
colitis with 92% sensitivity and 91% specificity (when the score is 5 and above) 
(Walmsley et al. 1998).  Active colitis was excluded in this study as the 
interpretation of samples and the data generated from such participants may be 
difficult.  Saito et al. (2011) found there was increased DNA methylation in 
active inflamed colon mucosa compared with quiescent mucosa in UC patients 
when they investigated 6 genes in 28 surgically resected UC patients.      
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Table 3.3 Clinical scoring system for simple clinical colitis activity index 
(Walmsley et al. 1998) 
Symptom Score 
Bowel frequency (day) 
- 1-3 
- 4-6 
- 7-9 
- >9 
Bowel frequency (night) 
- 1-3 
- 4-6 
Urgency of defecation 
- Hurry 
- Immediately 
- Incontinence 
Blood in stool 
- Trace 
- Occasionally frank 
- Usually frank 
General well being 
- Very well 
- Slightly below par 
- Poor 
- Very poor 
- Terrible 
Extracolonic features 
 
- 0 
- 1 
- 2 
- 3 
 
- 1 
- 2 
 
- 1 
- 2 
- 2 
 
- 1 
- 2 
- 3 
 
- 0 
- 1 
- 2 
- 3 
- 4 
1 per manifestation 
 
 
3.2.2 Biological samples 
Rectal mucosal samples were collected by biopsy from each participant in both 
the BORICC Study (Mathers et al. 2010) and the DISC Study (2011) for 
immediate use in each study and to create a “biobank” for future studies.  Blood 
samples collected by venepuncture were also taken from the participants in the 
BORICC1 Study (Mathers et al. 2010).  Samples were analysed by the 
biochemistry laboratory at the Royal Victoria Infirmary, Newcastle to quantify 
the plasma concentration of 25(OH)D3. 
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3.2.2.1 Rectal biopsies 
Each participant in both the BORICC Study (Mathers et al. 2010) and the DISC 
study (2011) donated multiple colorectal mucosal samples, which were taken by 
“pinch” biopsy from the rectum 10cm from the anal verge at the time of 
endoscopic examination using a flexible sigmoidoscopy or colonoscopy.  2.3mm 
spiked flexible endoscopy forceps were used to obtain the biopsy (Biobite 
forceps, Medical Innovations, Essex, UK).  The biopsy samples used in this 
research project had been immediately snap-frozen in liquid nitrogen and, upon 
return to the laboratory, transferred to a −80°C freezer. 
 
3.2.3 Laboratory methods 
The following laboratory methods were used in this research project:  DNA 
extraction, bisulphite modification, polymerase chain reaction (PCR), gel 
electrophoresis and pyrosequencing.  The final methods chosen for the project 
were based upon:  Available resources, cost effectiveness, experience and 
personal preference within the laboratory of the research group, time 
constraints and the production of high quality, reproducible results. 
 
3.2.3.1 DNA extraction: Mucosal rectal biopsies 
Mucosal rectal biopsies were removed from -80C storage and thawed at room 
temperature.  500μl of SET-sodium dodecyl sulphate (SET-SDS) made from 
25μl 50mM Tris, 12.5mM ethylenediaminetetracetic acid (EDTA) and 0.5% 
sodium dodecyl sulphate (SDS), and 16μl proteinase K (Fermantas) was used 
to homogenize the rectal biopsy at 55C, shaking at 900rpm for 8 hours.  The 
homogenized solution was centrifuged at 13,000rpm for 3 minutes at room 
temperature and 600µl 24:1 chloroform:isoamyl alcohol (Fermentas) was added 
to precipitate the DNA.  2ml heavy phase lock gel (5-Prime) centrifuged at 
10,000rpm for 5 minutes separated the DNA from interphase proteins.  The 
DNA was incubated with 16µl RNAase/T1 (Fermentas) for 37°C for 30 minutes, 
and 42µl 3M sodium acetate, 400µl isopropanolol and 2.5µl (20mg/ml solution) 
glycogen (Fermentas) was added.  The DNA pellet after centrifugation was 
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washed twice with 500μl 70% ethanol and centrifuged at 13,000rpm for 2 
minutes at room temperature.  The DNA pellet was air dried for 1 hour and re-
suspended in 50μl 2mM Tris.  The DNA purity and concentration were then 
measured using a spectrophotometer (NanoDrop 1000). 
 
3.2.3.2 Bisulphite modification 
This was performed using EZ DNA Methylation GoldTM Kit (Zymo research).  A 
20μl solution of DNA in water [(500 ÷ DNA concentration as determined by the 
NanoDrop 1000 spectrophotometer) microlitres DNA and volume of water to 
make a 20μl solution] was prepared and added to 130μl CT conversion reagent 
(900μl water, 300μl M dilution buffer and 50μl M dissolving buffer).  This was 
placed in a thermal cycler and programmed to run at 98C for 10 minutes; 64C 
for 2.5 hours; and then to hold at 4C.  Six hundred microlitres M binding buffer 
was added to a Zymo-SpinTM IC Column, to which the DNA sample was added.  
This was then centrifuged at full speed for 30 seconds and the flow-through 
discarded. One hundred microlitres of M wash buffer was then added to the 
column and the mix centrifuged at full speed for 30 seconds. Two hundred 
microlitres M desulphonation buffer was then added to the column and the mix 
left to incubate at room temperature for 20 minutes.  After incubation, the mix 
was centrifuged at full speed for 30 seconds.  Two hundred microlitres of M 
wash buffer was added to the column and the mix centrifuged at full speed for 
30 seconds.  A further 200μl M wash buffer was added to the column, and 
centrifuged at full speed for an additional 30 seconds.  The column was then 
placed into a microcentrifuge tube and 10μl M elution buffer added to the 
column.  The mix within the column and the microcentrifuge tube it was in was 
then centrifuged at full speed for 30 seconds to elute the DNA. 
 
3.2.3.3 SFRP4 assay design 
Genomatix software was used to identify SFRP4 promoter sequences.  The 
sequences generated with a cytosine and guanine content greater than 50% 
within a 200 base pair sequence with a cytosine-guanine ratio greater than 0.6 
were selected.  The selected CpG rich SFRP4 promoter sequences were 
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bisulphite modified, and inputted into Pyrosequencing Assay Design software to 
allow SFRP4 primers to be generated.  The set of SFRP4 primers with the 
highest suitability score (as determined by the Pyrosequencing Assay Design 
software) was selected for use in this research project.   
 
The SFRP4 primers chosen for this research project are located within 411 to 
657 base pairs downstream from the transcription start site (Genomatix) (Figure 
3.1-Figure 3.3).  This primer which is located downstream of the transcription 
start site was chosen in preference of other primers, some of which were 
upstream of the transcription start site, because it had a high cytosine-guanine 
ratio, scored a high suitability score on the Pyrosequencing Assay Design 
software and was the only primer that had a correlation coefficient greater than 
0.95 at each CpG site in the valiation process (section 3.2.3.4).   
 
There is limited literature on SFRP4 methylation and its association with CRC 
risk.  Only 2 studies have quanitified SFRP4 methylation in rectal mucosal 
biopsies, (Belshaw et al. 2008, Qi et al. 2006) both of which used different 
methods of SFRP4 methylation quantification from that used in this research 
project.  Therefore, there are no published data that are directly comparable 
with the data obtained in this research project.  The lack of published literature 
regarding SFRP4 gene expression and its possible involvement in the pathways 
that lead to CRC limits the interpretation of data on SFRP4 methylation at 
whichever DNA site it is measured. 
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Figure 3.1SFRP4 DNA sequence 411 to 657 base pairs downstream from the 
transcription start site (Genomatix) 
CTGTGCCTGTGGCTGCACCTGGCGCTGGGCGTGCGCGGCGCGCCCTGCGAGGCGGTGC
GCATCCCTATGTGCCGGCACATGCCCTGGAACATCACGCGGATGCCCAACCACCTGCACC
ACAGCACGCAGGAGAACGCCATCCTGGCCATCGAGCAGTACGAGGAGCTGGTGGACGTG
AACTGCAGCGCCGTGCTGCGCTTCTTCCTCTGTGCCATGTACGCGCCCATTTGCACCCTG
GAGTTCCTGC 
CpG sites of interest 
 
Figure 3.2 SFRP4 DNA sequence 411 to 657 base pairs downstream from the 
transcription start site following predicted bisulphite modification and showing 
locations of primer sequences generated by Pyrosequencing Assay Design 
Software 
TTGTGTTTGTGGTTGTATTTGGC/TGTTGGGC/TGTGC/TGC/TGGC/TGC/TGTTTTGC/TGAG
GC/TGGTGC/TGTATTTTTATGTGTC/TGGTATATGTTTTGGAATATTAC/TGC/TGGATGTTTA
ATTATTTGTATTATAGTAC/TGTAGGAGAAC/TGTTATTTTGGTTATC/TGAGTAGTAC/TGAGG
AGTTGGTGGAC/TGTGAATTGTAGC/TGTC/TGTGTTGC/TGTTTTTTTTTTTGTGTTATGTAC/T
GC/TGTTTATTTGTATTTTGGAGTTTTTGT 
Forward primer: TTGTGTTTGTGGTTGTAT 
Reverse primer: ACAAAAACTCCAAAATAC 
Sequence primer:TGTTTAATTATTTGTATTATAG 
CpG sites of interest 
 
Figure 3.3 Location of CpG sites in SFRP4 DNA sequence 532 to 584 base 
pairs downstream from the transcription start site  
CGCAGGAGAACGCCATCCTGGCCATCGAGCAGTACGAGGAGCTGGTGGACGT 
 
 
  
CpG site 5 CpG site 3 CpG site 4 CpG site 1 CpG site 2 
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Nuclease-free water was added to the designed forward, reverse and sequence 
SFRP4 primers (MWQ Eurofins) to make a concentration of 10pmol/µl.  PCR 
(section 3.2.3.5) using a temperature gradient was used to establish the optimal 
annealing temperature which was 47C.  The PCR product size and purity were 
assessed using agarose gel electrophoresis (section 3.2.3.6). 
 
3.2.3.4 Assay validation 
PCR (section 3.2.3.5) and pyrosequencing (section 3.2.3.7) were used to 
validate the SFRP4 gene assay.  For pyrosequencing, the reverse primer 
(MWQ Eurofins) was biotin-labelled at the 5’ end.  Epitect Control DNA (Qiagen) 
allowed PCR and pyrosequencing with known percentages of methylation using 
0% methylated and 100% methylated DNA to make up the different methylation 
levels (0%, 25%, 50%, 75%, 100%).  This was performed using pre- and post-
PCR dilutions and the observed methylation levels were then correlated with the 
known methylation levels and plotted using Microsoft Excel 2010.  The 
correlation coefficient was determined and if this was greater than 0.95 at each 
CpG site, the assay was validated. 
 
3.2.3.5 Polymerase Chain Reaction 
Two microlitres of bisulphite modified DNA was added to a mix of 12.5μl 
HotStarTaq DNA polymerase (Qiagen), 1μl 10pmol/μl forward SFRP4 primer 
(MWQ Eurofins), 1μl 10pmol/μl biotin labelled reverse SFRP4 primer (MWQ 
Eurofins)  and 9.5μl water and then placed in a thermal cycler and following an 
initiation step of 95C for 15 minutes, the thermal cycler was programmed to 
perform 50 cycles of: (i) denaturation step 95C for 30 seconds; (ii) annealing 
step 47C for 90 seconds; (iii) elongation step 72C for 45 seconds.  PCR was 
completed with the final elongation step (72C for 5 minutes). 
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3.2.3.6 Agarose Gel Electophoresis 
Agarose gel electrophoresis was used to determine whether PCR has 
generated the anticipated DNA fragment.  The agarose gel was made using 
0.5g 1% agarose powder in 60ml of 1TBE (Tris, boric acid and EDTA) buffer.  
3μl SafeView nucleic acid stain (NBS Biological) was added before the gel was 
left to set.  Once the agarose gel had set, 1TBE buffer was added and 5μl 
PCR product was mixed with 2μl bromophenol blue loading buffer (Fermentas) 
and placed into the agarose gel wells.  Gel electrophoresis was run at 70V for 
40 minutes before immediate viewing under ultraviolet (UV) light to compare the 
size of the PCR product against a DNA ladder (Fermentas). 
 
3.2.3.7 Quantification of DNA Methylation: Pyrosequencing 
DNA methylation was quantified by Pyrosequencing using a PyroMark MDTM 
(biotage) platform; using PyroMark Gold Q96 reagents (Qiagen).  Ten 
microlitres of PCR product was added to the PCR mix (2μl streptavidin beads, 
38μl binding buffer, 30μl nuclease free water) and shaken at 15rpm for 10 
minutes.  The plate containing the PCR mix was loaded onto the vacuum prep 
worktable, the vacuum turned on, and the vacuum prep tool used to capture the 
streptavidin beads.  The vacuum prep tool was then transferred to a trough 
containing 70% ethanol (wash step) for 5 seconds, a trough containing 0.2M 
sodium hydroxide solution (denaturation step) for 5 seconds, and a trough 
containing wash buffer (10mM Tris acetate buffer (Qiagen)) (wash step) for 5 
seconds on the vacuum prep worktable.  The vacuum was turned off and the 
streptavidin beads transferred into the pyrosequencing plate containing the 
pyrosequencing mix (11.5μl annealing buffer (Qiagen), 0.5μl SFRP4 
sequencing primer (MWQ Eurofins)).  The pyrosequencing plate was heated at 
80°C for 2 minutes.  The pyrosequencing plate and cartridge containing the 
enzyme, substrate and nucleotides (Qiagen) (volumes dictated by the PyroMark 
CpG Software 1.0.11) were loaded into the PyroMark MD Genetic Analysis 
System and analysed to quantify DNA methylation. 
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3.2.4 Reproducibility of results 
All analyses of SFRP4 DNA promoter methylation levels were run in duplicate.  
The results for a given sample were deemed reproducible if the values for the 
repeat samples were within 5% of each other. If the initial results were not 
reproducible, the pyrosequencing assay was repeated.  If after further 
pyrosequencing runs, the values for SFRP4 methylation were not reproducible, 
the values for this sample were excluded from analysis.  When comparing study 
participant groups, mean values for each sample were used for statistical 
analysis. 
 
3.2.5 Comparability of BORICC and DISC data 
The analysis of samples for the BORICC Study was undertaken first followed by 
analysis of samples from the DISC Study. Therefore there is a hypothetical risk 
of systematic bias associated with the temporal difference in analysing samples 
from the 2 studies.  To investigate the possibility of systematic bias between 
analyses of samples from the 2 studies, samples of BORICC and DISC DNA 
were selected and SFRP4 methylation was quantified for these selected 
samples under exactly the same conditions. The samples were run 
simultaneously on the same plates using the same reagents in the same 
machines under the same conditions (Figure 3.4).  Each DNA sample was 
analysed in duplicate within the same plate and to further assess reproducibility, 
the experiment was repeated using the same DNA samples and an identical 
arrangement on the pyrosequencer plate.  This quantified SFRP4 promoter 
methylation 4 more times for each of the selected DNA samples.   
 
The DNA chosen for this quality control assessment study were obtained from 4 
groups 1) baseline “before intervention” samples from healthy participants in the 
DISC Study, 2) BORICC1 participants, 3) polyp patients from the DISC Study 
and 4) BORICC2 participants.  DNA samples that had the lowest and highest 
SFRP4 promoter methylation levels when analysed originally and a random 
selection of samples with intermediary methylation levels were selected for 
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each of the study groups.  The samples selected in each group were matched 
for participant characteristics. 
 
Figure 3.4 Assessment of the reproducibility of SFRP4 methylation in rectal 
DNA obtained from the BORICC Study and the DISC Study 
Diagram representing the set-up of the pyrosequencing plate.  Two identical  
plates were analysed  on two separate occasions. 
B B 0 0 100 100 222 222 214 214 165 165 
126 126 260 260 004 004 067 067 207 207 108 108 
046 046 101 101 039 039 100 100 096 096 083 083 
041 041 074 074 057 057 044 044 095 095 11 11 
79 79 17 17 01 01 12 12 43 43 62 62 
89 89 43 43 06 06 05 05 07 07 11 11 
16 16 14 14 12 12 24 24     
 
BORICC 1  BORICC 2  DISC NORMAL   DISC POLYP 
B = blank/control 0 = 0% control  100 = 100% control  
The numbers in each box represent the ID of the study participant who donated 
the colorectal biopsy from which the DNA sample was isolated.  
    
3.2.6 Measurement of serum vitamin D concentration 
Serum vitamin D concentration measurements were obtained in the BORICC1 
Study only.  Circulating concentrations of vitamin D were measured as serum 
25(OH)D3.  This was determined using a commercial enzyme immunoassay kit 
(Immunodiagnostics Systems Limited, Tyne & Wear, UK). 
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3.2.7 Statistical analyses 
3.2.7.1 Comparison of characteristics of BORICC1 and BORICC2 participants 
Characteristics of the participants of the BORICC1 Study and BORICC2 Study 
were compared using: Unpaired t-test to identify any significant differences in 
the ages and BMI of the two groups; 2 test to identify any significant difference 
in the smoking status of the two groups; and Fisher’s exact test to identify any 
significant difference in the male:female ratio between the two study groups. 
p<0.05 was considered to be significant. 
 
3.2.7.2 Comparison of participant characteristics in the DISC Study 
Characteristics of the participants from the 3 risk groups (healthy volunteers, 
patients with adenomatous polyp(s) and patients with UC) were compared 
using:  Analysis of variance (ANOVA) in a general linear model to identify any 
significant differences in the ages and BMI between the groups; 2 test to 
identify any significant difference in the smoking status and the male:female 
ratio between the different groups. p<0.05 was considered to be significant. 
 
3.2.7.3 Comparison of characteristics of the BORICC Study and the DISC 
Study participants 
Characteristics of the participants in the BORICC Study and the DISC Study 
were compared using: Unpaired t-test to identify any significant differences in 
the ages and BMI between the two groups; 2 test to identify any significant 
difference in the smoking status between the two groups; and Fisher’s exact 
test to identify any significant difference in the male:female ratio between the 
two study groups.  In each case, the characteristics of the participants of the 
BORICC1 Study were compared with the healthy volunteers from the DISC 
Study and the characteristics of the participants of the BORICC2 Study were 
compared with the patients with adenomatous polyps in the DISC Study.  
p<0.05 was considered to be significant. 
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3.2.7.4 SFRP4 methylation in rectal DNA: Comparison between low and high 
CRC risk groups 
Differences between the levels of SFRP4 promoter DNA methylation between 
volunteers of low and higher CRC risk were analysed using ANOVA in a 
general linear model.  Age, sex, smoking status and BMI were used as 
covariates.  Results were expressed as least square means  standard error of 
the mean (SEM).  p<0.05 was considered to be significant. 
 
3.2.7.5 Comparability of the BORICC Study and DISC Study data 
Further data generated to assess the comparability of the BORICC Study and 
DISC Study data were compared and analysed using ANOVA in a general 
linear model.  Results were expressed as least square means  SEM.  p<0.05 
was considered to be significant. 
 
3.2.7.6 Correlation between SFRP4 methylation and vitamin D concentration 
Regression analysis was used to investigate associations between SFRP4 
promoter methylation in rectal DNA and circulating concentrations of vitamin D 
measured as 1,25(OH)2D3 in serum.  This analysis was performed for the 
BORICC 1 Study data only because this was the only study in which serum 
vitamin D concentrations were measured. p<0.05 was considered to represent 
a significant correlation. 
 
3.2.7.7 Sensitivity and specificity of SFRP4 as a biomarker of CRC risk 
Minitab (version 16) statistical software was used to perform binary logistic 
regression to assess potential variation in SFRP4 promoter methylation levels 
between those at lower and higher risk for CRC.  This allowed the sensitivity 
and specificity of SFRP4 promoter methylation to identify those at a higher or 
lower risk of CRC to be calculated.  Receiver operating curves (ROCs) were 
plotted to represent the results of the binary logistic regression and the area 
under the curve (AUC) represented how well SFRP4 methylation can 
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distinguish between those at a higher and lower risk for CRC and therefore its 
potential to be used as a diagnostic test.   Table 3.4 shows how the AUC is 
used to determine the accuracy of the diagnostic test.   
 
Table 3.4 How the area under the receiver operating curve is used to determine 
the accuracy of a diagnostic test (Hanley & McNeil 1982) 
Area under curve (AUC) Accuracy of diagnostic test 
0.90-1 Excellent 
0.80-0.89 Good 
0.70-0.79 Fair 
0.60-0.69 Poor 
<0.60 Fail 
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3.3 Results 
3.3.1 Patient demographics 
3.3.1.1 Biomarkers of Risk in Colon Cancer (BORICC) Study: Rectal Biopsies 
SFRP4 methylation was quantified in DNA extracted from biopsies of 
macroscopically normal rectal mucosa obtained from 253 healthy individuals 
(relatively lower CRC risk) who were participants in the BORICC1 Study. 
SFRP4 methylation was also quantified in DNA extracted from biopsies from a 
further 96 patients with adenomatous polyps (relatively higher CRC risk) who 
were participants in the BORICC2 Study.  DNA was available from 268 biopsies 
of macroscopically normal rectal mucosa from healthy individuals and 101 
biopsies of macroscopically normal rectal mucosa from patients with 
adenomatous polyps. However 15 normal samples and 5 polyp samples were 
excluded from this analysis because of an inability to obtain reproducible values 
for SFRP4 methylation.  The demographics of study participants are shown in 
Table 3.5.  The BORICC2 Study (higher risk group) participants were 
significantly (p<0.001, unpaired t-test) older than the BORICC1 Study 
participants.  BORICC2 patients were older as would be expected by the 
increasing incidence of polyps with age (Grahn & Varma 2008).  There were no 
significant differences in BMI (p=0.3010, unpaired t-test) or smoking status 
(p=0.99, 2 test) between the participants of the BORICC1 Study and the 
BORICC2 Study.  The male:female ratio was significantly different (p<0.001, 
Fisher’s exact test) between the 2 groups (see Table 3.5). The rate of CRC is 
similar in males and females up to the age of 50 years, but after this age, CRC 
becomes more common in males (CRUK 2013).  The difference in the 
male:female ratio between the participants in the BORICC1 Study and in the 
BORICC2 Study was addressed by including sex as a covariate in the analyses. 
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Table 3.5 Demographics of participants in the BORICC1 and BORICC2 Studies 
 Rectal biopsies 
 Normal participants Patients with polyps 
Number of participants  
(male:female) 
253 
(115:138) 
(45%:55%) 
96 
(63:33) 
(66%:34%) 
Mean age 
(standard deviation) 
50 years 
(13.48) 
60 years 
(11.64) 
Mean BMI  
(standard deviation) 
28.44 
(5.63) 
29.15 
(5.82) 
Smoking status 
(non/ex/current) 
109/69/59 
(43%/28%/23%) 
43/27/24 
(45%/28%/25%) 
 
 
3.3.1.2 Dietary Intervention and Stem Cells (DISC) Study: Lower vs. higher 
CRC risk 
SFRP4 methylation was quantified in DNA extracted from biopsies of 
macroscopically normal rectal mucosa obtained from 88 healthy volunteers, 26 
patients with adenomatous polyps, and 12 patients with non-active UC.  A 
further 12 biopsies of macroscopically normal rectal mucosa were available 
from healthy volunteers.  However, these were excluded from the study 
because of an inability to obtain reproducible values for SFRP4 methylaton.  
The demographics of the study participants are shown in Table 3.6.  There were 
no significant differences in BMI (p=0.401, ANOVA) or smoking status 
(p=0.0551, 2 test) between the 3 different groups of participants in the DISC 
Study (healthy volunteers, patients with a history of adenomatous polyp, 
patients with a history of UC).  Age (p=0.003, ANOVA) and the male:female 
ratio (p=0.004, Fisher’s exact test) were both significantly different between the 
different groups of participants.  On average, patients with polyps were 9 and 6 
years older than normal participants and patients with UC respectively. 
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Table 3.6 Demographics of participants in the DISC Study by risk group 
 Normal 
participants 
Patients with 
polyps 
Patients with UC 
Number of 
participants 
(male:female) 
88 
(39:49) 
(44%:56%) 
26 
(20:6) 
(77%:23%) 
12 
(9:3) 
(75%:25%) 
Mean age   
(standard 
deviation) 
53 years 
(12.62) 
62 years 
(9.53) 
56 years 
(11.52) 
Mean BMI  
(standard 
deviation) 
30.09 
(5.34) 
28.82 
(4.96) 
28.39 
(4.59) 
Smoking status 
(non/ex/current) 
44/22/17 
(50%/25%/19%) 
[5 (6%) unknown] 
8/10/5 
(31%/38%/19%) 
[3 (12%) 
unknown] 
3/8/1 
(25%/67%/8%) 
 
 
3.3.2 SFRP4 methylation: Comparison of those at higher v. lower risk for CRC 
3.3.2.1 BORICC Study 
In the BORICC Study, SFRP4 promoter methylation was quantified in DNA 
extracted from 253 volunteers at a relatively lower CRC risk (normal healthy 
volunteers) and 96 volunteers at a relatively higher CRC risk (patients with 
adenomatous polyps).  Methylation of SFRP4 was quantified at 5 CpG sites 
within the promoter.  SFRP4 methylation was highest at CpG site 4 and lowest 
at CpG site 1 with similar methylation at the other 3 sites.  Across all 5 sites, 
methylation ranged from approximately 12-19% (Figure 3.5).  At all 5 CpG sites, 
SFRP4 methylation was higher in the higher CRC risk group.  This difference 
was significant at CpG site 4 (p=0.021), CpG site 5 (p=0.001) and the mean of 
the 5 CpG sites (p=0.036) investigated.  Averaged across all 5 CpG sites, 
methylation was 1.42% higher in polyp patients than in controls (15.33% and 
13.91% methylation respectively; p=0.036) (Figure 3.5). 
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Figure 3.5 SFRP4 methylation in DNA from rectal mucosa from participants in 
the BORICC Study (analysis has been adjusted for age) 
 
 
Age was the only covariate which affected SFRP4 promoter methylation 
significantly (p<0.004) in rectal DNA at all CpG sites individually and overall.  At 
all 5 CpG sites, increasing age was significantly associated with higher SFRP4 
promoter methylation levels (p<0.004) and, therefore, all statistical analyses 
have been adjusted for age (Table 3.7). 
 
At CpG sites 1 and 3, smoking was associated with significantly higher levels of 
SFRP4 promoter methylation (p=0.024 and p=0.032 respectively).  Smoking 
status was also associated with raised SFRP4 methylation at the average of 
CpG sites 1-5 and at CpG site 2 but these effects were not statistically 
significant (p=0.056 and p=0.071 respectively) (Table 3.7).   
 
There were no significant (p>0.441) associations between BMI and SFRP4 
methylation levels in rectal DNA for participants in the BORICC Study (Table 
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3.7).  At CpG site 4, SFRP4 methylation was significantly higher (p=0.046) in 
females than in males, but there were no significant differences between males 
and females in SFRP4 methylation at the other CpG sites investigated (Table 
3.7). 
 
Table 3.7 Associations between age, sex, smoking and BMI and SFRP4 
methylation in DNA from rectal mucosa from participants in the BORICC Study 
(statistical analysis using ANOVA in Minitab (version 16) with age, sex, smoking 
and BMI as covariates) 
Factor CpG site 
1 
CpG site 
2 
CpG site 
3 
CpG site 
4 
CpG site 
5 
Average 
Age  
(p-value) 
0.001 0.004 <0.001 <0.001 0.001 <0.001 
Sex  
(p-value) 
0.758 0.242 0.483 0.046 0.167 0.229 
Smoking 
(p-value) 
0.024 0.071 0.032 0.136 0.203 0.056 
BMI 
(p-value) 
0.441 0.674 0.907 0.886 0.975 0.798 
 
 
3.3.2.2 SFRP4 methylation in healthy volunteers and in patients with polyps 
and patients with UC in the DISC Study  
Details of subjects in the DISC study are shown in Table 3.6.  Methylation of 
SFRP4 was quantified at 5 CpG sites within the promoter.  SFRP4 methylation 
was highest at CpG site 4 and lowest at CpG site 1 with similar methylation at 
the other 3 sites.  Across all 5 sites, methylation ranged from approximately 7-
14% (Figure 3.6).  There was no detectable difference between patient groups 
(p>0.150) in percentage of SFRP4 methylation at any CpG site.  However, 
levels of SFRP4 methylation tended to be lower at all CpG sites in those in the 
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lower CRC risk group (healthy volunteers) when compared with those in the 
higher CRC risk groups (patients with adenomatous polyps or UC) (Figure 3.6).   
 
Figure 3.6 SFRP4 methylation in DNA from rectal mucosa from participants in 
the DISC Study (analysis has been adjusted for age) 
 
 
As with SFRP4 promoter methylation in rectal DNA from participants in the 
BORICC Study, age was a significant (p<0.010) determinant of  SFRP4 
methylation in rectal DNA from participants in the DISC Study with significant 
positive associations with age at CpG sites 1, 3, and 4 and at CpG sites 1-5 
combined.  Increasing age was associated with increased levels of SFRP4 
promoter methylation.  For participants in the DISC Study, BMI was associated 
positively and significantly (p<0.011) with SFRP4 promoter methylation at all 
CpG sites investigated in rectal DNA.  Neither sex nor smoking status was a 
significant covariate (Table 3.8). 
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Table 3.8 Associations between age, sex, smoking and BMI and SFRP4 
methylation in DNA from rectal mucosa from participants in the DISC Study 
(statistical analysis using ANOVA in Minitab (version 16) with age, sex, smoking 
and BMI as covariates)   
Factor CpG site 
1 
CpG site 
2 
CpG site 
3 
CpG site 
4 
CpG site 
5 
Average 
Age 
(p-value) 
0.004 0.106 0.010 0.008 0.060 0.007 
Sex 
(p-value) 
0.884 0.923 0.989  0.299 0.798 0.742 
Smoking 
(p-value) 
0.467 0.519 0.490 0.836 0.607 0.676 
BMI 
(p-value) 
0.005 0.033 0.027 0.021 0.051 0.011 
 
 
3.3.3 Comparison of SFRP4 methylation in rectal DNA obtained from the 
participants in the BORICC Study and in the DISC Study 
The BORICC Study and DISC Study are two independent studies that share 
several similarities including the medical history and geographical origin of the 
study participants and the protocols used for participant recruitment and for 
collection, storage and processing of biological samples.  Both studies used 
similar inclusion and exclusion criteria to recruit adult volunteers at a relatively 
lower and higher risk for CRC from referrals to gastrointestinal outpatient clinics 
in Northumberland in the North East of England.  Although the biological 
samples for the BORICC Study were collected in 2004/2005, and the biological 
samples for the DISC Study were collected in 2010/2011, it was expected that 
the lower CRC risk groups (healthy volunteers) would have similar levels of 
SFRP4 promoter methylation between the 2 studies as would the higher CRC 
risk groups (patients with adenomatous polyps).   
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There were greater number of participants in the BORICC Study (253 healthy 
volunteers and 96 patients with adenomatous polyps) compared to the DISC 
Study (88 healthy volunteers and 26 patients with adenomatous polyps).  
Despite this, there was no significant difference between the male:female ratios 
of the lower risk group in both studies(p=0.9013, Fisher’s exact test).  Similarly, 
there was no significant age difference between the lower risk group 
participants in both of the studies(p=0.1809, unpaired t-test):  The mean age of 
the BORICC Study and DISC Study lower risk groups was 50 years and 53 
years respectively.  In the BORICC2 Study the ratio was 66% male:34% female 
whereas in the DISC Study it was 77% male:23% female.  These differences 
were not significantly different (p=0.3466, Fisher’s exact test).  There was no 
significant difference between the ages (p=0.4899, unpaired t-test) or the BMI 
(p=0.7971, unpaired t-test) of the higher risk groups in the BORICC Study and 
the DISC Study.  There were no significant differences in the smoking status 
between the lower risk groups (p=0.5273, 2 test) in the BORICC Study and the 
DISC Study; or the higher risk groups (p=0.3887, 2 test) in the BORICC Study 
and the DISC Study (Table 3.5;Table 3.6).  Based on the characteristic data 
available (age, sex, BMI, smoking status) for the two studies, the higher and 
lower CRC risk groups in the BORICC Study are comparable to the higher and 
lower CRC risk groups in the DISC Study. 
 
Figure 3.5 and Figure 3.6 show that for the healthy volunteers, SFRP4 promoter 
methylation ranged from 12-17% in the rectal DNA obtained in the BORICC 
Study whereas in the DISC Study, SFRP4 promoter methylation levels were 
consistently lower ranging from 7-14%.  The SFRP4 promoter methylation 
levels also differed in the two groups of adenomatous polyp patients with 
SFRP4 promoter methylation ranging between: 13% and 19% in the BORICC 
Study rectal DNA; and 7% and 14% in the DISC Study rectal DNA.   
 
Figure 3.7 shows SFRP4 promoter methylation for the average of all CpG sites 
for both the BORICC Study and the DISC Study, grouped into the lower risk 
group (healthy volunteers) and higher risk group (patients with adenomatous 
polyps).  There is a significant (p<0.001) difference observed between the 
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percentage SFRP4 promoter methylation quantified in the BORICC Study and 
the DISC Study for both participant groups.  This between study difference was 
also significant (p<0.001) at all CpG sites individually (data not shown).   
 
Figure 3.7 SFRP4 methylation in DNA from rectal mucosa from participants in 
the BORICC Study and in the DISC Study 
(Averages for CpG sites 1-5 shown) 
 
 
 
3.3.3.1 Analysis of comparability of SFRP4 methylation in rectal DNA obtained 
from the BORICC Study and the DISC Study  
Section 3.2.5 details a set of experiments designed to assess the comparability 
of the BORICC Study and DISC Study data and to investigate the possibility of 
systematic bias between analyses of samples from the two different studies.  
Selected samples from the BORICC Studies and the DISC Study were 
processed under exactly the same conditions and methylation of SFRP4 was 
quantified by Pyrosequencing in both sample sets simultaneously on the same 
plate.  Each DNA sample was analysed in duplicate, both within the same plate, 
and in a further (second) identical experiment. 
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Figure 3.8 shows SFRP4 promoter methylation for the average of all CpG sites 
for the samples of DNA from the BORICC Studies and the DISC Study chosen 
to assess study comparability as described in section 3.2.5.  SFRP4 promoter 
methylation has been grouped into the lower risk group (healthy volunteers) and 
higher risk group (patients with adenomatous polyps).  There is a significant 
difference observed between the percentage SFRP4 promoter methylation 
quantified in the BORICC Study and the DISC Study for both participant groups 
(lower CRC risk p=0.007; higher CRC risk p=0.018).  As observed in Figure 3.7, 
Figure 3.8 shows that the levels of SFRP4 promoter methylation in the DISC 
Study are significantly lower for both participant groups than the BORICC 
Studies.  There was a significant (p<0.001, R=0.961-R=0.99) positive 
correlation between the duplicate selected BORICC Study and DISC Study 
rectal DNA samples between the first and second analysis at all CpG sites.  
Figure 3.9 shows the line of regression for SFRP4 methylation at CpG site 4. 
 
Figure 3.8 SFRP4 methylation in DNA from rectal mucosa from a sample of 
participants in the BORICC Study and in the DISC Study (section 3.2.5) 
(Averages for CpG sites 1-5 shown) 
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Figure 3.9 SFRP4 methylation at CpG site 4 in the rectal DNA samples 
obtained from a sample of BORICC Study and DISC Study participants as 
detailed in section 3.2.5: Plate 1 Vs. Plate 2 
 
 
 
3.3.4 SFRP4 methylation and serum vitamin D concentration 
SFRP4 promoter methylation data from the BORICC1 samples were regressed 
against the participant’s serum vitamin D concentration.  Serum vitamin D 
concentration measurements were not made in any of the other studies. 
 
Table 3.9 tabulates the outcomes of the regression analysis of vitamin D serum 
concentration versus percentage SFRP4 promoter methylation. There were 
negative correlations between the 2 variables at all CpG sites investigated and 
these were significantly negative at CpG site 4 (p=0.014, R=-0.16), CpG site 5 
(p=0.009, R=-0.17) and at all CpG sites combined (p=0.023, R=-0.14). Figure 
3.10 shows the line of regression for SFRP4 promoter methylation in rectal DNA 
from participants in the BORICC 1 Study versus serum vitamin D concentration 
at all CpG sites combined. 
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Table 3.9 Regression analysis of serum vitamin D concentration versus 
percentage SFRP4 methylation in rectal DNA from participants in the BORICC 
Study 
 CpG site 
1 
CpG site 
2 
CpG site 
3 
CpG site 
4 
CpG site 
5 
Average 
R 
coefficient 
-0.12 -0.11 -0.13 -0.16 -0.17 -0.14 
p-value 0.065 0.085 0.052 0.014 0.009 0.023 
 
 
Figure 3.10 Average SFRP4 methylation across all CpG sites Vs. serum vitamin 
D concentration 
 
 
 
 
 
 
 
 
 
 
3.3.5 SFRP4 methylation as a screening test for risk of CRC 
Figure 3.5 and Figure 3.6 show that there were differences in SFRP4 promoter 
methylation in rectal DNA between those at higher and lower risk for CRC.  
These differences could be clinically important if SFRP4 promoter methylation 
could be used to identify those at an increased CRC risk with a high sensitivity 
and specificity and therefore have the potential for use as a diagnostic test.  
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Logistic regression was used to investigate differences in SFRP4 promoter 
methylation levels in those at lower and at higher risk for CRC with age as a 
covariate.  The BORICC Study and DISC Study data were each analysed 
separately (section 3.2.7.7). 
 
3.3.5.1 SFRP4 methylation as a screening test for risk of CRC: BORICC Study 
data 
SFRP4 promoter methylation in rectal DNA obtained from the BORICC Studies 
were highly specific at identifying those at a lower risk of CRC (specificity > 0.91 
for all CpG sites individually and combined) (Table 3.10).  However sensitivity 
was relatively poor. The highest sensitivity was 0.28 (all CpG sites combined) 
(Table 3.10). 
  
ROCs demonstrated that SFRP4 methylation in rectal DNA from the BORICC 
Studies would be a “fair” test to differentiate between those at a higher and 
lower risk for CRC (AUC 0.70-0.78) (Table 3.4; Table 3.10; Table 3.11) (Hanley 
& McNeil 1982). 
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Table 3.10 SFRP4 methylation in rectal DNA obtained from participants in the 
BORICC Study: Sensitivity and specificity for differentiating between those at a 
lower and higher risk for CRC 
 Specificity Sensitivity AUC* 
CpG site 1 0.94 0.19 0.71 
CpG site 2 0.95 0.18 0.71 
CpG site 3 0.95 0.17 0.70 
CpG site 4 0.94 0.22 0.71 
CpG site 5 0.9 0.21 0.71 
CpG sites 
averaged 
0.94 0.19 0.71 
CpG sites 
combined 
0.91 0.28 0.78 
*AUC refers to the area under the ROC curve. 
These calculations have been adjusted for age. 
 
Figure 3.11 ROC curve: SFRP4 methylation in rectal DNA obtained from the 
BORICC Study:  All CpG sites combined 
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3.3.5.2 SFRP4 methylation as a screening test for risk of CRC: DISC Study 
data 
SFRP4 promoter methylation in rectal DNA obtained from the DISC Study was 
highly specific at identifying those at a lower risk of CRC (specificity > 0.84 for 
all CpG sites individually and combined) (Table 3.11).  However sensitivity was 
very poor. The highest sensitivity was 0.077 (all CpG sites combined) (Table 
3.10).  The ROCs demonstrated that SFRP4 methylation in rectal DNA would 
“fail” as a test to differentiate between those at a higher and lower risk for CRC 
(AUC 0.49-0.57) (Table 3.4) 
 
Table 3.11 SFRP4 methylation in rectal DNA obtained from participants in the 
DISC Study: Sensitivity and specificity for differentiating between those at a 
lower and higher risk for CRC 
 Specificity Sensitivity AUC* 
CpG site 1 1.00 0 0.55 
CpG site 2 1.00 0 0.49 
CpG site 3 0.86 0 0.54 
CpG site 4 1.00 0 0.53 
CpG site 5 0.84 0.038 0.54 
CpG sites 
averaged 
1.00 0 0.55 
CpG sites 
combined 
0.85 0.077 0.57 
*AUC refers to the area under the ROC curve. 
These calculations have been adjusted for age. 
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3.4 Discussion 
3.4.1 SFRP4 methylation: Comparison of those at higher v. lower risk for CRC 
In the BORICC Study, the mean percentage SFRP4 promoter methylation of 
the 5 CpG sites investigated was significantly (p=0.036) higher in the higher 
CRC risk group.  In the DISC Study, there was no significant difference between 
patient groups (p>0.150) in SFRP4 promoter methylation at any of the 5 CpG 
sites investigated.  However, levels of SFRP4 methylation tended to be lower at 
all CpG sites in those in the lower CRC risk group when compared to those in 
the higher CRC risk groups (section 3.3.2).  This trend (higher SFRP4 
methylation in the higher risk groups) may not have reached a significance level 
of p<0.05 because of the small sample size (88 healthy volunteers vs. 26 polyp 
patients vs. 12 UC patients).  A retrospective power analysis showed that for 
the differences in SFRP4 methylation observed between the three different 
groups of study participants in the DISC Study, to achieve a power of 80%, 
1569 study participants would be needed.  This demonstrates that the sample 
size for the DISC Study was too small.  The data range of SFRP4 methylation in 
the BORICC Study differed from the DISC Study.  If it is assumed that the 
BORICC Study, with a larger number of study participants (253 healthy 
individuals and 96 patients with adenomatous polyps), where a difference in 
SFRP4 methylation was identified, is a better representation of the range of 
SFRP4 methylation levels in rectal DNA, using the BORICC Study SFRP4 
methylation data, a power analysis shows that 228 study participants would 
have been needed in the DISC Study to identify a significant difference in 
SFRP4 methylation. 
 
Although, no strong conclusions regarding SFRP4 methylation in those at a 
higher risk of CRC can be made from this research project, the trend is that 
SFRP4 methylation is higher in the higher CRC risk groups.  This adds to the 
limited SFRP4 literature available, but still, it is difficult to make general 
conclusions. 
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Qi et al. (2006) examined the methylation and expression of SFRP genes in 
colorectal tumours, comparing methylation levels of SFRP1, SFRP2, SFRP4 
and SFRP5 in DNA extracted from CRC, colorectal adenoma, ACF and normal 
mucosa.  Qi et al. (2006) found that there were significant differences in SFRP4 
methylation between: (i) CRC and normal mucosa (p=0.002), (ii) adenoma and 
normal mucosa (p<0.0462) and (iii) ACF and normal mucosa (p=0.017), where 
there was no detectable SFRP4 methylation in the normal mucosa.  However, 
there were no significant differences in SFRP4 methylation between: (i) CRC 
and adenoma (p=0.228), and (ii) ACF and adenoma (p=1.00).  This suggests 
that hypermethylation of SFRP4 occurs as an early event in Fearon and 
Vogelstein’s (1990) adenoma-carcinoma sequence; and a lack of difference in 
SFRP4 methylation levels between ACF and adenoma, and adenoma and CRC, 
suggests that unlike SFRP1 and SFRP2, SFRP4 promoter hypermethylation 
does not increase from normal mucosa to hyperplastic polyp to adenoma to 
CRC (Wang & Tang 2007). 
 
Section 1.10 describes how promoter hypermethylation is a mechanism that 
can suppress gene expression and there appears to be a reciprocal relationship 
between the density of methylated cytosine residues in promoter regions and 
the transcriptional activity of the corresponding gene (Wong et al. 2007).  Qi et 
al.’s (2006) findings are in keeping with this – reduced expression of SFRP4 
was significantly associated with hypermethylation of the SFRP4 gene.  SFRP4 
expression was down-regulated in CRC, though unlike the reduced expression 
of SFRP1, SFRP2 and SFRP5, this was not to a level of significance (SFRP4 
p=0.438; SFRP1, SFRP2, SFRP5 p<0.001).  Therefore Qi et al (2006) came to 
the conclusion that SFRP1, SFRP2 and SFRP5 were more specific to CRC 
than SFRP4 and would be more suitable as biomarkers for CRC.  It is plausible 
that SFRP4 may differ in its suitability as a biomarker for CRC in comparison to 
SFRP1, SFRP2 and SFRP5 because it shows less homology with the other 
members of the SFRP family (Bovolenta et al. 2008). 
 
Qi et al.’s (2006) study suggests that hypermethylation of SFRP4 occurs as an 
early event in the development of CRC.  The patients with polyps in this 
94 
 
research project are at a relatively increased risk of CRC and higher levels of 
SFRP4 methylation were found in DNA extracted from the rectal mucosa of 
these patients.  Therefore the findings of this research project are in keeping 
with the findings of the Qi et al.’s (2006) study. 
 
In contrast, Huang et al. (2010) found that SFRP4 was overexpressed in CRC.  
SFRP4 gene expression was investigated in DNA from 95 CRC, 51 colorectal 
adenomas and 38 normal colon epithelial samples.  This included 20 paired 
CRC and adjacent normal mucosa.  Huang et al. (2010) found that SFRP4 
protein and RNA expression was significantly increased (RNA expression 
p=0.001, protein expression p<0.0001) in CRC compared to non-cancerous 
tissue.  In the same study, Huang et al. (2010) demonstrated that SFRP1 and 
SFRP5 gene expression were down-regulated in CRC, and there was no 
difference in the levels of SFRP2 gene expression amongst cancerous and non-
cancerous tissue. 
 
A study by Feng Han et al. (2006) also reported findings which differed from 
those of Qi et al. (2006).  Feng Han et al. (2006) evaluated the expression of 
SFRP4 in 1044 CRC samples to investigate possible associations with clinical 
pathological features and prognosis. No significant associations were found.  
Although in their study there was no comparison with normal colorectal mucosa, 
Feng Han et al. (2006) state that CRC expressed higher levels of SFRP4 
compared with adjacent normal mucosa.  This is the opposite of what Qi et al. 
(2006) found in their study:  SFRP4 promoter methylation was significantly 
higher (p<0.001) in DNA from CRC compared to DNA from the adjacent normal 
mucosa.  As it is expected that promoter hypermethylation results in 
transcriptional silencing, increased SFRP4 methylation would translate into a 
lower level of SFRP4 expression. 
 
Belshaw et al. (2008) investigated the methylation levels of 18 genes, including 
SFRP4 in rectal DNA from 20 morphologically normal colonic mucosa of 
neoplasia-free subjects, 13 adenomatous polyp patients and 19 CRC patients.   
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There was no significant difference (p=0.511) in SFRP4 methylation between 
normal mucosa and CRC.  The median (range) percentage SFRP4 methylation 
for DNA extracted from normal mucosa and from morphologically normal 
mucosa from patients with polyps was 0.77% (0.3-3.9%) and 1.99% (0.5-4.6%) 
respectively but this comparison was not tested statistically.  However, these 
data suggest that there was higher SFRP4 methylation levels in the higher risk 
group (polyp patients) and this is similar to findings of the present research 
project and Qi et al.’s (2006) study. 
 
Although there was only a significant difference in SFRP4 methylation between 
the different CRC risk groups in the BORICC Study, the findings of this study 
appear to be in keeping with studies published by Qi et al. (2006) and Belshaw 
et al. (2008). 
 
3.4.1.1 Difference in SFRP4 methylation between the BORICC Study and the 
DISC Study 
This project quantified SFRP4 promoter methylation in DNA obtained from 
rectal biopsies from participants in two independent studies: The BORICC 
Study and the DISC Study.  The laboratory methods used to quantify SFRP4 
promoter methylation was the same for both studies and the promoter region of 
interest was identical (section 3.2.3).  The values obtained for SFRP4 
methylation were significantly (p<0.001) different between the two studies 
(Figure 3.7).  Levels of SFRP4 methylation from participants in the BORICC 
Study were significantly greater than those from participants in the DISC Study 
(Figure 3.5; Figure 3.6). 
 
Further experiments to assess the comparability of SFRP4 methylation in rectal 
DNA obtained from the BORICC Study and the DISC Study were conducted to 
investigate the possibility of systematic bias between analyses of samples from 
the 2 different studies (Section 3.2.5).  In this second set of experiments, there 
are also significant differences (lower CRC risk p=0.007; higher CRC risk 
p=0.018) observed in the levels of SFRP4 methylation quantified in the 
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BORICC Study and DISC Study (Figure 3.9), where SFRP4 methylation in the 
DISC Study are lower for both participants groups than the BORICC Studies. 
The difference in the studies is unexpected so it is important to examine 
possible explanations for these inter-study differences.   
 
3.4.1.1.1 Participant characteristics 
Section 3.3.1 describes the characteristics of the study participants for both the 
BORICC Studies and the DISC Study (Table 3.5; Table 3.6).  Section 3.3.3 
compares the characteristics of the participants of the BORICC Studies with the 
DISC Study.  Although there were a greater number of participants in the 
BORICC Study (253 healthy volunteers and 96 patients with adenomatous 
polyps) compared to the DISC Study (88 healthy volunteers and 26 patients 
with adenomatous polyps), there was no statistically significant difference in any 
of the characteristics (age, sex, BMI, smoking status) recorded for each of the 
study participants in either risk group.  Therefore the higher and lower CRC risk 
groups in the BORICC Studies are comparable to the higher and lower CRC 
risk groups in the DISC Study. 
 
3.4.1.1.2 Methods and analysis 
The rectal biopsies for both studies were obtained from the same endoscopy 
departments in the North of England.  Both studies used the same participant 
recruitment methods and targeted similar patient groups and the same 
techniques were used to obtain the rectal biopsies and process them.  The 
rectal biopsies in the BORICC Studies were collected in 2004/05, whereas the 
rectal biopsies in the DISC Study were collected in 2010/11.  It is possible to 
hypothesize that methylation marks may be affected over time.  However there 
is limited literature investigating stability of methylation marks over time in 
biopsy samples stored at -80 degrees. 
 
DNA methylation refers to the modification of DNA and is thought to be the most 
stable, heritable and well conserved epigenetic change, and persists even in the 
absence of the conditions that established them (Bird 2002).  Byun et al. (2012) 
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suggest that DNA methylation can exhibit different temporal behaviours, varying 
between stability and instability of the DNA sequence.  There is no human data 
available that allows distinction between stable and non-stable methylation 
marks. 
 
Byun et al. (2012) and Talens et al. (2010) conducted two independent studies 
analysing a panel of DNA methylation markers to assess variability in 
methylation marks over time. Neither included the SFRP4 gene in their study. 
Byun et al. (2012) investigated short term variability in blood DNA methylation of 
12 genes in 63 healthy individuals, where 2 sets of blood samples were 
obtained; one on day 1, and the following on day 4.  This study found that DNA 
methylation of different genes in blood DNA have different degrees of short-
term variability (Byun et al. 2012).  Though whether these results can be 
extended to other cell types requires further investigation. 
 
Talens et al. (2010) investigated whether pre-existing stored DNA would be 
suitable for epigenetic epidemiological studies.  Thirty-four individuals were 
selected to allow an assessment of the stability of DNA methylation in a panel of 
16 genes over time.  DNA samples from blood and buccal cells were obtained 
in these individuals and processed to allow comparison with previously 
collected DNA samples from the same individuals 11-20 years (blood) and 2-8 
years (buccal cells) previously. Overall, DNA methylation was similar at the two 
time points.  The study by Talens et al. (2010) is more applicable to this 
research project because the time frame is in years as opposed to days as in 
the Byun et al. (2012) study.  It shows that methylation levels do appear to be 
stable over time, and that therefore the difference in timing of collection of the 
rectal biopsies in the BORICC study and DISC study is unlikely to account for 
the significant differences in SFRP4 methylation levels. 
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3.4.1.2 Difference in SFRP4 methylation between the BORICC Study, the 
DISC Study and the published literature 
The levels of SFRP4 promoter methylation quantified in this research project 
differ from the values published by Qi et al. (2006) and Belshaw et al. (2008).  
This may be the result of different research methods or different sites within the 
SFRP4 promoter that the various research groups have focussed upon.  The 
studies by Feng Han et al. (2006) and Huang et al. (2010) did not measure 
levels of SFRP4 promoter methylation. 
 
Qi et al.’s (2006) method for measuring SFRP4 methylation was methylation-
specific PCR (MSP) whereas Belshaw et al. (2008) used real-time quantitative 
methylation specific PCR (RT-QMSP).  The data in Qi et al.’s (2006) study is 
presented as the number of samples in which SFRP4 methylation could be 
detected (24.2% of DNA samples from patients with adenomatous polyps 
compared to 0% of DNA samples from healthy volunteers).  This differs from 
the data collected in Belshaw et al.’s (2008) study and that of this research 
project, where the data are presented as a percentage methylation of each CpG 
site within each DNA sample.  Therefore, the results of this research project are 
not directly comparable to the results of the study by Qi et al. (2006). 
 
Both this research project and Belshaw et al.’s (2008) study generated data on 
the percentage SFRP4 promoter methylation at various CpG sites of interest.  
Furthermore, Belshaw et al. (2008) recruited the participants of their study from 
the same population as the BORICC Studies and the DISC Study.  The rectal 
biopsies obtained in Belshaw et al.’s (2008) study were collected from the same 
endoscopy departments using similar methods to the BORICC Studies and the 
DISC Study. 
 
The CpG sites of interest in this research project differ from those of Belshaw et 
al.’s (2008).  This may account for the differences in SFRP4 methylation levels 
between the two studies.  For the BORICC Study and the DISC Study, SFRP4 
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methylation was quantified at 5 CpG sites 411 to 657 base pairs downstream to 
the transcription start site, whereas Belshaw et al. (2008) quantified SFRP4 
methylation at 6 CpG sites 123 base pairs upstream to 128 base pairs 
downstream of the transcription start site (Figure 3.12)  
 
Figure 3.12 SFRP4 DNA sequence 123 base pairs upstream to 657 base pairs 
downstream of the transcription start site (adapted from Genomatix)  
GAAGAAAAAAGACTGGCCAGACTAAAAAGGAGGGACTTTAGGGGGAAAGCAGGCTTCCAGCCCTGGGCTGCGG
CCCAGAGGGGGTGATGTCACCGCTTCTGCACCGACGGGCCTGGGGGTGGGGCGGCCGAGGGGGAGCCCGCGCC
GCGGCTGCAGCTGCCAAGGGAGCGTTCCGAGCCCACGTCAGGGGAGGTGTCGGGATAAATAGGGTCCCGCAATG
GCCGTGGCTGGCTGCGCTCCGAGCTGCGGAGTCCGGGACTGGAGCTGCCCGGGCGGGTTCGCGCCCCGAAGGCT
GAGAGCTGGCGCTGCTCGTGCCCTGTGTGCCAGACGGCGGAGCTCCGCGGCCGGACCCCGCGGCCCCGCTTTGCT
GCCGACTGGAGTTTGGGGGAAGAAACTCTCCTGCGCCCCAGAGGATTTCTTCCTCGGCGAAGGGACAGCGAAAG
ATGAGGGTGGCAGGAAGAGAAGGGCGCTTTCTGTCTGCCGGGGTCGCAGCGCGAGAGGGCAGTGCCATGTTCCT
CTCCATCCTAGTGGCGCTGTGCCTGTGGCTGCACCTGGCGCTGGGCGTGCGCGGCGCGCCCTGCGAGGCGGTGC
GCATCCCTATGTGCCGGCACATGCCCTGGAACATCACGCGGATGCCCAACCACCTGCACCACAGCACGCAGGAGA
ACGCCATCCTGGCCATCGAGCAGTACGAGGAGCTGGTGGACGTGAACTGCAGCGCCGTGCTGCGCTTCTTCCTCT
GTGCCATGTACGCGCCCATTTGCACCCTGGAGTTCCTGC 
     G Transcription start site 
Locations of CpG sites in Belshaw et al.’s (2008) Study: 123 base pairs upstream to 128 
base pairs downstream of the transcripton start site 
Location of CpG sites in current research project (BORICC Study and DISC Study): 411 
to 657 base pairs downstream to the transcription start site 
 
 
3.4.1.3 The effect of age on SFRP4 methylation in rectal DNA  
Age was the only statistically significant (p<0.01) covariate affecting SFRP4 
promoter methylation in rectal DNA extracted from both the BORICC Study and 
the DISC Study participants although the age effect was not statistically 
significant  at CpG site 2 (p=0.105) or CpG site 5 (p=0.06) in the DISC Study.  
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Importantly, in both studies and at all CpG sites investigated, SFRP4 
methylation levels increased with age. 
 
CRC risk increases with age (CRUK 2013) and the age-related greater 
methylation of SFRP4 observed in the present project was also reported in 
Belshaw et al.’s (2008) study.  At present it is not known whether the age-
related increase in SFRP4 methylation is causal for CRC or an association.  
The hypothesis that the accumulation of epigenetic alterations such as SFRP4 
hypermethylation that may occur during the ageing process, may directly 
contribute to the formation of CRC needs further investigation. 
 
The process of ageing comprises anatomical, physiological, biochemical and 
epigenetic changes during an individual’s life time.  Epigenetic factors are 
heritable at the cellular level and may be modulated by external factors such as 
the environment (Choi & Friso 2010).  Interestingly, the epigenetic changes that 
occur during the ageing process are the same epigenetic changes associated 
with cancer i.e. promoter hypermethylation and genomic global DNA 
hypomethylation (Ehrlich 2002). 
 
Cancer, ageing, environmental factors and specific epigenetic alterations such 
as DNA hypermethylation and global genomic hypomethylation, theoretically 
may all occur together; yet they all do not have to occur together – not everyone 
develops cancer as they age.  Perhaps, the SFRP4 methylation occurring 
during the ageing process may not directly cause the development of CRC in 
isolation, but, in association with modifiable environmental factors such as diet, 
may initiate the pathway of genetic and epigenetic alterations that accumulate 
and result in CRC formation. 
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3.4.1.4 SFRP4 methylation in patients with ulcerative colitis 
SFRP4 methylation at all CpG sites investigated tended to be higher in rectal 
DNA extracted from patients with non-active UC in comparison with the healthy 
volunteers, but this difference was not statistically significant (p=0.339).  It is 
possible that the lack of statistical significance is affected by the relatively small 
number of UC patients investigated in the DISC Study.   
 
This is the first study which has investigated methylation of the WNT antagonist 
SFRP4, or any other members of the SFRP family, in UC patients.  However, 
van Dekken et al. (2007) demonstrated the involvement of the WNT signalling 
pathway in the development of CRC in patients with UC by evaluating the 
immunolabelling patterns of -catenin and products of WNT-related genes (E-
cadherin, cyclin D1 and c-myc) along the successive stages of inactive colitis, 
dysplasia and adenocarcinoma in UC using surgical resection specimens from 
18 CRCs, 17 dysplastic lesions and 11 inactive colitis (normal control).  The 
findings were up-regulation of -catenin, cyclin D1 and c-myc in the 
preneoplastic state and down-regulation of E-cadherin, in keeping with an 
activated WNT signalling pathway.  This study suggests that the WNT pathway 
is activated early in the malignant progression of UC (van Dekken et al. 2007).  
Since SFRP4 is a WNT antagonist, this implies a possible role for SFRP4 gene 
expression in the development of CRC in patients with UC (Baylin & Ohm 2006, 
Bovolenta et al. 2008) and may account for the increased SFRP4 methylation in 
patients with UC. 
 
Sporadic CRC in patients without UC follows the adenoma-carcinoma sequence 
(Fearon & Vogelstein 1990). The mechanisms that cause the transition from UC 
to CRC are unclear but may involve the “inflammation-dysplasia-carcinoma 
progression sequence”.  This sequence, similar to the adenoma-carcinoma 
sequence, may involve changes to the WNT signalling pathway (Harpaz & 
Polydorides 2010, Shenoy et al. 2012). 
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3.4.2 SFRP4 methylation and serum vitamin D concentration 
Circulating concentrations of Vitamin D were available for the participants in the 
BORICC1 Study only.  In this study there were associations between 
percentage SFRP4 methylation and serum vitamin D concentration (section 
3.3.4).  There were negative correlations between the 2 variables at all CpG 
sites investigated (Table 3.9) which were significantly negative at CpG site 4 
(p=0.014, R=-0.16), CpG site 5 (p=0.009, R=-0.17) and at all CpG sites 
combined (p=0.023, R=-0.14).  For the remainder of the CpG sites, the p-value 
approached significance (p<0.064).  These findings support the proposed link 
between SFRP4 promoter methylation and vitamin D concentration described in 
the literature (Section 1.8.1).  
 
It is not known whether a low vitamin D intake and subsequent low vitamin D 
serum concentrations are causal for raised SFRP4 promoter methylation levels, 
and whether this may be a mechanism by which low vitamin D status increases 
the risk of CRC. Alternatively, serum concentrations of vitamin D, CRC risk and 
their associations with SFRP4 methylation may be mechanistically independent 
of each other and low vitamin D status may lead to increased risk of CRC via 
different mechanisms. 
 
Cutaneous biosynthesis following skin exposure to ultraviolet light is the 
predominant source of vitamin D for most people (Parfitt et al. 1982) and 
seasonal differences in circulating concentrations of 25(OH)D3 are well 
documented (McKenna et al. 1985; Rapuri et al. 2002; Webb et al. 1988).  In 
northern latitudes such as the UK, sunlight during winter is insufficient to 
stimulate cutaneous biosynthesis of vitamin D (van der Wielen et al. 1995).  
Serum vitamin D concentration data are available for the participants of the 
BORICC1 Study only which investigated novel biomarkers of CRC risk in a low 
CRC risk healthy population, and data collection spanned a year-long period 
over 2004-2005.  At latitudes similar to the UK, there is good evidence for 
seasonal variation in circulating concentrations of 25(OH)D and future work 
should include estimation of season-specific 25(OH)D and use of these 
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adjusted values in investigation of relationships with SFRP4 methylation 
(Shoben et al, 2005).  
 
3.4.3 SFRP4 methylation as a screening test for CRC 
SFRP4 methylation is significantly different in the DNA extracted from the rectal 
mucosa of BORICC1 and BORICC2 Study participants.  Although a similar 
difference between those at higher and lower risk for CRC in the DISC Study 
was also observed, this difference was not statistically significant.  These 
differences observed would be clinically applicable if SFRP4 methylation could 
identify those at an increased CRC risk with high sensitivity and specificity.  
Only 50% of those diagnosed with CRC survive more than 5 years from 
diagnosis (CRUK 2013).  CRC incidence has not been affected by changes in 
treatment and survival although it has been shown to be influenced by improved 
diagnostic techniques and screening programmes (Hagger & Boushev 2009).  
Therefore, the emphasis should be on improving screening and diagnosis for 
CRC. 
 
Although endoscopic examination of the colon is the gold standard investigation 
for screening for CRC, it is a time consuming procedure and requires skilled 
healthcare professionals to carry out the procedure.  Other simpler 
investigations can be used to help prioritise which individuals within the 
population should undergo endoscopic evaluation of their bowel to assess risk 
of CRC.  FOBT is a non-invasive screening method and involves the individual 
providing a stool sample for assessment which is then tested for any evidence 
of blood (Strul & Arber 2007).  FOBT has decreased mortality from CRC by 15-
33% due to the early detection of colorectal adenoma (Hardcastle et al. 1986, 
Mandel et al. 1993, Kronborg et al. 1996, Niv et al. 2002). 
 
Since the development of FOBT, further non-invasive screening tests for CRC 
have been developed.  Stool-based DNA tests involve the individual providing a 
stool sample, which is then processed to identify a panel of epigenetic and 
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genetic alterations that are thought to relate to CRC risk.  Stool-based DNA 
tests are 4 times more effective than FOBT for detecting CRC (Salehi et al. 
2012).  Also, stool-based DNA tests specifically designed to test for CRC are 
theoretically more accurate than FOBT because the stool-based DNA test 
assesses the stool sample for evidence of known biomarkers of CRC risk 
whereas FOBT assesses the stool sample for blood.  Blood in the stool is a 
potential sign of CRC, but there are other causes such as benign conditions 
such as haemorrhoids, or secondary to dietary red meat intake. 
 
This research project has investigated the potential use of tissue biopsies in 
DNA tests using mucosal biopsies from the rectum and SFRP4 as a biomarker 
of CRC risk. SFRP4 promoter methylation in rectal DNA obtained from the 
BORICC Studies were highly specific at identifying those at a lower risk of CRC 
(specificity > 0.91 for all CpG sites individually and combined) (Table 3.10).  
However sensitivity was relatively poor. The highest sensitivity was 0.28 (all 
CpG sites combined) (Table 3.10).  ROCs demonstrated that SFRP4 
methylation in rectal DNA from the BORICC Study would be a “fair” test to 
differentiate between those at a higher and lower risk for CRC (AUC 0.70-0.78) 
(Table 3.4; Table 3.10; Table 3.11) (Hanley & McNeil 1982) (section 3.3.5.1).  
However, ROCs demonstrated that SFRP4 methylation in rectal DNA obtained 
from the DISC Study would “fail” as a test to differentiate between those at a 
higher and lower risk for CRC (AUC 0.49-0.57) (Table 3.4; Table 3.11).  SFRP4 
promoter methylation in rectal DNA obtained from the DISC Study were highly 
specific at identifying those at a lower risk of CRC (specificity > 0.84 for all CpG 
sites individually and combined) (Table 3.11).  However sensitivity was very 
poor. The highest sensitivity was 0.077 (all CpG sites combined) (Table 3.10) 
(section 3.3.5.2).   
 
SFRP4 methylation in rectal DNA is not sensitive for identifying those at a 
higher risk of CRC; and would underestimate the true number of people at 
higher CRC risk.  However, it should be noted that the data in this research 
project were generated from a case control study. In order to classify 
participants as high or low risk for CRC, a prospective study design is required 
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in which participants are followed over until it is determined whether or not they 
develop CRC.  It is only then that a true sensitivity and specificity can be 
calculated. 
 
In Belshaw et al.’s (2008) study, SFRP4 was one of the 6 (out of 18) informative 
genes in classifying study samples into CRC, polyps and neoplasia free.  
Collectively, all 18 genes investigated in Belshaw et al’s (2008) study were able 
to correctly classify 67.3% of study samples; and when the classifications were 
grouped into cancer and no cancer, the panel of 18 genes were able to correctly 
classify 87.9% of study samples, where SFRP4 was one of the three most 
informative genes. 
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3.5 Conclusions 
This research project has shown that SFRP4 promoter methylation is greater in 
those at a higher CRC risk.  Mean SFRP4 methylation was significantly greater 
(p=0.036) in those at a higher risk for CRC in the BORICC Study.  SFRP4 
methylation was also greater in those at a higher CRC risk in the DISC Study, 
though this difference was not significant (p>0.15).  This direction of change is 
in keeping with studies published in the literature by Qi et al. (2006) and 
Belshaw et al. (2008). 
 
Further studies investigating the differential methylation of SFRP4 in those at a 
lower and higher risk for CRC should include investigating why there were 
differences in SFRP4 methylation levels in rectal DNA from the BORICC and 
DISC Studies.  Also, the patients in the BORICC Study and DISC Study could 
be followed to establish whether or not they develop CRC and to determine 
whether or not the SFRP4 methylation level quantified in this study was 
predictive of CRC risk. 
 
This study also found a negative correlation between percentage SFRP4 
methylation and serum vitamin D concentration at all CpG sites investigated, 
and this supports the literature which proposes that there is a link between 
SFRP4 methylation and vitamin D concentration.  Further investigation is 
required to assess whether low vitamin D concentrations are causal for a raised 
SFRP4 methylation level, and whether this may be a possible mechanism by 
which low vitamin D status increases the risk of CRC. 
 
This research project has found that SFRP4 is not a suitable epigenetic 
biomarker for CRC risk.  Although SFRP4 methylation levels in rectal DNA 
obtained from the BORICC Studies and the DISC study were both highly 
specific in identifying those at a lower risk of CRC (specificity>0.84), SFRP4 
methylation levels in rectal DNA obtained from both studies had poor sensitivity 
levels (sensitivity<0.28).  Both this project and the literature has suggested that 
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there are differences in SFRP4 methylation in those at a higher and lower risk 
for CRC.  Further investigations should focus on whether SFRP4 could be used 
in combination with other genes as an epigenetic biomarker of CRC risk. 
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4 Buccal cells as a surrogate tissue for CRC 
biomarker assay using SFRP4 promoter 
methylation as an exemplar 
 
4.1 Introduction 
Although colorectal mucosal biopsies are a good source of information about 
molecular events which may lead to CRC development, collecting such tissue 
biopsies is an invasive process.  It requires specific medical skills and may 
involve some discomfort for the study participant.  In contrast, samples of 
buccal cells can be collected safely and readily by the participant without the 
need for skilled assistance.  The buccal mucosa is part of the gastrointestinal 
mucosa and is exposed to some of the same factors as the colorectum e.g. host 
genotype, endogenous factors such as obesity-related inflammation and dietary 
factors.  As a consequence, it is hypothesised that the buccal mucosa might be 
a useful surrogate for measurement of biomarkers of CRC risk including SFRP4 
promoter methylation.  Therefore, this chapter aims to investigate relationships  
between SFRP4 promoter methylation in matched samples of DNA from rectal 
mucosal biopsies and from buccal cells from participants  at lower (normal 
healthy volunteers) and higher (patients with a history of adenomatous polyps) 
risk for CRC using rectal mucosal biopsies and buccal cells obtained in the 
BORICC Study (Mathers et al. 2010).   
 
4.2 Methods 
Participants were recruited to the BORICC Study (Mathers et al. 2010) from 
endoscopy lists within Northumbria Healthcare NHS Foundation Trust as 
outlined in section 2.5.  Those without any exclusion criteria as described in 
section 3.2.1.1 were invited to participate. 
 
109 
 
4.2.1 Biological samples 
Rectal samples and matched buccal cell swabs were collected at the same time 
from each participant in the BORICC Study.  Rectal biopsies were sampled and 
stored as described in section 3.2.2.1.   
 
4.2.2 Buccal cell samples 
Buccal cells were collected using Catch-AllTM swabs (Epicentre Bio 
Technologies).  Participants were asked to avoid food and drink for at least 2 
hours before collection of the sample. To do so, participants were asked to rinse 
their mouth twice with water before a buccal swab was rolled against the inside 
of their cheek firmly 20 times on each side.  The buccal swab was then placed 
back inside its original packaging and transported to the laboratory where it was 
stored at −80°C.   
 
4.2.3 Laboratory methods 
In addition to the laboratory methods described in section 3.2.3, the following 
technique for DNA extraction from the buccal cell swabs was used. 
 
4.2.3.1 DNA extraction: Buccal cell samples 
Buccal cell samples were removed from -80C storage and thawed at room 
temperature.  The BuccalAmpTM DNA Extraction Kit (Epicentre Bio 
Technologies) was used to extract DNA from the buccal cell samples.  The 
swab end of the Catch-AllTM sample collection swab (Epicentre Bio 
Technologies) was placed into a tube containing QuickExtract DNA extraction 
solution (Epicentre Bio Technologies) and vortexed for 10 minutes.  The mixture 
was then incubated at 65C for 1 minute followed by incubation at 98C for 2 
minutes.  The DNA purity and concentration were then measured using a 
spectrophotometer (NanoDrop 1000) 
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4.2.4 Statistical analyses 
4.2.4.1 Comparison of participant characteristics: BORICC1 Vs. BORICC2 
participants 
Characteristics of the participants of the BORICC1 Study (healthy volunteers) 
and BORICC2 Study (patients with polyps) were compared using: Unpaired t-
test to identify any significant differences in the ages and BMI of the two groups; 
2 test to identify any significant difference in the smoking status of the two 
groups; and Fisher’s exact test to identify any significant difference in the 
male:female ratio between the two study groups. p<0.05 was considered to be 
significant. 
 
4.2.4.2 SFRP4 methylation in buccal DNA: Comparison between low and high 
CRC risk groups 
Levels of SFRP4 promoter DNA methylation in buccal DNA for participants at 
lower (BORICC1) and higher (BORICC2) CRC risk were analysed using 
ANOVA in a general linear model, as described in section 3.2.7.4.  Age, sex, 
smoking status and BMI were used as covariates.    Results were expressed as 
least square means  SEM.  p<0.05 was considered to be significant. 
 
4.2.4.3 Relationships between SFRP4 promoter methylation in DNA from 
Rectal Biopsies and from Buccal Cell Samples 
Regression analysis using Minitab (version 16) statistical software was used to 
investigate potential linear relationships between SFRP4 promoter methylation 
in DNA from the rectal biopsies and from the buccal cells.  p<0.05 was 
considered to represent a significant correlation. 
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4.2.4.4 Sensitivity and specificity of SFRP4 methylation in buccal DNA as a 
biomarker of CRC risk 
Minitab (version 16) statistical software was used to perform binary logistic 
regression to examine variation in SFRP4 promoter methylation levels in buccal 
DNA in those at a lower and higher risk for CRC (section 3.2.7.7).   
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4.3 Results 
4.3.1 Patient demographics 
SFRP4 methylation was quantified in DNA extracted from buccal cells from 233 
healthy individuals who were at a relatively lower risk of CRC (BORICC1 Study) 
and from 89 patients with adenomatous polyps who were at a relatively higher 
risk of CRC (BORICC2 Study).  DNA was available from 268 buccal cells 
obtained from healthy individuals and 99 buccal cells from patients with 
adenomatous polyps. However 35 samples from healthy individuals and 10 
samples from patients with polyps were excluded because of an inability to 
obtain reproducible values for SFRP4 methylaton.  The demographics of study 
participants are shown in Table 4.1.  There were no significant differences in 
BMI (p=0.3291, unpaired t-test) or smoking status (p=0.8437, 2 test) between 
the participants of the BORICC1 Study and the BORICC2 Study.  On average, 
the participants with polyps group was approximately 10 years older (p<0.001, 
unpaired t-test) and had a higher proportion of males (p<0.001, Fisher’s exact 
test) than the healthy group within the BORICC Study. 
 
Table 4.1 Demographics of participants in the BORICC1 and BORICC2 Studies 
for whom buccal cell samples were available for analysis 
 Normal participants Patients with polyps 
Number of participants 
(male:female) 
233 
(93:140) 
(40%:60%) 
89  
(63:26) 
(71%:29%) 
Mean age  
(standard deviation) 
50 years 
(13.50) 
60 years 
(11.62) 
Mean BMI 
(standard deviation) 
28.37 
(5.61) 
29.04 
(5.85) 
Smoking status  
(non/ex/current) 
104/70/57 
(45%:30%:24%) 
[2 (1%) unknown] 
42/24/23 
(47%/27%/26% 
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4.3.2 Methylation of SFRP4 in DNA from buccal cells: Comparison of those at 
lower vs. higher risk for CRC 
Using DNA from buccal cells from the individuals detailed in Table 4.1, 
methylation was quantified at 5 CpG sites within the promoter of SFRP4.  
SFRP4 methylation was highest at CpG site 4 and lowest at CpG site 1 with 
similar methylation at the other 3 sites.  Across all 5 sites, methylation ranged 
from approximately 8-17% (Figure 4.1).  At all 5 CpG sites, SFRP4 promoter 
methylation was significantly (p<0.001) higher in the lower CRC risk group.  
Averaged across all 5 CpG sites, methylation was 2.34% lower in DNA from 
polyp patients than in controls (10.75% and 13.09% methylation respectively; 
p<0.001).   
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Figure 4.1 SFRP4 methylation in DNA from buccal mucosa from participants in 
the BORICC Study (analysis has been adjusted for age) 
 
 
Sex, smoking and BMI had no significant effects on SFRP4 promoter 
methylation in the buccal DNA obtained from BORICC Study participants.  
However, age was a significant covariate for methylation at CpG site 3, CpG 
site 4 and all CpG sites combined, where increasing age was significantly 
(p<0.02) associated with a higher levels of SFRP4 promoter methylation (Table 
4.2). 
  
0
2
4
6
8
10
12
14
16
18
1 2 3 4 5 Average
%
 S
F
R
P
4
 m
e
th
y
la
ti
o
n
 
(m
e
a
n
 ±
 S
E
M
) 
CpG site 
Normal
Polyps
r  
p<0.001 
p<0.001 p<0.001 
p<0.001 
p<0.001 
p<0.001 
115 
 
Table 4.2 The effect of covariates upon SFRP4 methylation in DNA from buccal 
cells obtained from participants in the BORICC Study 
Factor CpG site 
1 
CpG site 
2 
CpG site 
3 
CpG site 
4 
CpG site 
5 
Average 
Age 
(p-value) 0.396 0.166 0.004 0.02 0.102 0.02 
Sex 
(p-value) 0.262 0.405 0.456 0.532 0.619 0.542 
Smoking 
(p-value) 0.807 0.293 0.404 0.274 0.427 0.289 
BMI 
(p-value) 0.396 0.377 0.802 0.08 0.905 0.478 
 
 
4.3.3 Correlation between SFRP4 methylation in matched samples of buccal 
DNA and rectal DNA obtained from participants in the BORICC Study 
Table 4.3 shows that there were relatively weak, but statistically significant, 
negative correlations between SFRP4 promoter methylation in buccal cells and 
that in rectal mucosa at CpG site 1 (Figure 4.2) and CpG site 4 (Figure 4.3) only, 
(p=0.001, R=-0.184 and p=0.041 R=-0.114 respectively).   
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Table 4.3 Results of regression analysis of SFRP4 promotor methylation in 
DNA from rectal biopsies and  buccal cells (matched samples obtained from 
participants in the BORICC Study) 
 CpG site 
1 
CpG site 
2 
CpG site 
3 
CpG site 
4 
CpG site 
5 
Average 
R 
coefficient 
-0.184 -0.032 0.044 -0.114 -0.063 -0.084 
Slope -0.285 -0.055 0.105 -0.245 -0.168 -0.199 
SE of the 
slope 
0.083 0.093 0.151 0.119 0.147 0.127 
Intercept 15.45 15.19 12.71 21.34 15.06 16.76 
SE of the 
intercept 
0.94 1.19 1.96 1.95 1.61 1.61 
p-value 0.001 0.554 0.487 0.041 0.255 0.117 
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Figure 4.2 Relationship between SFRP4 methylation at CpG site 1 in DNA from 
buccal cells with that from rectal mucosa obtained from participants in the 
BORICC Study 
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Figure 4.3 Relationship between SFRP4 methylation at CpG site 4 in DNA from 
buccal cells and  that from rectal mucosal biopsies  obtained from participants in 
the BORICC Study 
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4.3.4 SFRP4 methylation as a screening test for risk of CRC 
Figure 4.1 shows that SFRP4 promoter methylation in DNA from buccal cells 
was consistently greater in those at lower risk for CRC. This difference could be 
clinically important and might be the basis for development of a diagnostic test 
which uses SFRP4 promoter methylation to identify those at an increased CRC 
risk.  To investigate this potential, logistic regression was used to investigate 
differences in SFRP4 promoter methylation levels in those at lower and at 
higher risk for CRC.  Since age was significantly (p<0.001) lower in the “Normal” 
participants than in the patients with polyps, age was used as a factor in the 
analysis (section 4.3.1). 
 
SFRP4 promoter methylation in buccal DNA was highly specific at identifying 
those at a lower risk of CRC (specificity > 0.93) for all CpG sites individually and 
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combined) (Table 4.4).  However sensitivity was relatively poor. The highest 
sensitivity for SFRP4 promoter methylation in buccal DNA was 0.65 (all CpG 
sites combined) (Table 4.4).   
  
Table 4.4 Outcomes of ROC analysis of SFRP4 methylation in DNA from buccal 
cells obtained from participants in the BORICC Study: Sensitivity and specificity 
for differentiating between those at a lower and higher risk for CRC 
 Specificity Sensitivity AUC* 
CpG site 1 0.96 0.64 0.88 
CpG site 2 0.96 0.53 0.84 
CpG site 3 0.93 0.30 0.78 
CpG site 4 0.93 0.41 0.80 
CpG site 5 0.93 0.23 0.75 
CpG sites 
averaged 
0.93 0.53 0.84 
CpG sites 
combined 
0.94 0.65 0.88 
*AUC refers to the area under the ROC curve. 
These calculations have been adjusted for age. 
 
ROCs demonstrated that SFRP4 methylation in  DNA from buccal cells would 
be a “fair to good” test for  differentiating between those at a higher and lower 
risk for CRC (AUC 0.75-0.88) (Table 3.4; Table 4.4; Figure 4.4) (Hanley & 
McNeil 1982). 
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Figure 4.4 ROC curve: SFRP4 methylation in buccal DNA obtained from the 
BORICC Study: All CpG sites combined 
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4.4 Discussion 
4.4.1 SFRP4 methylation in buccal DNA: Comparison of those at higher v. 
lower risk for CRC 
The main finding from the work described in this chapter was that SFRP4 
promoter methylation in DNA from buccal cells from participants in the BORICC 
Study was significantly (p<0.001) higher in the lower CRC risk group at all 5 
CpG sites investigated.  This between risk group difference is the opposite to 
that observed for SFRP4 promoter methylation in rectal DNA. 
 
This is the first study which has investigated SFRP4 promoter methylation in 
DNA from buccal cells from colorectal polyp patients.  Indeed, there is limited 
literature on SFRP4 promoter methylation in buccal cells under any 
circumstances.  One study reported that SFRP4 promoter methylation was 
increased in primary OSCC compared with matched normal oral mucosa 
(Pannone et al. 2010).  Pannone et al. (2010) compared SFRP4 methylation 
levels in DNA extracted from 37 OSCC and 37 controls of normal oral 
epithelium and found that the SFRP4 promoter was significantly more (p<0.001) 
methylated in OSCC than in normal controls.   None of the participants in the 
BORICC Study had OSCC. In addition, there is no literature investigating 
associations between CRC and OSCC  which suggest that if an individual was 
at an increased risk of CRC, they would be at a decreased risk of OSCC and 
vice versa. 
 
Since at the level of the individual genome (DNA molecule) methylation of a 
CpG site is binary i.e. the cytosine residue is either methylated or not 
methylated, it is expected that the percentage of SFRP4 methylation in a tissue 
sample will reflect the proportion of cells within the buccal mucosa that are 
methylated (Mathers & Ford 2009). In other words, at the tissue level, a lower 
level of SFRP4 promoter methylation suggests that there are fewer methylated 
cells within the buccal mucosa.  It is also expected that SFRP4 promoter 
methylation is correlated inversely with SFRP4 gene expression. Therefore the 
percentage of SFRP4 promoter methylation may allow the prediction of the 
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proportion of cells within the buccal mucosa in which the SFRP4 gene is 
suppressed.  This suggests that in buccal mucosa, the lower levels of SFRP4 
methylation in the higher risk group reflect a lower level of SFRP4 gene 
expression in the lower CRC risk group.  This is the opposite to the findings in 
the rectal DNA and to what is expected given that SFRP4 is a tumour 
suppressor gene.  This may be because:  
 SFRP4 promoter methylation in DNA from buccal cells is not different in 
those at a higher or lower risk for CRC and the results obtained in this 
research project have been due to chance. Whilst confounding by factors 
not considered in this study cannot be ruled out, the consistent difference 
in methylation between the Polyp group and the Normals in this study 
which was evident at all 5 CpG sites investigated suggests strongly that 
this is not a chance observation.  
 The epigenetic processes that lead to SFRP4 promoter methylation are 
influenced by the local environment and differ between mouth and 
rectum.  For example, smoking and alcohol intake are both known risk 
factors for CRC and OSCC (CRUK 2013).  However, they may affect 
DNA in cells in the mouth differently to DNA in cells from colonic tissue.  
This may be because of a more direct and concentrated effect in the 
mouth.  Section 1.4.2.1 details how butyrate is a natural histone 
deacetylase inhibitor and is a product of dietary fibre fermentation in the 
colon.  By preventing deacetylation, butyrate halts the process that leads 
to tumour gene expression suppression (Davis 2003, Rada-Iglesias et al. 
2007).  If butyrate plays a role in SFRP4 gene expression, which may 
impact upon SFRP4 methylation because of the inverse relationship 
between DNA methylation and gene expression, it may be partly 
accountable for the levels of SFRP4 methylation quantified in rectal DNA.  
Butyrate is not present in the mouth and so if not available to produce the 
effects described for the large bowel.  These possible differing effects of 
the local environment in the mouth and the large bowel will be addressed. 
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4.4.1.1 The effect of smoking on oral mucosa compared to the rectal mucosa 
Cigarette smoke and its carcinogens come into direct contact with buccal 
mucosa and therefore may have more effect on buccal DNA than rectal DNA.  
The carcinogens in cigarette smoke may reach the colonic lumen as they are 
swallowed by the smoker.  However, by the time these carcinogens reach the 
colon, their concentrations may be lower than when they were first ingested.   
 
Naderi et al. (2012) used the micronucleus assay to assess the effect of 
smoking on DNA in buccal cells of smokers and non-smokers.  Micronuclei 
result from chromosome fragments that are not included in the main daughter 
nuclei during nuclear division and provide a measure of chromosome breakage 
and chromosome loss, and is an indicator of DNA damage at the chromosome 
level (Fenech 1994).  Naderi et al. (2012) assessed 500 buccal cells per study 
participant in 23 non-smokers, 14 participants who had smoked for up to 10 
years and 26 participants who had smoked for more than 10 years.  The mean 
percentage of micronuclei for each study group was quantified and found to be 
statistically different (p<0.002), where the lowest numbers of micronuclei were 
seen in the non-smokers.  This suggests that smoking plays a role in buccal 
DNA damage.  There are no studies assessing the same marker of DNA 
damage in both buccal and rectal mucosa which would allow a direct 
comparison. 
 
Section 1.4.2.8 describes how smoking may be causally linked to CRC and 
polyp formation by exposure of the colonic epithelium to carcinogenic 
compounds in the cigarette smoke via the systemic circulation or from direct 
exposure from their ingestions (Chan & Giovannucci 2010).  The mechanisms 
by which smoking may lead to polyp formation are not clear and require further 
investigation.   
 
In this study, there was evidence that smoking behaviour influenced SFRP4 
methylation at CpG sites 1 and 3 in buccal DNA (Table 4.2).  It is surprising that 
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not all CpG sites were influenced by smoking.  This is because smoking has 
generally been associated with increased DNA promoter methylation 
(Zochbauer-Muller et al. 2003, Enokida et al. 2005, Marsit et al. 2007).  
However, as there is limited literature on SFRP4 methylation, it is not known 
whether cigarette smoke has effects on methylation of specific genes such as 
SFRP4. 
 
4.4.1.2 The effect of alcohol on oral mucosa compared to the rectal mucosa 
Alcohol is an established risk factor for both CRC and OSCC (CRUK 2013) but   
the mechanisms through which alcohol affects  CRC and OSCC development 
may differ.  For example, alcohol may play a role in OSCC development as a 
result of direct contact of oral mucosa with alcohol.  This is less likely in CRC 
development as the majority of alcohol is absorbed by the stomach and small 
intestine before it is able to reach the large intestine (Mumenthaler et al. 1999).  
The systemic effects of alcohol and its metabolism within the body are more 
likely to exert effects that play a role in CRC development.  These same 
systemic mechanisms may also play a role in the development of OSCC.  
 
Simanowski et al. (1995), Maier et al. (1994) and Seitz et al. (1998) have all 
investigated chronic alcohol consumption as a risk factor for various 
gastrointestinal cancers, including OSCC and CRC.  Susceptibility to cancer 
development is the result of increased regeneration of gastrointestinal mucosa 
which has an increased susceptibility towards the action of carcinogens.  
Chronic alcohol use results in oral mucosal atrophy, which may play a role in 
OSCC development.  Excess alcohol intake may also stimulate crypt cell 
production in the rectum, thus playing a role in the development of rectal cancer. 
 
A more direct effect of alcohol on the oral mucosa was suggested by Zamora-
Parez et al. (2013), who investigated the effects of alcohol-containing 
mouthwash on the induction of nuclear anomalies in buccal cells in 38 
participants who used alcohol-containing mouthwash (26% ethanol 
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concentration) twice a day for 30 consecutive days, 36 participants who used a 
non-alcohol-containing mouthwash for the same time period, and 33 
participants who did not use any mouthwash.  There were significantly greater 
(p<0.05) nuclear anomalies in the group who used alcohol-containing 
mouthwash compared with both the control group and the non-alcohol 
mouthwash group. 
 
4.4.1.3 The effect of diet on oral mucosa compared to the rectal mucosa 
Dietary factors may affect buccal DNA and rectal DNA differently because food 
may be in one form in the mouth and another in the colon.  Also, the different 
local environments may result in different effects upon buccal DNA and rectal 
DNA.  To demonstrate this difference, an item of food may be followed from 
initial ingestion to the large intestine (should it reach that far along the 
alimentary canal).  In the mouth, food will initially be in its undigested form.  
Digestion begins mechanically and the teeth break food into smaller pieces.  
Salivary glands release saliva to lubricate food to aid its digestion.  Saliva also 
contains amylase and lipase which digest starches and fats respectively.  The 
temperature of the food may be important.  Food that is too cold or too hot may 
be irritant to the oral mucosa or it may cause the oral enzymes to work less 
efficiently because at extremes of temperatures, enzymes will denature and fail 
to function.  Each of these aspects of the local oral mucosal environment may 
have an effect on buccal DNA and possibly its methylation. 
 
Once swallowed, the food bolus passes down the oesophagus and into the 
stomach, where pepsinogen begins to digest proteins.  In the small intestine, 
the now partially digested food comes into contact with amylases, trypsinogen 
and other proteases, nucleases and lipase secreted from the pancreas to 
further digest starches, proteins, nucleic acids and fats respectively the latter 
aided by bile from the gallbladder.  The result is that most of the food is 
digested into simpler monomeric forms including sugars, amino acids, fatty 
acids, vitamins and minerals which are absorbed along the small intestine.  In 
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summary, the majority of nutrients from the initial ingested food will not reach 
the large intestine.   
 
In contrast, dietary fibre and resistant starches resist degradation and pass into 
the large intestine.  Resistant starches and soluble dietary fibres are fermented 
in the colon to produce SCFA, such as butyrate, which has a local protective 
effect on colonic epithelium (Section 1.4.2.4).  Butyrate is not present in the 
mouth on initially ingesting dietary fibres or resistant starch to have the same 
local effect on the oral mucosa. 
 
4.4.1.4 Microflora of the oral mucosa compared with the rectal mucosa 
The microflora of the oral mucosa and rectal mucosa differ, and this may 
account for some of the difference in SFRP4 methylation at the two locations.  
Oral bacteria include streptococci, lactobacilli, staphylococci and anaerobes 
such bacteroides, whereas in the colon, whilst bacteroides are also present, 
coliforms are more prominent.  The microflora in both the mouth and colon 
synthesises vitamins.  Both are also able to stimulate the development and 
activity of immunological tissues, but the microflora of the colon has a greater 
ability to do this.  Some of the bacteria found in the colon may be harmful, for 
example, bacteroides produce metabolites that are carcinogenic (Todar 2013). 
 
4.4.2 Colorectal cells versus buccal cells 
In evaluating the utility of buccal cells as surrogates for molecular events in the 
colorectal epithelium relevant to the development of CRC, it is useful to 
consider similarities and differences between the epithelia per se, and the 
nature of the collected samples, at the two ends of the GI tract. Buccal DNA 
was extracted from samples taken from the buccal mucosa.  This is relatively 
thick non-keratinised epithelium that forms the lining of the mucous membrane 
in the mouth.  The mucous membrane in the mouth consists of stratified 
squamous cells.  In comparison, rectal DNA was extracted from mucosal 
biopsies obtained from the “simple” columnar lining of the rectum.     
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A rectal mucosal biopsy takes a piece of tissue from the rectum.  This will 
contain cells from the single layer of epithelial cells that line the colon, and also 
other structures such as immune cells, epithelial cells of the crypt and blood 
vessels.  In contrast, the buccal cells sampled when obtaining a buccal swab 
are the cells residing on the surface of the mucous membrane in the mouth, and 
this may not represent the level of SFRP4 methylation in all layers of the 
stratified squamous epithelium.  There is no literature available to suggest that 
SFRP4 methylation or methylation of any other gene differ across these layers.  
However, in oral stratified squamous epithelium, cell division occurs at the 
deeper layers, and not in the cells available at the surface which are most likely 
to be sampled with a buccal swab.  These cell differences could cause a 
difference in SFRP4 methylation levels.   
 
The alimentary canal starts at the mouth and ends at the anus, and involves 
both the mouth and rectum.  It consists of continuous regions although some 
organs, for example the oesophagus, stomach, small and large bowel have 
distinct boundaries separating them.  Field changes include abnormalities of 
epithelial gene expression affecting the mucosa rendering it vulnerable to 
neoplasia.  This phenomenon has been described in the colon in which DNA 
extracted from the colon has shown changes in methylation levels when 
neoplasia is present at any site within that colon (Belshaw et al. 2008).  As yet, 
there is no literature investigating whether field changes can be applied across 
the boundaries of different organs to different tissue types within the GI tract. 
For example, are changes in methylation levels in rectal DNA reflected in buccal 
DNA and vice versa?  If so, there is the possibility that CRC screening tests 
could use buccal DNA – a test which may be more acceptable to patients than 
rigid sigmoidoscopies to obtain rectal biopsies for DNA extraction or 
measurement of other biomarkers. 
 
The observation of significant negative correlations between SFRP4 promoter 
methylation in rectal DNA and buccal DNA at CpG site 1 (p=0.001, R=-0.184) 
(Figure 4.2) and CpG site 4 (p=0.041, R=-0.114) (Figure 4.3) was a further 
novel finding from this study.  This observation suggests that methylation of this 
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gene, at least at these 2 CpG sites, may be related in the 2 parts of the GI tract 
considered in this project. If similar factors influence SFRP4 promoter 
methylation in these 2 gut regions, one might have expected that the 
correlations would have been positive. The finding of significant negative 
correlations is intriguing and implies that, if there is a mechanistic connection, 
then the mediating factor(s) operates in opposite directions in the mouth and the 
rectum. This is the first study investigating relationships between methylation 
levels of the SFRP4 promoter in DNA from matched samples of rectal and 
buccal cells and further studies are needed to confirm, or to refute, these 
observations. 
 
4.4.3 SFRP4 methylation in buccal DNA as the basis for development of a 
screening test for CRC risk 
This research project has investigated the use of buccal cells as a surrogate 
tissue for rectal biopsies when investigating potential biomarkers of risk of 
developing CRC.  Collection of buccal cells has many practical advantages over  
obtaining biopsies from the rectum including i) the collection can be done 
anywhere and does not require that participants attend a clinic, ii) study 
participants can collect the buccal cells unaided i.e. without the requirement for 
specialised (expensive) medical staff, iii) sample collection is relatively non-
invasive and essentially hazard-free e.g. there is no risk of significant bleeding 
or perforation which can occur with rectal biopsies and iv) the collected samples 
can be preserved immediately in tubes provided as part of the collection kit 
without recourse to specialised equipment (e.g. liquid nitrogen storage) and 
transferred to the laboratory by hand or by post.  It is not known whether the 
field effect (changes in DNA methylation and gene expression which are 
indicative of vulnerability to CRC) that occurs in the colon extends to the mouth.  
However this study has shown that there are differences in SFRP4 methylation 
in buccal DNA extracted from those at a higher and lower risk for CRC and this 
promising finding requires further investigation.  If the hypothesis that buccal 
DNA can be used as a surrogate for rectal DNA is investigated rigorously and 
found to be true, DNA biomarkers specific to CRC may be measurable in buccal 
cells. 
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SFRP4 promoter methylation in buccal DNA obtained from the BORICC Studies 
were highly specific at identifying those at a lower risk of CRC (specificity > 0.93 
for all CpG sites individually and combined) (Table 4.4).  However sensitivity 
was relatively poor. The highest sensitivity was 0.65 (all CpG sites combined) 
(Table 4.4).  ROCs demonstrated that SFRP4 methylation in buccal DNA from 
the BORICC Study would be a “fair” to “good” test to differentiate between those 
at a higher and lower risk for CRC (AUC 0.75-0.88) (Table 3.4; Table 4.4; 
Figure 4.4) (Hanley & McNeil 1982) (section 4.2.4.4).  Similar to SFRP4 
methylation in rectal DNA, SFRP4 methylation in buccal DNA is not sensitive for 
identifying those at a higher risk of CRC (section 3.4.3).   
 
It is unlikely that any test measuring DNA biomarkers to assess risk for CRC 
would rely on only 1 gene.  All current DNA biomarker tests to assess risk for 
CRC use a panel of genes that are known to play a role in CRC development.  
This would be more reliable than measuring just 1 biomarker because CRC is a 
complex disease and aberrant expression of multiple tumour suppressor genes 
and oncogenes have been described.  SFRP4 promoter methylation in buccal 
DNA obtained from the BORICC Studies were highly specific at identifying 
those at a lower risk of CRC (specificity > 0.93).  This needs further 
investigation to ensure the high level of specificity is reproducible, and if found 
to be, SFRP4 methylation in buccal DNA could be used potentially as a 
biomarker for CRC risk.  It is likely that such use would be as a component of a 
panel of genes assessing risk and that the other selected biomarkers had high 
sensitivity to compensate for the poor sensitivity of SFRP4 at identifying CRC 
risk. 
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4.5 Conclusions 
This research project has shown that SFRP4 promoter methylation in buccal 
DNA is significantly greater (p<0.001) in those at a lower CRC risk, and this 
between risk group difference is the opposite to that observed for SFRP4 
methylation in rectal DNA.  
 
Possible correlations between SFRP4 promoter methylation levels in matched 
samples of rectal DNA and buccal DNA were investigated.  Although the 
direction of change was opposite, at CpG site 1 and CpG site 4 only, there was 
a relatively weak, but statistically significant, negative correlation between 
SFRP4 promoter methylation in buccal cells and that in rectal mucosa (p=0.001, 
R=-0.184, and p=0.041, R=-0.114 respectively). 
 
This is the first study which has investigated SFRP4 promoter methylation in 
DNA from buccal cells from colorectal polyp patients and further investigation is 
required to establish if these results are reproducible and to investigate causes 
for the unexpected difference in SFRP4 methylation.  In addition, further 
investigations should include the possible confounding effect of the local 
environment upon the differences in SFRP4 methylation in buccal DNA and 
rectal DNA. 
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5 Effect of short-term supplementation with resistant 
starch and polydextrose on SFRP4  methylation in 
the human colorectal mucosa. 
 
5.1 Introduction 
Chapter 3 of this thesis reports that methylation of the SFRP4 promoter was 
consistently greater in patients with polyps i.e. at higher CRC risk than in 
“normal” volunteers without evidence of colorectal neoplasia.  This suggests 
that SFRP4 promoter methylation might be a useful biomarker of CRC risk.  In a 
systematic review of 21 prospective cohort studies, including over 1.7 million 
participants and 12000 CRC cases, Aune et al. (2011) found that individuals 
with diets rich in dietary fibre have lower CRC risk.  On this basis we 
hypothesised that dietary factors such as resistant starch and polydextrose 
which lower CRC risk might alter methylation of the SFRP4 promoter. To test 
this hypothesis SFRP4 promoter methylation levels were quantified in rectal 
DNA obtained from healthy volunteers who were participants in the DISC Study 
(2011). Rectal mucosal biopsies were collected before and after a randomised 
controlled trial of dietary supplementation with resistant starch and polydextrose 
in a 22 factorial design. 
 
5.2 Methods 
Participants were recruited to the DISC Study (2011) from endoscopy lists 
within Northumbria Healthcare NHS Foundation Trust as outlined in section 2.5.  
In addition to the exclusion criteria outlined in section 3.2.1.1., volunteers 
wishing to participate in the dietary intervention study could not have any of the 
exclusion criteria described in section 5.2.1. 
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5.2.1 Exclusion criteria for the healthy participants in dietary intervention 
component of the DISC Study  
Potential participants recruited for the DISC Study (2011) dietary intervention 
study were excluded if they were taking anticoagulant medication such as 
warfarin or low molecular weight heparin.  This exclusion criterion was included 
as a safety measure because participants taking such therapies would be at 
increased risk of bleeding when their second set of rectal biopsies was taken.  
Due to the relatively small carbohydrate doses used in the DISC Study (2011) 
RCT, it is unlikely that blood sugar control would be affected by the placebo 
dietary supplements used in the intervention study (amioca starch or 
maltodextrin).  However, potential participants were also excluded if they were 
diabetic because diabetes is a risk factor for CRC.  In a systematic review of 30 
cohort studies on diabetes and CRC incidence, Jiang et al. (2011) 
demonstrated that the Relative Risk (RR) of CRC among diabetics was 1.27 
(95% CI 1.21-1.34). By excluding diabetics, we were likely to reduce inter-
individual heterogeneity in CRC risk and, possibly, in response to the 
interventions, among the study participants. 
 
5.2.2 Randomisation to treatment within the DISC Study 
The DISC Study (2011) was a randomised, placebo-controlled study.  Recruited 
participants who had no exclusion criteria selected an opaque sealed envelope 
from a box which dictated which dietary supplements they would receive 
(section 5.2.5).  Participants were also stratified into two separate groups 
dependent on which endoscopy procedure (flexible sigmoidoscopy or 
colonoscopy) they received at the time of collection of their initial biopsies.  
Randomisation was double blinded and, as this is an ongoing study, the 
investigators will not be “unblinded” as to which combination of dietary 
supplements study participants received until after the submission of this thesis. 
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5.2.3 Biological samples 
Rectal mucosal biopsies were obtained from participants as described section 
3.2.2.1. 
 
5.2.4 The dietary intervention 
Participants in the DISC study (2011) RCT took a dietary supplement for 50 
days following collection of their initial rectal biopsies.  This supplementation did 
not start immediately after their first biopsies as it was possible the bowel 
mucosa and colorectal microbiome would be affected by the bowel preparation 
given prior to their initial endoscopy investigation.  Therefore a “washout” period 
of at least seven days was used before commencing the dietary supplements.  
A minimum of seven days “washout” period was deemed sufficient because 
colorectal stem cells divide and migrate from the base towards the surface of 
the colonic crypt, where they die or are sloughed off into the colonic lumen, in 4-
8 days (Stappenbeck et al. 1998, Radtke & Clevers 2005).   Upon completion of 
the 50 day supplementation, a repeat set of biological samples was collected. 
 
5.2.5 The dietary supplements 
The DISC Study used a 22 factorial design to test the impact of two “active” 
agents on colonic health The “active” agents were Hi-maize 260 (National 
Starch, USA) (resistant starch) and polydextrose (Danisco, Finland) and  the 
corresponding placebo agents were amioca starch and maltodextrin 
respectively.  This study design resulted in 4 intervention combinations: 
1. Hi-maize 260 (23g/d) and polydextrose (12g/d)  
2. Hi-maize 260 (23g/d) with maltodextrin (12g/d) (polydextrose placebo) 
3. Polydextrose (12g/d) with amioca starch (23g/d) (Hi-maize 260 placebo) 
4. Double placebo [amioca starch (23g/d) and maltodextrin (12g/d)]. 
 
All supplements were packaged into 88cm opaque silver sachets and coded 
according to their contents.  The sachets were then packed into boxes to 
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contain a week’s supply of supplements to make up each type of dietary 
intervention.  The daily dose of each supplement was split equally between two 
sachets.  Therefore each day, each participant was asked to consume 4 
sachets; and each weekly box of supplements contained 28 sachets.   
 
Participants were asked to consume the supplements on, or added to, cold food 
or mixed with cold water.  They were asked to retain the sachets whether or not 
the supplement had been eaten to allow compliance to be assessed. 
 
5.2.5.1 Hi-maize 260 
Hi-maize 260 is a source of resistant starch which is isolated from a hybrid corn 
(maize) that is naturally high in amylose.  It contains approximately 60% 
resistant starch and 40% digestible starch. 
 
5.2.5.2 Polydextrose 
Polydextrose is an indigestible synthetic polymer of glucose and sorbitol.  It is 
very poorly digested in the small intestine and more than 95% of polydextrose 
available for fermentation in the colon. 
 
5.2.5.3 Amioca starch 
This starch consists mainly of amylopectin, an α[1-6]-branched  polymer of 
glucose in which the glucose residues in the linear components are α[1-4]-
linked  It is completely digested in the small intestine and therefore none 
reaches the colon. 
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5.2.5.4 Maltodextrin 
Maltodextrin is an oligosaccharide made by partial hydrolysis of starch.  It is 
easily digestible and fully absorbed in the small intestine.  None reaches the 
colon.   
 
5.2.6 Laboratory methods 
DNA was extracted from rectal biopsies and processed to quantify SFRP4 
promoter methylation as described in section 3.2.3. 
  
5.2.7 Statistical analyses 
5.2.7.1 Comparison of participant characteristics in the DISC Study 
Characteristics of the participants in the four dietary intervention groups of the 
DISC Study were compared using ANOVA in a general linear model to identify 
any significant differences in the mean age and BMI between treatment groups; 
2 test to identify any significant difference in the smoking status and the 
male:female ratio of the treatment groups. p<0.05 was considered significant.  
 
5.2.7.2 Investigation of the effect of the dietary intervention within the DISC 
Study 
The dietary intervention within the DISC Study was arranged as a 22 factorial 
design with the aim of testing the effects of resistant starch and polydextrose. 
This allowed investigation of the effects of each dietary agent individually and 
also any potential interaction between them.  Data collected for this research 
project was analysed for the effects of “Treatment 1” and “Treatment 2”.  It is 
unknown which of resistant starch or polydextrose “Treatment 1” and 
“Treatment 2” refer to.  Minitab (version 16) statistical software was used to 
analyse the outcome data (after intervention) using ANOVA in a general linear 
model with the corresponding baseline data (before intervention) as a covariate.  
The direct effects of Treatment 1 and of Treatment 2 were assessed individually 
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and any potential interaction was also investigated.  Results were expressed as 
least square means  SEM.  p<0.05 was considered to be significant.  
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5.3 Results 
5.3.1 The DISC study 
1508 potential participants attending the endoscopy departments in 
Northumbria Healthcare NHS Trust were invited to participate in the dietary 
intervention in the DISC study.  Details are presented in the CONSORT 
diagram (Figure 5.1)  Of these, 86 participants who did not have any exclusion 
criteria (section 5.2.1) and who consented to participate were recruited to the 
dietary intervention study and were randomised into 4 groups according to a 
22 factorial design (section 5.2.2).  Seventy five participants completed the 
intervention study (section 5.2.4).  DNA was extracted from macroscopically 
normal rectal biopsies before and after the dietary intervention in 74 of the 
healthy volunteers.  For one participant, it was not possible to obtain safely 
rectal biopsies after completion of the dietary intervention study because of 
inability to visualise the lining of the rectum because of large amounts of stool in 
the rectum.  Therefore, for this individual, there was no DNA for quantification of 
SFRP4 promoter methylation levels after completion of the dietary intervention.  
It was not possible to quantify SFRP4 promoter methylation levels for DNA 
extracted from one other participant because the DNA extracted from the rectal 
biopsy obtained from this individual following completion of the dietary 
intervention was of insufficient quality to allow quantification of SFRP4 promoter 
methylation (Figure 5.1).   
 
5.3.2 Patient demographics 
The demographics of the dietary intervention participants are shown in Table 
5.1.  There were no significant differences in age (p=0.062, ANOVA), the 
male:female ratio (p=0.1078, 2 test), BMI (p=0.566, ANOVA) or smoking status 
(p=0.6686, 2 test) between the four different dietary intervention groups. 
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Figure 5.1 CONSORT diagram summarising  recruitment to, and participant 
flow through, the DISC Study (Schulz et al. 2011) 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Reasons for participant drop-out included: They did not like the intervention 
(n=2); they changed their mind (n=2); they were unable to participate because 
of time commitments (n=3); there were privacy issues with their family (n=1); 
they experienced bloating whilst taking the intervention (n=1); they became 
unwell during the intervention phase (not related to the intervention) (n=1); 
incorrect classification of endoscopy as “normal” by the study team (n=1). 
 
1508 potential participants 
attending endoscopy 
departments in Northumbria 
Healthcare NHS Trust. 
 
86 participants were 
randomised into 4 groups 
according to a 22 factorial 
design 
 
1422 patients had exclusion 
criteria or did not consent to 
participate. 
 
75 participants completed 
the dietary intervention study 
 
11 participants dropped out 
post randomisation* 
 
DNA extracted from rectal 
biopsies before and after the 
dietary intervention for 73 
participants. 
 
Unable to obtain rectal 
biopsy following completion 
of study for 1 participant. 
Poor quality DNA extracted 
from rectal biopsy from 1 
participant upon completion 
of study. Therefore unable to 
quantify SFRP4 methylation. 
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Table 5.1 Demographics of participants in the DISC Study by intervention group 
 Group A* Group B* Group C* Group D* 
Number of 
participants  
(male:female) 
18 
(9:9) 
(50%:50%) 
21 
(9:12) 
(43%:57%) 
17 
(5:12) 
(29%:71%) 
17 
(12:5) 
(71%:29%) 
Mean age   
(standard 
deviation) 
49 years 
(12.54 years) 
58 years  
(14.96) 
54 years  
(7.04) 
50 years  
(10.18) 
Mean BMI   
(standard 
deviation) 
29.50 
(4.84) 
29.36 
(6.10) 
31.68 
(5.00) 
30.04 
(5.60) 
Smoking 
status 
(non/ex/current) 
11/4/3 
(61:22:17%) 
12/6/2 
(57:28:10%) 
[1 (5%) 
unknown] 
8/5/4 
(47:29:24%) 
6/6/5 
(35:35:30%) 
 
*The four intervention groups are labelled groups “A-D” for purposes of 
illustration. It is not known what treatment combination each intervention group 
received. 
 
5.3.3 The dietary intervention 
DNA was extracted from macroscopically normal rectal mucosal biopsies before 
and after the dietary intervention for 73 healthy volunteers.   
 
5.3.4 The effects of Treatment 1 and Treatment 2 on SFRP4 methylation in 
rectal DNA   
Neither dietary intervention had any significant effect on SFRP4 methylation in 
rectal DNA at any of the CpG sites investigated; see Figure 5.2 (Treatment 1) 
and Figure 5.3 (Treatment 2). 
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For those participants randomised to Treatment 1, With the exception of CpG 
site 1, SFRP4 promoter methylation was higher in study participants before the 
treatment 1 (Figure 5.2).  These differences were not statistically significant 
(p>0.498).  SFRP4 methylation ranged from approximately 8-14% and was 
highest at CpG site 4 and lowest at CpG site 1 in study participants who were 
given Treatment 1 (Figure 5.2).  
 
Figure 5.2 SFRP4 methylation in rectal DNA obtained from participants of the 
DISC Study: Treatment 1 
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Figure 5.3 SFRP4 methylation in rectal DNA obtained from participants in the 
DISC Study: Treatment 2 
 
 
SFRP4 promoter methylation was higher in study participants after Treatment 2 
(Figure 5.3) but these differences were not statistically significant (p>0.178).  
SFRP4 methylation ranged from approximately 7-15% and was highest at CpG 
site 4 and lowest at CpG site 1 in study participants who were given Treatment 
2.  
 
5.3.5 SFRP4 methylation in rectal DNA: Potential interaction between 
Treatment 1 and Treatment 2  
Although there was no evidence that either Treatment 1 or treatment 2 
individually  had any significant effect on SFRP4 promoter methylation , the 
results shown in Figure 5.4-Figure 5.9 suggest that there may be interactions 
between the two dietary supplements on SFRP4 promoter methylation (“0” and 
“1” indicate the two levels of treatment (placebo and active) but the identity of 
each remains blinded; the p-value refers to the interaction of Treatment 1 and 
Treatment 2).   
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Figure 5.4 Potential interaction between resistant starch and polydextrose on 
SFRP4 methylation in rectal DNA obtained from the DISC Study – all CpG sites 
combined.  
 
 
Figure 5.5 Potential interaction between resistant starch and polydextrose on 
SFRP4 methylation in rectal DNA obtained from the DISC Study – CpG site 1 
 
 
 
0
2
4
6
8
10
12
14
1 2
%
 S
F
R
P
4
 m
e
th
y
la
ti
o
n
 (
m
e
a
n
) 
Treatment 1 
Series1
Series2
Treatment 2 
Level 0 
Level 1 
0
1
2
3
4
5
6
7
8
9
10
1 2
%
 S
F
R
P
4
 m
e
th
y
la
ti
o
n
 (
m
e
a
n
) 
Treatment 1 
Series1
Series2
0 1 
Treatment 2 
Level 0 
Level 1 
0 1 
0 and 1 represent 
the two levels of 
treatment (active 
and placebo) but 
the identity of 
each remains 
blinded 
0 and 1 represent 
the two levels of 
treatment (active 
and placebo) but 
the identity of 
each remains 
blinded 
p=0.067 
p=0.212 
143 
 
Figure 5.6 Potential interaction between resistant starch and polydextrose on 
SFRP4 methylation in rectal DNA obtained from the DISC Study – CpG site 2 
 
 
Figure 5.7 Potential interaction between resistant starch and polydextrose on 
SFRP4 methylation in rectal DNA obtained from the DISC Study – CpG site 3 
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Figure 5.8 Potential interaction between resistant starch and polydextrose on 
SFRP4 methylation in rectal DNA obtained from the DISC Study – CpG site 4 
 
 
Figure 5.9 Potential interaction between resistant starch and polydextrose on 
SFRP4 methylation in rectal DNA obtained from the DISC Study – CpG site 5 
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qualitatively similar at all CpG sites investigated. When Treatment 2 was given 
at Level 0, SFRP4 methylation was higher when Treatment 1 was given at 
Level 1 than when given at Level 0. In contrast, when Treatment 2 was given at 
Level 1, SFRP4 methylation was always lower when Treatment 1 was given at 
Level 1 than when given at Level 0. Although this interaction was apparent at all 
CpG sites, it is illustrated best at CpG site 2 (Figure 5.6) where the interaction 
was highly significant (p=0.008). 
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5.4 Discussion 
5.4.1 Resistant starch and polydextrose given as chemoprevention agents 
independently 
Resistant starch and polydextrose are so-called non-digestible carbohydrates 
i.e. they are not digestible in the small intestine and so flow to the large bowel 
where they are exposed to bacterial fermentation. As such, they may be 
classified as types of dietary fibre, and there have been multiple observational 
studies that show reduced CRC risk is associated with increased intake of 
dietary fibre (Bingham et al. 2003, Dahm et al. 2010, Aune et al. 2011).  
However, because of the close associations between dietary fibre and many 
other dietary components and, indeed, other lifestyle factors, it remains 
uncertain whether dietary fibre per se protects against the development of CRC 
or whether it is a marker of a lower risk diet/lifestyle. Chapter 3 shows that there 
are higher levels of SFRP4 methylation in those at increased risk (patients with 
polyps compared with “normal” volunteers) which suggests that SFRP4 is a 
possible biomarker of CRC risk.  If resistant starch or polydextrose were 
chemoprotective, it was expected rectal DNA extracted from individuals taking 
resistant starch and/or polydextrose would have lower levels of SFRP4 
methylation.  This difference was not seen.  When given individually, neither 
dietary intervention had any significant effect on SFRP4 methylation in rectal 
DNA at any of the CpG sites investigated.   
 
The CAPP1 Study (Burn et al. 2011) and CAPP2 Study (Mathers et al. 2012) 
found no significant effect of resistant starch (with or without aspirin) on the 
development of CRC in individuals with FAP (CAPP1 Study) and HNPCC 
(CAPP2 Study), where colorectal adenoma (CAPP1 Study) and colorectal 
neoplasia (CAPP2 Study) was the primary outcome.  In comparison, the study 
participants in this research project were healthy with no genetic predisposition 
to the development of CRC, and the outcome measure was the effect of 
resistant starch on SFRP4 methylation.  Therefore, the outcomes from the 
CAPP1 Study and CAPP2 Study are not directly comparable with those from 
this current research project.  It is possible that resistant starch affects 
individuals genetically predisposed to CRC development (e.g. HNPCC, FAP) 
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differently to the general population.  This is supported by Aune et al. (2011), 
who have reported that dietary fibre (e.g. resistant starch) significantly reduced 
CRC development in a meta-analysis. 
 
The apparently protective effect of higher intakes of dietary fibre against CRC 
development which has been reported in observational studies may be the 
result of the health benefit of the whole dietary habits and/or lifestyles of the 
study participants rather than of the dietary fibre per se.  This may explain why, 
in intervention studies, a protective effect of dietary fibre supplements alone has 
not been observed (Mathers et al. 2012). 
 
In the current study, the effect of resistant starch and polydextrose was 
investigated in a group of individuals at relatively low CRC risk.  As this group of 
study participants were already at lower CRC risk, it may not have been 
possible to reduce this risk further and this could account for why there was no 
significant drop in SFRP4 methylation levels following intervention.  It would 
have been interesting to investigate the effects of these dietary agents on those 
at a higher risk of CRC, who may have higher levels of SFRP4 methylation, and 
to identify whether or not these dietary agents were able to reduce the levels of 
SFRP4 methylation to those levels measured for the lower CRC risk group.   
 
The lack of any significant effect of either of the dietary agents may be due to 
the small sample sizes of participants in the intervention study.  A retrospective 
power analysis showed that for the differences in SFRP4 methylation observed 
between the different treatment groups, to achieve a power of 80%, 201 study 
participants would be needed.  This demonstrates that the sample size for the 
DISC Study was probably too small for this specific outcome measure.   
  
In addition, or alternatively, the dose of each chemoprevention agent (12 
grams/day of polydextrose and 23 grams/day of resistant starch) used in this 
study may have been too small.  This is the first study to investigate the effects 
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of resistant starch and polydextrose on SFRP4 methylation in colorectal DNA, 
and therefore there are no other studies for direct comparison.  The latest data 
from the CAPP2 Study has shown that 30 grams of resistant starch given daily 
for a median of 24.4 months had no effect on CRC development after a median 
follow up time of 52.7 months (Mathers et al. 2012).  Therefore, a dose of 23 
grams/day of resistant starch given in this study given for only 50 days with no 
follow up may have been too small to exert any significant effect.  However, 
contrasting to the results of the CAPP2 Study (Mathers et al. 2012), Aune et al. 
(2011) found that just 10g/day of dietary fibre was needed to reduce the risk of 
CRC risk by 10%.  There is no literature regarding the effect of polydextrose on 
DNA methylation and what quantity is likely to have a therapeutic effect in the 
context of colorectal cancer risk and development. 
 
The dietary agents may have been given for too small a time period for an effect 
to be observed.  Cells in the colorectal mucosa have a life span of 
approximately 5 days during which they arise from the stem cell at the colonic 
base and migrate along the colonic crypt to the mucosal surface from where 
they are shed into the colonic lumen (Bach et al. 2000).  Dronamraju et al. 
(2009) showed a significant reduction (p=0.028) in the proportion of mitotic cells 
in the top half of the colonic crypts in patients with CRC who were given 
resistant starch for just 2-4 weeks.  There was also an increase in the 
expression of CDK4 and GADD45A genes in CRC tissue following resistant 
starch intervention.  These genes are associated with reduced cell proliferation 
(CDK4) and genomic stability (GADD45A).  The participants in this research 
project (the DISC Study) took the intervention agent they were assigned for 50 
days – almost twice as long as Dronamraju et al.’s (2009) study, and therefore it 
is likely that the dietary agents in this study were given for a long enough time 
period to exert a biological effect. 
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5.4.2 Resistant starch and polydextrose given as chemoprevention agents in 
combination 
Resistant starch and polydextrose may interact together to affect SFRP4 
methylation.  In this study, it appears that the effect of one treatment depended 
upon the presence (or absence) of the other.  This is illustrated best for SFRP4 
methylation at CpG site 2 where the interaction was highly significant (p=0.008). 
However, the interaction was qualitatively similar at the 4 other CpG sites 
investigated which increases confidence that this may be a biologically 
important interaction. In each case, when Treatment 2 was present at Level 0, 
SFRP4 methylation was higher when Treatment 1 was given at Level 1 than 
when given at Level 0. The opposite response occurred when Treatment 2 was 
given at Level 1 i.e. SFRP4 methylation was reduced when Treatment 1 was 
given at Level 1 compared with that when given at Level 0. 
 
At present this study remains blinded so that the identities  of “Treatment 1” and 
“Treatment 2” are not known i.e. which is resistant starch and which is 
polydextrose, nor is it known which of Level 0 and Level 1 refers to “Placebo” 
and which to “Active agent”. As a consequence, the biological interpretation of 
the interaction summarised above cannot be determined until the DISC Study is 
unblinded. Of necessity, the following remarks are speculative and should be 
considered as ideas which will be pursued when the main study has been 
unblinded. Both resistant starch and polydextrose are substrates for colonic 
fermentation which produces butyrate and a range of other fermentation end-
products including other SCFA.  In addition, each individual carbohydrate may 
support the proliferation of a (subtly) different consortium of bacteria within the 
colon and it is likely that these bacteria or their metabolic end-products are 
responsible for effects in colonocytes within the epithelium including epigenetic 
marks such as DNA methylation. To my knowledge, there is no literature 
investigating whether resistant starch and polydextrose or other non-digestible 
carbohydrates interact in their effects on the gut microbiome, the metabolic end-
products of this bacterial metabolism or down-stream effects on the colorectal 
mucosa. However, collaborators working within the DISC Study have collected 
data on several relevant factors including in faeces: SCFA concentrations, 
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bacterial species and concentrations of compounds with pro- and anti-
inflammatory actions. In addition, the DISC team has undertaken extensive 
characterisation of cellular and molecular markers in the colorectal mucosal 
biopsies, including the methylation status of a larger panel of genes, which will 
be useful in determining i) whether interactions between polydextrose and 
resistant starch are apparent for other methylation of other genes involved in 
WNT signalling and  ii)  to help explain the biological basis for the observed 
interaction.   
  
151 
 
5.5 Conclusions 
This research project has shown that following a 50 day dietary intervention 
study, 23 grams/day of resistant starch and 12 grams/day of polydextrose, 
individually and in combination had no significant effect on the SFRP4 
methylation in DNA extracted from colorectal cells obtained from healthy 
volunteers.  Although the interaction effect was not statistically significant, this 
research project suggests that the direction of change exerted by the two 
dietary intervention agents on colon cell SFRP4 methylation is opposite.  The 
reasons for this are unknown and require further investigation. 
 
Another area of future research is to assess whether resistant starch and/or 
polydextrose can reverse the higher levels of SFRP4 methylation that have 
been observed in those at a higher risk of CRC in this research project. 
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6 Conclusions 
6.1 Summary of findings 
This research project aimed to test 3 hypotheses using pyrosequencing to 
quantify SFRP4 methylation in various DNA samples obtained from rectal 
mucosal biopsies and buccal swabs taken from participants in the BORICC 
Study (Mathers et al. 2010) and the DISC study (2011). 
 
The first hypothesis was that the SFRP4 promoter is differentially methylated in 
rectal DNA obtained from volunteers at a lower (normal healthy volunteers) and 
higher (patients with a history of adenomatous polyps or a history of non-active 
UC) risk for CRC using rectal mucosal biopsies obtained in the BORICC Study 
and the DISC Study.   There was strong evidence that SFRP4 promoter 
methylation in DNA extracted from colorectal cells is greater in those at a higher 
CRC risk as demonstrated by the significantly (p=0.036) higher levels of SFRP4 
methylation in those at higher CRC risk in the BORICC Study.  In addition, 
SFRP4 methylation was also greater in those at a higher risk in the DISC Study, 
though this difference was not significant (p>0.15) in this much smaller study.  
This direction of change in SFRP4 methylation is in keeping with studies 
published in the literature by Qi et al. (2006) and Belshaw et al. (2008). 
 
This study also found a negative correlation between percentage SFRP4 
methylation and serum vitamin D concentration at all CpG sites investigated, 
and this supports the literature which proposes that there is a link between 
SFRP4 methylation and vitamin D concentration. 
 
This research project has found that SFRP4 methylation alone is not a suitable 
epigenetic biomarker for CRC risk.  Although SFRP4 methylation levels in rectal 
DNA obtained from the BORICC Studies and the DISC study were both highly 
specific in identifying those at a lower risk of CRC (specificity>0.84), SFRP4 
methylation levels in rectal DNA obtained from both studies had poor sensitivity 
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levels (sensitivity<0.28). It remains to be discovered whether SFRP4 
methylation is a useful inclusion in a panel of markers of CRC risk. 
 
The second hypothesis was that buccal DNA will show the same pattern of 
SFRP4 promoter methylation as rectal biopsies in volunteers at a lower and 
higher risk of CRC and so will have potential as a surrogate tissue for CRC 
biomarker assay.  SFRP4 promoter methylation in matched samples of rectal 
DNA and buccal DNA from volunteers at a lower (normal healthy volunteers) 
and higher (patients with a history of adenomatous polyps) risk for CRC was 
quantified using rectal mucosal biopsies and buccal cells obtained in the 
BORICC study.  Surprisingly, SFRP4 promoter methylation in buccal DNA 
obtained from the BORICC Study was significantly (p<0.001) greater in those at 
a lower CRC risk. This between risk group difference is the opposite to that 
observed for SFRP4 methylation in rectal DNA and deserves further 
investigation.   
 
Possible correlations between SFRP4 promoter methylation levels in matched 
samples of rectal DNA and buccal DNA were also investigated.  At CpG site 1 
and CpG site 4 only, there were statistically significant, but relatively weak, 
negative correlations between SFRP4 promoter methylation in buccal cells and 
that in rectal mucosa (p=0.001, R=-0.184, and p=0.041, R=-0.114 respectively). 
 
The third hypothesis was that SFRP4 promoter hypermethylation in rectal 
biopsies is reversible by dietary supplements of resistant starch and 
polydextrose (both alone and in combination).  Pyrosequencing was used to 
quantify SFRP4 promoter methylation levels in rectal DNA obtained from 
healthy volunteers in the DISC Study (2011) before and after a randomised 
controlled trial of effects of dietary supplementation with 23 grams/day resistant 
starch and 12 grams/day polydextrose in a 22 factorial design.  In this study, 
resistant starch and polydextrose had no significant effect individually or in 
combination on SFRP4 methylation in colorectal DNA from healthy individuals 
after a 50 day trial.  However, this study revealed evidence of possible 
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interactions between resistant starch and polydextrose on SFRP4 methylation 
and this requires further investigation. 
 
6.2 Suggestions for future research 
Further studies investigating the differential methylation of SFRP4 in those at a 
lower and higher risk for CRC should include investigating why there were 
differences in SFRP4 methylation levels in rectal DNA from the BORICC and 
DISC Studies.  In addition, it would be valuable to undertake longer term follow 
up of the patients in the BORICC Study and DISC Study to establish which of 
them  develop CRC and to ascertain  whether or not the SFRP4 methylation 
level quantified at baseline in the present study predicted those who went on to 
develop CRC. 
 
Further investigation is required to assess whether low vitamin D concentrations 
are causal for raised SFRP4 methylation, and whether this may be a possible 
mechanism through which low vitamin D status increases the risk of CRC. 
 
This is the first study which has investigated SFRP4 promoter methylation in 
DNA from buccal cells from colorectal polyp patients and further investigation is 
required to establish if these results are reproducible and to investigate causes 
for the unexpected difference in SFRP4 methylation.  Further investigations 
should also include the possible confounding effect of the local environment 
upon the differences in SFRP4 methylation in buccal DNA and rectal DNA. 
 
Future research should determine whether or not resistant starch and/or 
polydextrose can reverse the higher levels of SFRP4 methylation that have 
been observed in those at a higher risk of CRC in the present study.  The 
apparent interaction between resistant starch and polydextrose on SFRP4 
methylation also requires further investigation. 
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Appendix I 
Letter to potential study participants 
 
Dept of Surgery 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
 
 
Dear 
 
We are writing to inform you about a study that we are conducting at North Tyneside 
General Hospital and Wansbeck General Hospital. We are writing to you because you 
have been booked for an endoscopy (a camera examination of the lower bowel). 
 
Our research aims to examine how diet can influence cells in the bowel wall and the 
changes they sometimes undergo to become a cancer. To conduct this study we require 
samples taken from the bowel wall from normal volunteers without a cancer.  
 
Please take your time reading the enclosed information. When you arrive for your 
endoscopy you will be seen by one of the research team who will be able to provide you 
with further information. If you decide to take part in the study you will have to sign a 
consent form. If you decide not to participate now, or at a later time within the study, it 
will not affect any other aspect of your treatment at the hospital. 
 
Thank you for your cooperation which is very much appreciated. 
 
Yours sincerely 
 
 
 
Naomi Willis 
Research Associate 
Newcastle University 
 
On behalf of the research team 
 
 
John Mathers    Iain McCallum  Naomi Willis 
Professor of Nutrition  Research Fellow  Research Associate 
Newcastle University  North Tyneside Hospital Newcastle University 
 
Seamus Kelly   Mike Bradburn   
Consultant Surgeon  Consultant Surgeon   
North Tyneside Hospital Wansbeck Hospital  
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Appendix II 
Letter of invitation/research participant information sheet 
 
 
Dear Sir/Madam, 
 
 
You are being asked if you would be willing to participate in one of our research 
projects that is being conducted by Northumbria NHS Foundation Trust and Newcastle 
University.  
 
Before you decide to participate, please read the details below. Take the time to read the 
following information carefully and discuss it with friends, relatives and your GP if you 
wish. Ask us if there is anything that is not clear to you or if you would like more 
information. Your GP will be informed if you decide to participate in the study. Take 
time to decide whether or not you wish to take part. Deciding to take part or not to take 
part will not affect any other aspect of the care that you will receive. 
 
Why have I been offered entry to the study? 
You have been offered entry to the study because your doctor (GP or hospital doctor) 
has requested that we perform an endoscopy (camera examination of the lower bowel). 
For our research we require biopsy samples from patients’ colons to examine particular 
cells. Depending on the findings at your endoscopy, you may be asked to participate in 
the study where a food supplement is taken for 50 days and a repeat camera test is done 
with new biopsies taken. 
 
Why is this study being performed? 
One part of the study is designed to examine colon stem cells (stem cell study). Stem 
cells are present in all tissues of the body and are responsible for renewing all cells in 
the body. Cancers are thought to originate from stem cells by a process of genetic 
alterations. If no abnormality is present on your endoscopy we would like to take nine 
biopsies (tiny tissue samples) so that we can count the number of stem cells present in 
the tissue. We will be able to compare your samples with other peoples’ to see how the 
distribution of stem cells varies between people. We will also compare your samples 
with other people who have precancerous abnormalities to see how normal is different 
from them. 
 
In the colon we know that a substance thought to be protective against cancer (non-
digestible carbohydrates) can reverse some very early precancerous changes at a 
microscopic level in tissue from people who have colon cancer. Two non-digestible 
carbohydrates are resistant starch and polydextrose. Non-digestible carbohydrates occur 
naturally in the diet. 
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We believe that the changes in the cells in the bowel caused by non-digestible 
carbohydrates may be due to changes in the numbers of stem cells in the colon. To test 
this we would like you to take a food supplement which will be a type of non-digestible 
carbohydrate or a placebo (a substance that has no effect) for 50 days. We would then 
take further biopsy samples with a different type of telescope that only examines the last 
15cm of the bowel to see if the number of stem cells has changed. This procedure 
doesn’t require any medicines to cleanse the bowel beforehand.  
 
The other part of the study (marker study) aims to help us understand the molecular 
changes that put some people at risk of colon cancer. We know that diet and lifestyle 
choices can affect the risk of developing colon cancer. However definite answers that 
would tell us how colon cancer could be prevented are hard to come by as we have to 
conduct experiments over very long time periods as we need to wait and see who 
develops a cancer and this is a very slow process (tens of years). We need to understand 
some of the changes that we can measure much earlier, particularly expression of 
certain molecules and genes. To know whether these molecules are sensitive enough to 
show the very early changes we are looking for we need to test their response to dietary 
supplementation. These tests would be carried out on the same samples that you 
provided for the stem cell part of the study. 
 
What exactly would I have to do as a participant? 
If you decide to participate and there are no abnormalities seen in your colon we will 
ask if you would carry on with the study. This would involve taking a food supplement 
twice a day for 50 days and then returning for a second endoscopy to look at the last 
15cm of the bowel to collect further biopsies. 
 
We would ask all patients to answer some questions at the start of the study about their 
lifestyle (smoking, dietary and exercise habits). We would take height, weight, waist, 
hip and thigh measurements at the start and end of the study. We would also like to 
collect a blood sample as well as a urine, stool and cheek cell sample at the start and the 
end of the study. To allow the effects of the bowel preparation to wear off so that our 
measurements are accurate we would ask that you wait for one week after your first 
endoscopy before starting the food supplement. Just before starting the food supplement 
we would ask you to give a urine and stool sample. We will give you more details on 
this if you decide to participate. 
 
Deciding not to participate will not affect any other treatments or investigations that the 
hospital would provide for you. 
 
How often do I need to visit the hospital during the study? 
You would need to attend for the first endoscopy as you normally would. If you are 
asked to participate further the food supplement would be supplied to you and you 
would be asked to attend again for one further examination of the last 15cm of the 
bowel after 50 days of treatment. Before you start taking your supplement we would ask 
you to provide a urine and stool sample. This would be one week after the first 
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endoscopy and we will provide you with equipment and instructions to collect this at 
home. We would pick up this sample from your home at a time that suits you. You 
would then take your food supplement after this. Just before your second endoscopy we 
would ask you to provide a urine and stool sample in the same way which we would ask 
you to bring with you at the time of your second appointment. 
 
There may of course be other clinic appointments or tests required due to the results of 
tests that are unrelated to this study. These would not alter although we would do our 
best to fit your one repeat endoscopy test around any other appointments that you had to 
minimise your inconvenience. 
 
What food supplement would I be taking? 
You will not be told and we would not know what supplement you were taking. You 
would either be taking resistant starch, polydextrose or a substance called a placebo 
which is something that will have no effect on your cells. Both the patient and the study 
staff not knowing what supplement anyone is taking makes the experiment fairer when 
it comes to looking at the results. 
 
What do we know about non-digestible carbohydrates? 
Non-digestible carbohydrate is a term for any starch molecule in the diet that is not 
broken down by the intestine until it reaches the colon. In the colon natural bacteria 
break down the resistant starch into active chemicals. We know that these chemicals 
have the ability to interact with genes in cells and are able to switch on anti-cancer 
genes. We have shown that treatment with resistant starch can alter very early pre-
cancerous changes in mature cells. This study aims to find the effects on the stem cells 
in the colon and the effects on molecules that could be tested for to show the earliest 
signs of cancer development. 
 
How is the supplement administered? 
We will ask you to take four sachets of the supplement each day for 50 days. The 
powder in these sachets can be put on cold food or sometimes dissolved in juice and 
does not have any taste. 
 
What side effects can I expect? 
Non-digestible carbohydrates are part of the normal diet although we are providing a 
supplement to exaggerate any effect that they have on colon cells. In larger amounts 
non-digestible carbohydrates are known to sometimes cause: increased flatulence, 
bloating sensation, mild abdominal pain and mild laxative effects. These will all stop 
when the supplementation is stopped. No serious side-effects have ever been reported 
from non-digestible carbohydrates. 
 
What are the risks of endoscopy examination and biopsies? 
All operations and procedures carry a small risk and it is important that you understand 
this before deciding whether or not to participate. There is a very small chance of a 
perforation (a hole made in the bowel) of the bowel (1 in 15 000). A perforation will 
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almost always require an operation to fix it. Bleeding occurs more frequently (1 in 100-
200) but is almost always minor and settles on its own. It is most common after removal 
of a polyp. Although you may require to have a polyp removed depending on what your 
consultant sees at your initial endoscopy this would not be a part of the study we are 
conducting. This risk of bleeding or perforation is obviously higher with each biopsy 
that is being taken. We plan to take nine biopsies at your first and second camera 
examinations. 
 
What happens if anything goes wrong? 
You are free to participate or not in the study and this will in no way affect your 
subsequent care in the hospital. There is no payment intended for patients or doctors. If 
you are harmed by taking part in this research project, there are no special compensation 
arrangements, but you will still be entitled to complain through your local NHS hospital 
procedure. If you are harmed due to someone’s negligence or wrong doing, then you 
may have grounds for a legal action but you may have to pay for it. You may withdraw 
from the study at any time without explaining why, this will not affect any future care 
that you may receive. 
 
Will the information be confidential? 
Yes. Only those involved will be able to look at any information records. Specific 
details which identify you will only be available to the study doctors. Your own doctor 
(GP) will be informed that you are taking part in this study.  
 
What will happen to the samples collected? 
The samples that are collected will be examined at laboratories in Newcastle University. 
All samples will be stored securely. We will perform tests to look for the stem cells and 
tests to look at the activity of the various markers we are looking into. After the study 
has finished the samples will be stored in our laboratory freezers in accordance with 
government regulations. Your name and details will no longer be associated with the 
samples. We keep the samples so that if new techniques or markers are discovered we 
can do further testing without having to collect new samples from other volunteers. 
 
What benefits may I get from the study? 
We do not believe that there will be any direct benefit to the health of those who 
participate in the study. The research may well help us to understand the development 
of bowel cancer and develop prevention or treatment strategies. 
 
We will give all the patients who take part in the intervention phase (i.e. taking the food 
supplement) a shopping voucher for £50 as a thank you for the extra time that they will 
have given up for the project. Travel expenses for the additional trip to hospital will also 
be provided. 
 
Who is performing the research? 
 
The research team consists of five members: 
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Mr Iain McCallum is a research fellow at Northumbria NHS Foundation Trust 
Dr Naomi Willis is a research associate at Newcastle University 
Professor John Mathers is the Professor of Human Nutrition at Newcastle University 
Mr Seamus Kelly is a consultant surgeon at North Tyneside General Hospital and a 
senior lecturer at Newcastle University 
Mr Mike Bradburn is a consultant surgeon at Wansbeck General Hospital 
 
 
We hope that you agree to participate, if you have any questions please ask. 
 
 
Study coordinator, Naomi Willis 
 
Research Associate 
Human Nutrition Research Centre 
Newcastle University 
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Appendix III 
Permission/copyright clearance for use of images 
1. Figure 1.1, 1.2, 1.3 (CRC statistics): Permission obtained from Cancer 
Research UK 
2. Figure 1.4 (Histology of hyperplastic polyp): Permission obtained from 
Nature publishing group 
3. Figure 1.5 (Histology of tubular adenoma (A) and tubulovillous adenoma 
(B)): Permission obtained from Journal of Gastrointestinal Oncology 
4. Figure 1.6 (Fearon and Vogelstein’s (1990) adenoma-carcinoma model 
of CRC): Permission obtained from Nature publishing group 
5. Figure 1.8 (Acquired capabilities of cancer): Permission obtained from 
Elsevier Limited 
6. Figure 1.9 (The colonic crypt): Permission obtained from Nature 
publishing group 
7. Figure 1.10 (The actions of APC within the WNT signalling pathway): 
Permission obtained from BMJ publishing group 
8. Figure 1.11 (The classification of colorectal cancers): Permission 
obtained from American Society of Clinical Oncology 
9. Figure 1.12 (WNT signalling pathway and the actions of SFRP): 
Permission obtained from Nature publishing group 
10. Figure 1.13 (Overview of Vitamin D synthesis): Permission obtained from 
Nature publishing group 
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1. Figure 1.1, 1.2, 1.3 (CRC statistics): Permission obtained from Cancer 
Research UK 
From: Supporter Services <supporter.services@cancer.org.uk> 
Subject: Email Enquiry 
Date: Thu, 22 May 2014 15:35:51 +0100 
To: <helen.staley@doctors.org.uk> 
 
 
 
 
 
Dear Helen 
I can confirm that you can use the figures as long as Cancer Research UK is referenced. 
If there's anything else I can help with please feel free to get back in contact by e-mail, 
by telephone or through our website. 
Kind regards, 
Jamie Cotton 
Supporter Contact Advisor 
Supporter Services & Operations 
   0300 123 1022 (Mon-Fri, 08:00-18:00) 
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2. Figure 1.4 (Histology of hyperplastic polyp): Permission obtained from 
Nature publishing group 
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Group ("Nature Publishing Group") provided by Copyright Clearance Center 
("CCC"). The license consists of your order details, the terms and conditions provided 
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3. Figure 1.5 (Histology of tubular adenoma (A) and tubulovillous adenoma 
(B)): Permission obtained from Journal of Gastrointestinal Oncology 
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4. Figure 1.6 (Fearon and Vogelstein’s (1990) adenoma-carcinoma model 
of CRC): Permission obtained from Nature publishing group 
This is a License Agreement between Helen Staley ("You") and Nature Publishing 
Group ("Nature Publishing Group") provided by Copyright Clearance Center 
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